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ABSTRACT 
 
Programmed cell death is an important physiological cellular process 
that maintains homeostasis and protects multicellular organisms from 
diseases. Apoptosis is the principal mode of cell death, which eliminates 
unwanted cells and an enormous effort has been made to understand the 
molecular mechanisms of the signaling pathway and its regulatory 
systems. Irregular apoptosis often has life-threatening consequences to 
humans, including cancer, autoimmune diseases and degenerative 
diseases. In cancer for example, cell death is an attractive target to 
eradicate uncontrollably proliferating cells that have disregard pro-
apoptotic signaling. Targeted therapeutic approaches are not as effective 
as once expected, since now we know that the cell death pathways are 
not sole entities in cells, but are highly associated with various cellular 
processes. Proteins that regulate apoptosis can also control non-apoptotic 
signaling pathways. For example, c-FLIP is a protein that can either 
inhibit or promote caspase-8 activation, which is required to induce 
apoptosis. Not only has c-FLIP opposing effects on initiating apoptosis, 
but it also regulates various pro-survival signaling pathways in the cell. 
It is well known that protein expression level is a determinant of how c-
FLIP can regulate different signaling pathways, but other regulatory 
mechanisms potentially affecting the role of c-FLIP are less well 
understood. This work addresses novel insights into the mechanisms of 
c-FLIP post-translational modifications and their functional 
consequences. We have identified that phosphorylation is an important 
inception for subcellular localization of c-FLIP, thereby dictating which 
apoptotic and non-apoptotic signaling pathways c-FLIP could regulate to 
promote cell survival. Furthermore, we have constructed mathematical 
models to unite independent studies to establish more systematic c-FLIP 
signaling pathways to understand the dynamics of extrinsically-induced 
apoptosis. 
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INTRODUCTION 
 
The term cell was first described by Robert C. Hooke in 1665, when he 
viewed a thinly sliced cork under a crude compound microscope and 
observed a multitude of small individual compartments. With advances 
in microscopy, the cell theory was developed by Theodor Schwann and 
Matthias Jakob Schleiden in 1839. It was adapted by Rudolf Virchow in 
1855, when he published the work of Robert Remak, hypothesizing that 
all living organisms are composed of cells and that they originated from 
pre-existing cells. Numerous observations of dying cells were made 
already by the pioneering cell biologists, which contributed to the 
fundamental understanding of the cell. Carl Vogt was the first to 
describe the principle of cell death in toad development in 1842, and 
Walther Flemming described a systematic cell death following tissue 
injury in 1885. Flemming continued to depict chromatolysis, which today 
we call apoptosis, as a physiological cellular process but his findings were 
not appreciated at the time. He himself deviated from the research to 
study the cell cycle, which was a favored topic of his and many following 
generations of cell biologists. Thereby, concept of cell death was held in 
abeyance by developmental biologists for over half a century. 
 
The term programmed cell death was introduced by Lockshin and Williams 
in 1964, and John Kerr and colleagues characterized common 
morphological features of apoptotic cells in various cell types in 1972. 
Apoptosis was defined critical for multicellular organisms and the 
interests in cell death reemerged. Since then, rapid development of the 
cell death field revealed the mechanisms and functions of apoptosis. 
Sydney Brenner, Robert Horvitz, and John Sulston jointly received the 
Nobel Prize in Physiology and Medicine 2002 for their works on genetic 
regulation of organ development and cell death. Studies continue to 
demonstrate the importance of cell death in life, which is reflected by 
over 335,000 articles that have been written on cell death, two-third 
accounting for publications in the last decade (NCBI –Pubmed). 
 
It has been estimated that there is a turnover of over 60 billion cells 
everyday to maintain a human adult. Emerging studies are revealing just 
how closely cell death and proliferation signaling pathways crosstalk to 
restrain irreversible cell death, until it is absolutely required. In this 
thesis, I focused on how a protein, named c-FLIP, and its cellular 
localization may regulate the opposing cellular outcomes in response to 
cell death signals. 
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REVIEW OF THE LITERATURE 
 
1. To be, or not to be, that is the question:   
 
Multicellular organisms originate from a single cell. One cell divides to 
increase in number and differentiate into more specialized entities to 
form tissues where they serve precise functions necessary for life. The 
adult human is estimated to comprise of 1013 cells and there is a turnover 
of more than 60 billion cells each day to maintain the homeostasis of the 
normal tissues (Reed, 2002). Such equilibrium is strictly maintained by 
cellular processes that eliminate cells to balance their mitotic activity, a 
theory proposed by Ludwig Graper a hundred years ago. 
 
The existence of a cell is determined by the status of the cell itself and its 
surrounding environment. Diverse biological signals must be interpreted 
and processed by the cell to reflect its overall response. If a cell is 
damaged or unwanted, death-inducing signals dominate over survival-
promoting signals and the cell commits suicide to avoid further injury to 
the functioning tissue. Cell proliferation and regulated cell death are two 
antagonizing outcomes that must be adequately balanced, and 
disturbance of these processes results in devastating physiological 
consequences, many of which are life-threatening (Fig 1). The decision of 
cells to stay alive or to eliminate themselves from the body is essential for 
every multicellular organism from worm to human, and cells are 
constantly in the state of asking the question to die or not, to prevent 
themselves from becoming a burden on the organism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Homeostasis is balanced by cell death and proliferation. 
Various physiological impairments are caused by uncontrolled 
increase or decrease in cell death. Diseases may result from 
accumulation of cells due to lack of cell death (left) or too scarce 
number of cells due to extreme cell death (right). SLE; systemic 
lupus erythematous, ALS; amyotrophic lateral sclerosis, AIDS; 
acquired immunodeficiency syndrome (From Nobel Foundation). 
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2. The meaning of death for a cell 
 
We are destined to live to age, during which we must maintain 
homeostasis and overcome or adapt to different stresses. Cell death is an 
important regulatory process that disposes of any unnecessary or 
harmful cells, which may provoke harm to the organism. There are 
numerous modes of cell death and they can be classified as genetically 
programmed, regulated or accidental cell death. Apoptosis is genetically 
programmed and apoptosis-regulating genes are exceptionally well 
conserved throughout the evolution (Liu and Hengartner, 1999). Cell 
death is pivotal in the elimination of unwanted cells during embryonic 
development and normal cell turnover in proliferating tissues, and 
therefore the ability for a cell to die on cue must be precise.  The degree 
of how well apoptosis is regulated can be demonstrated in Caenorhabditis 
elegans, where exactly 131 of the 1090 somatic cells generated during 
development undergo apoptosis (Horvitz et al., 1994). Likewise, this 
programmed cell death serves for a definition of finger digits in 
mammalian embryo, as well as regulation of the immune system in 
adult. Apoptosis is the best characterized among all cell deaths. It is a 
distinct form of cell death that is energy-dependent and follows a 
sequence of genetically predetermined events (Kroemer et al., 1997). If 
not, cells may be eliminated before they function properly, or may 
provide resistance to death signals, leading to unwanted cells lingering 
for an undefined time. On the molecular level, apoptosis can be defined 
in initiation, decision and execution phases, which will be discussed in 
the following chapters. 
 
 
2.1 Initiation of apoptosis  
 
Apoptosis is induced by various stimuli and cells have complex 
mechanisms to sense and respond to death signals. The common modes 
of early phase apoptosis are extrinsically-induced apoptosis, which occur 
upon receiving a killing signal from outside the cell and intrinsically-
induced apoptosis, which is induced by intracellular stress. 
 
 
Extrinsic apoptosis signaling commence from death receptors 
 
The extrinsic apoptotic pathway occurs during normal physiological cell 
turnover. Killing signals are normally presented in the form of death 
ligands, typically expressed by cells of the immune system. The extrinsic 
apoptotic pathway is a common way by which a cell is removed by 
immune cells, for example to eradicate infected or transformed cells to 
avoid the development of infection or tumor, respectively. The death 
ligands belong to the tumor necrosis factor receptor (TNFR) ligand 
family of type II transmembrane proteins and they contain a conserved 
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C-terminal extracellular TNF homology domain (THD), which is
required for ligand trimerization to signal for killing (Bodmer et al., 2002; 
Orlinick et al., 1997). The death ligands can exist as membrane-bound or 
soluble forms, depending on the activity of proteolytic enzymes that 
cleave and release the protein at the cell surface.  
 
The extracellular death ligands are sensed by death receptors (DRs) on 
the cell surface. The DRs are members of the TNFR superfamily of type I 
transmembrane proteins. There are more than twenty DRs, which are 
characterized by extracellular cysteine-rich domains and a conserved 
intracellular death domain (DD) (Ashkenazi and Dixit, 1998). Upon 
binding of homo-trimeric death ligands, the DRs oligomerize at the 
membrane lipid rafts, which are small sphingolipid-enriched 
microdomains that function to efficiently compartmentalize signaling 
platforms for membrane receptors (Simons and Ikonen, 1997). The 
receptor clustering causes conformation changes of the intracellular 
region of the DRs to provide binding sites for cytoplasmic proteins. 
Adaptor molecules are recruited and the death signal is transduced to an 
intracellular signaling machinery to activate the extrinsic apoptosis 
signaling pathway (Feig and Peter, 2007). Eight members of the DR 
family have been reported to induce apoptosis, of which the best-
characterized members are TNFR1, CD95, and TRAIL-receptors (TRAIL-
Rs) (Figure 2). The DRs in the same subfamily participates in similar 
signaling and most cells express multiple DRs to enable the cell to 
respond to diverse death signals. 
 
Figure 2. Schematic picture of common DRs at the cell surface. 
Selected death-inducing DRs with their corresponding natural death 
ligands are shown. TNF-α activates TNFR1 and TNFR2, CD95L (as 
indicated by trimerized oval complex) activates CD95, and TRAIL 
binds to various TRAIL-Rs and soluble OPG. The DRs have similar 
extracellular domains within the subfamily, which are denoted by 
different shades of gray circles. Transmembrane region anchors the 
protein in the membrane, except for OPG. Intracellular C-terminal 
regions of the receptors contain conserved protein-protein 
interaction domain, the DD, shown as rectangles. TRAIL-R3 has a 
glycolipid anchor with no DD and TRAIL-R4 has a truncated DD. 
OPG; osteoprotegerin. 
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TNFR1 (also known as DR1, CD120a, p55, and p60) is present in most 
cells and exert pleiotropic biological activities upon binding of TNF-α, a 
cytokine predominantly produced by activated macrophages in response 
to infections. The receptor regulates cellular processes such as 
inflammation, proliferation, differentiation and cell death (Ashkenazi 
and Dixit, 1998; Wajant et al., 2003). TNFR1 can induce formation of two 
distinct signaling complexes via recruiting its adaptor protein TNFR-
associated death domain (TRADD) in the intracellular region of the 
receptor (Hsu et al., 1995). The TNFR1-TRADD complex subsequently 
transduces either pro-survival or pro-apoptotic signaling by recruiting 
different cytoplasmic proteins. Inhibition of TNF-TNFR1 signaling 
pathways has emerged as an effective therapeutic target for autoimmune 
diseases (Muppidi et al., 2004). TNFR2, on the other hand, lacks the DD 
and thus has lesser potency and no cytotoxic activity (Baker and Reddy, 
1998; Tartaglia et al., 1993).  
 
CD95 (also known as Fas, DR2, and APO-1) is expressed in various 
tissues, whereas CD95 ligand (CD95L) is expressed mainly by 
lymphocytes to kill target cells (Griffith et al., 1995; Suda et al., 1993). The 
membrane-bound CD95L is suggested to have more effective cytotoxic 
activity in vivo compared to the soluble oligomerized ligands (O’Reilly et 
al., 2009). CD95-mediated apoptosis appears to be necessary in the 
immune system, for example to eliminate autoreactive lymphocytes, 
delete activated lymphocytes after an immune response, and restrict 
immune system access from privileged sites. Additionally, it plays a role 
in eliminating cancer cells and virally infected cells (Curtin and Cotter, 
2003; Krammer, 2000; Kurts et al., 1998; Nagata, 1999). CD95L-CD95 
death signaling is transduced into the cell via the death-inducing 
signaling complex (DISC), a multiprotein platform where the decision to 
execute apoptosis occurs (Itoh et al., 1991). 
 
There are five TRAIL-R members of which two are agonistic, TRAIL-R1 
(also known as DR4 and APO-2) and TRAIL-R2 (or DR5, KILLER, 
TRICK2), while other members are antagonistic decoy receptors, TRAIL-
R3/DcR1, TRAIL-R4/DcR2, and osteoprotegerin (Fig 2) (Degli-Esposti et 
al., 1997; Degli-Esposti et al., 1997; Emery et al., 1998; MacFarlane et al., 
1997; Pan et al., 1997; Screaton et al., 1997; Walczak et al., 1997). These 
antagonistic TRAIL-Rs inhibit TRAIL-mediated cell death by competing 
with TRAIL-R1 and TRAIL-R2 for the ligand binding (Sheridan et al., 
1997). TRAIL posses a strong apoptosis inducing activity in a wide range 
of human cancer cells while it has minimum cytotoxicity to normal cells, 
making TRAIL a potential target for cancer therapy (Ashkenazi and 
Dixit, 1998; Griffith and Lynch, 1998; Lin et al., 2002; Pitti et al., 1996; 
Walczak et al., 1999). Similar to the CD95 DISC, the TRAIL-R DISC 
formation is required to initiate the downstream apoptosis.  
 
? ??
Despite their name, the DRs are not simply dedicated to induce cell 
death but also mediate diverse non-apoptotic functions, including cell 
survival, differentiation, and regulation of the immune response 
(Locksley et al., 2001). For example, CD95 provide a co-stimulatory 
signal to T cells upon activation (Alderson et al., 1995). While much of 
this introduction will be focused on cell death, the non-apoptotic aspect 
of the DR-mediated signaling will be discussed throughout this book. 
 
 
Intrinsic apoptotic pathway is initiated by mitochondria 
 
Apoptosis induced via the intrinsic pathway is another form of 
programmed cell death, which is also referred to as the mitochondria 
initiated pathway, since the majority of regulations occur in the 
mitochondria. When cells sense intracellular stresses such as DNA 
damage, growth factor deprivation, and hypoxia, they trigger the stress 
response pathways in attempt to mend subsequent damages. If the stress 
signal is too severe, however, cells induce the intrinsic apoptotic 
pathway to eliminate themselves. Upon receiving a death signal, 
mitochondrial outer membrane permeabilization (MOMP) occurs, 
leading to efflux of proteins from the mitochondrial intermembrane 
space to the cytoplasm, which are sensed as killing signals and the 
apoptotic signaling is initiated (reviewed by Galluzzi et al., 2012). It 
causes dysfunction of the mitochondria, inducing transmembrane 
potential dissipation and arrest of adenosine triphosphate (ATP) 
synthesis. 
 
B cell CLL/lymphoma-2 (Bcl-2) proteins, which are the central regulators 
of the intrinsically-induced apoptosis, respond to multiple intracellular 
stresses, and determine the mitochondrial integrity. Bcl-2 proteins are 
either pro-survival or pro-apoptotic to their nature and are categorized 
into three functional groups (Fig 3) (Adams and Cory, 1998; Antonsson 
and Martinou, 2000). The anti-apoptotic Bcl-2 proteins, Bcl-xL being the 
most potent, prevent the initiation of apoptosis and preserve the integrity 
of the mitochondria to carry out efficient energy metabolism, production 
of membrane lipids and cell growth (Chen et al., 2005; Willis and Adams, 
2005). When a death signal arrives, the anti-apoptotic Bcl-2 proteins are 
inhibited by Bcl-2 homology-3 (BH3)-only proteins. This leads to the 
oligomerization of the effector pro-apoptotic Bax (Bcl-2 associated x 
protein) and Bak (Bcl-2 antagonist killer 1) to create pores on the 
mitochondrial outer membranes and causes the intermembrane space 
contents to leak out (reviewed by Hengartner, 2000). 
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Fig 3. Regulation of the intrinsic apoptotic pathway by the Bcl-2 
proteins. The Bcl-2 family comprises of three subfamilies that 
contain between one and four BH domains (BH1-4). The anti-
apoptotic Bcl-2 proteins, including Bcl-2, Bcl-xL and Mcl-1, contain 
four BH domains. The pro-apoptotic subfamily is subdivided into 
effector and BH3-only members. The anti-apoptotic Bcl-2 proteins 
are differentially inhibited by the BH3-only proteins. Some BH3-only 
proteins interact with all, whereas others interact only with certain 
anti-apoptotic members (adapted from Taylor et al., 2008).  
 
 
2.2 The killing signal is verified in cell death signaling complexes 
 
Once cells receive enduring killing signals that dominate over pro-
survival signalings, they initiate the suicidal process by structuring 
multiprotein complexes to converge the death signals to activate 
caspases (cysteine-dependent aspartate-specific protease). Thus, 
formation of these complexes is a crucial regulatory step in transducing 
the apoptotic signals (reviewed by Bao and Shi, 2006). There are several 
complexes that determine if the cell will die or not. 
 
The assembly of death signaling complexes relies on protein-protein 
interactions to effectively facilitate the activation and amplification of the 
downstream signaling. The members of the DD superfamily contain 
interaction domains, which have no enzymatic function but their 
structures allow homotypic binding with other proteins that contain the 
same domains (Weber and Vincenz, 2001). Such interaction motifs
include the DDs and the death effector domain (DED) in DR signaling,
and caspase recruitment domain (CARD) in the intrinsic cell death 
pathway (Reed et al., 2004). Some caspases contain DED or CARD 
prodomains that mediate recruitment of the molecules to adjacent death 
signaling complexes for their activation. 
 
 
The DISC formation at the death receptors 
 
The DISC is critical for initiating the DR signaling for CD95 and TRAIL-
Rs. The DISC is assembled by DED-containing proteins, including an 
adaptor Fas-Associated Death Domain (FADD), procaspase-8 (also 
known as FADD-like interleukin-1 beta-converting enzyme (FLICE)), 
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procaspase-10, and the regulatory protein FLICE-inhibitory protein
(FLIP). The DEDs are predominantly confined to seven proteins and
considerable studies focus on FADD, caspase-8 and FLIP that commonly 
regulate the DISC signaling (Fig 4). These subgroups, which are major 
components of the DISC, are present in higher quantities compared to 
the other DED-containing proteins (Schleich et al., 2012). Intriguingly, 
highly structurally similar DEDs between different species of DED-
containing proteins can have opposing effects and they are not 
functionally interchangeable. 
 
Figure 4. Representation of DED-containing proteins. FADD, 
procaspases and c-FLIP are fundamental components of the DISC. 
Although PEA-15, DEDD and DEDD2 have regulatory roles in the 
extrinsic apoptotic signaling, they are less known. There are also 
additional proteins that contain variant DEDs, but they are not 
shown in the figure nor discussed in the text. C-terminal number 
represents the number of amino acids in each protein (adapted from 
Yu and Shi, 2008). 
 
FADD (also known as MORT1) is a critical adaptor protein that 
transduces signaling from the DRs to intracellular signaling machinery. 
It possesses a C-terminal DD, which binds directly to the DR and a N-
terminal DED in turn recruits other DED-containing proteins (Boldin et 
al., 1996; Fernandes-Alnemri et al., 1996; Muzio et al., 1996). 
Furthermore, oligomerization of the FADD DED drive homotypic DD 
interactions, thus functioning as a linker to enhance binding affinity to 
oligomeric ligand-bound DRs and forming a stable signaling complex 
(Carrington et al., 2006; Sandu et al., 2006; Thomas et al., 2004). FADD 
self-association is also implicated in generation of clusters of receptor 
termed SPOTS (signaling protein oligomeric transduction structure), 
which rapidly amplifies the apoptotic signal (Kischkel et al., 1995; Siegel 
et al., 2004).  
 
The initiator caspases, namely procaspase-8 (also known as FLICE, 
MACH and Mch5) and procaspase-10, interact with FADD via their N-
terminal tandem DEDs (Reed et al., 2004; Tsukumo and Yonehara, 1999). 
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apoptotic Bcl-2 proteins, including Bcl-2, Bcl-xL and Mcl-1, contain 
four BH domains. The pro-apoptotic subfamily is subdivided into 
effector and BH3-only members. The anti-apoptotic Bcl-2 proteins 
are differentially inhibited by the BH3-only proteins. Some BH3-only 
proteins interact with all, whereas others interact only with certain 
anti-apoptotic members (adapted from Taylor et al., 2008).  
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The DISC formation at the death receptors 
 
The DISC is critical for initiating the DR signaling for CD95 and TRAIL-
Rs. The DISC is assembled by DED-containing proteins, including an 
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procaspase-10, and the regulatory protein FLICE-inhibitory protein
(FLIP). The DEDs are predominantly confined to seven proteins and
considerable studies focus on FADD, caspase-8 and FLIP that commonly 
regulate the DISC signaling (Fig 4). These subgroups, which are major 
components of the DISC, are present in higher quantities compared to 
the other DED-containing proteins (Schleich et al., 2012). Intriguingly, 
highly structurally similar DEDs between different species of DED-
containing proteins can have opposing effects and they are not 
functionally interchangeable. 
 
Figure 4. Representation of DED-containing proteins. FADD, 
procaspases and c-FLIP are fundamental components of the DISC. 
Although PEA-15, DEDD and DEDD2 have regulatory roles in the 
extrinsic apoptotic signaling, they are less known. There are also 
additional proteins that contain variant DEDs, but they are not 
shown in the figure nor discussed in the text. C-terminal number 
represents the number of amino acids in each protein (adapted from 
Yu and Shi, 2008). 
 
FADD (also known as MORT1) is a critical adaptor protein that 
transduces signaling from the DRs to intracellular signaling machinery. 
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terminal DED in turn recruits other DED-containing proteins (Boldin et 
al., 1996; Fernandes-Alnemri et al., 1996; Muzio et al., 1996). 
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oligomeric ligand-bound DRs and forming a stable signaling complex 
(Carrington et al., 2006; Sandu et al., 2006; Thomas et al., 2004). FADD 
self-association is also implicated in generation of clusters of receptor 
termed SPOTS (signaling protein oligomeric transduction structure), 
which rapidly amplifies the apoptotic signal (Kischkel et al., 1995; Siegel 
et al., 2004).  
 
The initiator caspases, namely procaspase-8 (also known as FLICE, 
MACH and Mch5) and procaspase-10, interact with FADD via their N-
terminal tandem DEDs (Reed et al., 2004; Tsukumo and Yonehara, 1999). 
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Cells without caspase-8 are resistant to DR-mediated apoptosis but not to 
mitochondria-dependent apoptosis, indicating that caspase-8 plays 
indispensable roles in the extrinsic apoptosis signaling, but is expendable 
for other modes of cell death (Varfolomeev et al., 1998). The DISC 
provides a platform where the C-terminal protease domains of the 
procaspase are recruited and dimerized, which is a prerequisite for 
caspase activation. Further cleavage of the proteins stabilizes the dimers 
and increases their activity (Fig 5) (Martin et al., 1998; Muzio et al., 1996; 
Oberst et al., 2010; Wang et al., 2001). The activation liberates caspase-8 
dimers from the DISC into the cytoplasm and in turn activates a 
downstream caspase cascade to execute cell death (reviewed by Salvesen, 
2002). Active caspase-8 and caspase-10 have similar substrate 
specificities, but caspase-10 cannot functionally substitute caspase-8 in 
initiating the extrinsic apoptosis signaling pathway (Engels et al., 2005; 
Kischkel et al., 2001; Milhas et al., 2005; Vincenz and Dixit, 1997). c-FLIP 
is another DED-containing protein, which can bind to the DISC and 
modulate caspase-8 activation, thereby determining the outcome of DISC 
signaling (Fig 5). c-FLIP is the focus of my thesis work and its detailed 
regulatory mechanisms will be discussed later.  
 
Figure 5. Schematic diagram of the DISC complex. DED-containing 
proteins form the DISC through homotypic DD and DED 
interactions in the intracellular region of the DRs. The right side of 
the DISC: procaspase-8 recruitment via FADD (black) results in full 
caspase-8 activation and apoptotic signal transduction. The left side: 
simplified view of c-FLIP inhibiting caspase activation at the DISC 
by binding to FADD. Numbers on the molecules indicate DED 
domains, 1; DED1 and 2; DED2. Different shades of grey depict one 
molecule of procaspase-8. 
 
 
The receptor-bound DISC can dissociate into the cytoplasm to form DISC 
complex II, which is composed only of the DED-containing proteins (Jin 
and El-Deiry, 2006; Lavrik et al., 2008). The CD95 DISC may internalize 
to amplify the receptor-mediated death signal (Lee et al., 2006), whereas 
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internalized TRAIL-R DISC has been shown to activate both apoptotic 
and survival signaling pathways (Varfolomeev et al., 2005). 
 
Other DED-containing proteins include the anti-apoptotic PEA-15 
(phospho-protein enriched in astrocytes 15 kDa), which can regulate the 
DISC signaling (Xiao et al., 2002). Other DED-containing proteins can 
regulate apoptosis independent of the DISC. For example, DED-
containing DNA binding protein (DEDD) in the nucleolus activates 
caspase-6 and inhibits transcription mediated by RNA polymerase I 
(Schickling et al., 2001). Its analog DEDD2 can sequester c-FLIP in the 
nucleoli to regulate the DR-induced apoptosis (Roth et al., 2002). 
 
 
The deadly Complex II formed by TNFR1 is active in the cytosol 
 
Whilst CD95 and TRAIL-Rs predominantly activate the extrinsic 
apoptotic pathway, TNFR1 primarily induces pro-inflammatory and 
immune-stimulatory activities, and apoptosis is secondary. When TNFR1 
is stimulated, TRADD binds at the receptor via DD homotypic 
interactions, which in turn recruits other proteins to form complex I to 
induce nuclear factor-κB (NF-κB) activation. The complex may dissociate 
from the receptor to form two types of complex II (Fig 6) (Micheau and 
Tschopp, 2003). In complex IIa, FADD and procaspase-8 are assembled to 
induce apoptosis. Formation of complex IIa is a prerequisite for TNFR1-  
 
 
Figure 6. TNF-α-TNFR1 can signal for cell survival, apoptosis or 
necroptosis. TNFR1 signaling primarily induce pro-survival 
signaling via the formation of complex I at the receptor. If this 
signaling pathway is incompetent however, either complex IIa or 
complex IIb is subsequently formed to activate caspase-8 or RIPKs 
and induce apoptosis or necroptosis, respectively. 
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dimers from the DISC into the cytoplasm and in turn activates a 
downstream caspase cascade to execute cell death (reviewed by Salvesen, 
2002). Active caspase-8 and caspase-10 have similar substrate 
specificities, but caspase-10 cannot functionally substitute caspase-8 in 
initiating the extrinsic apoptosis signaling pathway (Engels et al., 2005; 
Kischkel et al., 2001; Milhas et al., 2005; Vincenz and Dixit, 1997). c-FLIP 
is another DED-containing protein, which can bind to the DISC and 
modulate caspase-8 activation, thereby determining the outcome of DISC 
signaling (Fig 5). c-FLIP is the focus of my thesis work and its detailed 
regulatory mechanisms will be discussed later.  
 
Figure 5. Schematic diagram of the DISC complex. DED-containing 
proteins form the DISC through homotypic DD and DED 
interactions in the intracellular region of the DRs. The right side of 
the DISC: procaspase-8 recruitment via FADD (black) results in full 
caspase-8 activation and apoptotic signal transduction. The left side: 
simplified view of c-FLIP inhibiting caspase activation at the DISC 
by binding to FADD. Numbers on the molecules indicate DED 
domains, 1; DED1 and 2; DED2. Different shades of grey depict one 
molecule of procaspase-8. 
 
 
The receptor-bound DISC can dissociate into the cytoplasm to form DISC 
complex II, which is composed only of the DED-containing proteins (Jin 
and El-Deiry, 2006; Lavrik et al., 2008). The CD95 DISC may internalize 
to amplify the receptor-mediated death signal (Lee et al., 2006), whereas 
??
?
???????? ??
?
??
??
??
?
??
??
X 
Death ligand 
Death receptors 
Plasma membrane 
c-FLIP Procaspase-8 
Active  
caspase-8 
1  2    1  2   2  1 
FADD 
? ??
internalized TRAIL-R DISC has been shown to activate both apoptotic 
and survival signaling pathways (Varfolomeev et al., 2005). 
 
Other DED-containing proteins include the anti-apoptotic PEA-15 
(phospho-protein enriched in astrocytes 15 kDa), which can regulate the 
DISC signaling (Xiao et al., 2002). Other DED-containing proteins can 
regulate apoptosis independent of the DISC. For example, DED-
containing DNA binding protein (DEDD) in the nucleolus activates 
caspase-6 and inhibits transcription mediated by RNA polymerase I 
(Schickling et al., 2001). Its analog DEDD2 can sequester c-FLIP in the 
nucleoli to regulate the DR-induced apoptosis (Roth et al., 2002). 
 
 
The deadly Complex II formed by TNFR1 is active in the cytosol 
 
Whilst CD95 and TRAIL-Rs predominantly activate the extrinsic 
apoptotic pathway, TNFR1 primarily induces pro-inflammatory and 
immune-stimulatory activities, and apoptosis is secondary. When TNFR1 
is stimulated, TRADD binds at the receptor via DD homotypic 
interactions, which in turn recruits other proteins to form complex I to 
induce nuclear factor-κB (NF-κB) activation. The complex may dissociate 
from the receptor to form two types of complex II (Fig 6) (Micheau and 
Tschopp, 2003). In complex IIa, FADD and procaspase-8 are assembled to 
induce apoptosis. Formation of complex IIa is a prerequisite for TNFR1-  
 
 
Figure 6. TNF-α-TNFR1 can signal for cell survival, apoptosis or 
necroptosis. TNFR1 signaling primarily induce pro-survival 
signaling via the formation of complex I at the receptor. If this 
signaling pathway is incompetent however, either complex IIa or 
complex IIb is subsequently formed to activate caspase-8 or RIPKs 
and induce apoptosis or necroptosis, respectively. 
??
??
?????????????
??
?
??
?
??
?
??
????? ???
???
??
?
??
?
??
?
??
?
??
??
??
???
?
Ub Ub Ub 
????????
??
??
X 
Apoptosis 
Survival 
???
?
????????
??
??
Necroptosis 
Complex I 
Complex IIa 
Complex IIb 
c-FLIP 
Caspase-8 
molecules 
? ??
mediated apoptosis, since DED-containing proteins cannot bind directly 
at the receptors (Harper et al., 2003). Complex IIb, also known as the 
necrosome, is formed when caspase-8 activation in complex IIa is 
impaired and do not cleave necrosis inducing kinases, initiating 
necroptosis, a different form of regulated cell death (Fig 6). Death 
through TNFR1 complex II is typically a result of inefficient pro-survival 
signals induced by complex I. 
 
 
Mitochondria-mediated apoptosome formation 
 
Upon activation of the intrinsic apoptotic pathway, mitochondria are 
permeabilized by the Bcl-2 proteins to release various pro-apoptotic 
molecules and induce a potent cell death (reviewed by Chipuk and 
Green, 2008). Among these, cytochrome c is a major apoptogen that 
interacts with a cytoplasmic adaptor receptor Apaf-1 (Apoptotic protease 
activating factor-1) to form a large molecular weight oligomeric caspase 
activation complex known as the apoptosome (Fig 7) (Li et al., 1997; Liu 
et al., 1996; Zou et al., 1997). The apoptosome recruits procaspase-9 via 
CARD-CARD interaction with Apaf-1 and oligomerization of the 
procaspases lead to their activation (Adrain and Martin, 2001; Hofmann 
et al., 1997). This step in the mitochondrial pathway is often implied as 
the point of no return, since the function of mitochondria deteriorate and 
downstream signaling of MOMP is irreversible. In addition to the release 
of cytochrome c, mitochondria release other proteins that aid in 
amplifying the apoptotic signaling (Barnhart et al., 2003). For example, 
Smac/Diablo (the second mitochondrial activator of caspases/Direct IAP 
binding protein with low PI) binds to IAPs (inhibitor of apoptosis 
proteins), thereby blocking the ability of IAPs to inhibit initiator caspase-
9 and downstream effector caspases (Deveraux et al., 1998; Du et al., 
2000; Verhagen et al., 2002). Interestingly, XIAP (X-linked IAP) can 
inhibit caspase-9 activated in the apoptosome, but it can no longer inhibit 
those activated by downstream effector caspases in a feedback 
amplification loop (Holcik and Korneluk, 2001). 
 
 
The PIDDosome induces caspase-2 activation 
 
In response to genotoxic stress, p53 induces the expression level of PIDD 
(p53-induced protein with a DD). PIDD forms the core moiety of a large 
oligomeric complex known as the PIDDosome, where it binds to a 
CARD-containing protein RAIDD (RIP-associated Ich-1/CED 
homologous protein with DD). Procaspase-2 also contains a CARD that 
facilitates its recruitment to the PIDDosome and dimerization activates 
the caspase to regulate inflammation or apoptosis signaling pathways. 
Even though caspase-2 was one of the first caspases discovered, its 
detailed physiological function remains to be established (Janssens and 
? ??
Tinel, 2011; Zhivotovsky and Orrenius, 2005). Emerging studies have 
described caspase-2 as a tumor suppressor in vivo, by providing 
protection against cellular stress and transformation (Puccini et al., 2013).  
 
Figure 7. MOMP and formation of the apoptosome. Following an 
irreparable cellular stress, pro-apoptotic signaling leads to MOMP 
and allows the release of mitochondrial intermembrane space 
proteins to the cytoplasm. The release of cytochrome c (denoted by 
black circles) promotes Apaf-1 oligomerization and formation of the 
apoptosome. This complex provides a platform for caspase-9 
activation. Other apoptogens, such as Smac/Diablo and Omi/HtrA2 
facilitate caspase activation by inhibiting several members of the IAP 
family. In addition, activated caspase-8 can truncate Bid, a BH3-only 
pro-apoptotic protein, which in turn directly activate Bak and Bax to 
form lipoprotein pores in the outer membranes of mitochondria to 
induce MOMP.
Crosstalk between the extrinsic and intrinsic apoptotic pathways 
 
While the extrinsic and intrinsic apoptosis signaling are distinct from 
each other in the modes of initiation, they may crosstalk to amplify the 
killing signals and robustly execute apoptosis (Kuwana et al., 1998). A 
well-known example is the induction of mitochondria-dependent 
apoptosis by activated caspase-8 (Kantari and Walczak, 2011). Some cells 
(Type I) are characterized by rapid high level of DISC formation by lipid 
raft-associated DRs, which efficiently cleave procaspase-8 and directly 
activate its downstream caspase cascade leading to apoptosis. Other cells 
(Type II), however, lack such strong initiation of cell death, thus requires 
an amplification loop. The activated caspase-8 truncate the BH3-only Bcl-
2 protein Bid, which in turn promote oligomerization of pro-apoptotic 
Bcl-2 proteins to initiate the mitochondrial-pathway (Fig 7) (Eskes et al., 
2000; Li et al., 1998; Li and Yuan, 2008; Luo et al., 1998). The type II 
apoptosis pathway can be inhibited by overexpression of Bcl-2 and Bcl-
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xL or inhibiting caspase-9 activity (Scaffidi et al., 1999). Furthermore, 
once the decision is made to die, cells often shuts down pro-survival 
signaling pathways to further reinforce the death machinery. 
 
 
2.3 Execution of apoptosis 
 
After cells receive killing signals and the decision is made to transduce 
the apoptotic signaling, a well-characterized chronological execution of 
cell suicide follows. The final stages of apoptosis orchestrate and compile 
the killing signals to successfully eliminate the cells in a highly ordered 
manner. 
 
 
Activation of the caspase cascade 
 
Execution of apoptosis is ultimately carried out by the caspase family. 
The caspases are an evolutionary conserved family of enzymes that 
proteolytically cleave their substrates after an aspartic acid residue by 
using their catalytically active cysteine to either deactivate or activate the 
targeted proteins (Dales et al., 2001; van Raam and Salvesen, 2012). There 
are twelve caspases characterized in humans and their proteolytic 
activity is responsible for many cellular processes (Fig 8). All caspases 
are synthesized as inactive precursors, called the zymogens or 
procaspases, with an N-terminal prodomain and C-terminal protease 
domain, containing a large and a small subunit. When activated, the 
zymogens are proteolytically cleaved to generate active subunits, which 
heterodimerize with one another to form a mature heterotetramer 
caspases (Degterev et al., 2003; Fuentes-Prior and Salvesen, 2004). 
Caspase-1 (ICE; interleukin-1β conversion enzyme), caspase-4, and 
caspase-5 are involved in the regulation of inflammatory responses. 
Upon activation, they form a complex called the inflammasome, which 
leads to secretion of pro-inflammatory cytokines (Martinon and Tschopp, 
2006; Pétrilli et al., 2007). Caspase-14 is required for keratinocyte 
maturation in the epidermis (Denecker et al., 2007). Other caspases are 
primarily committed in apoptosis, although at least one non-apoptotic 
function has been attributed for these caspases. Diverse stimuli cause the 
activation of caspases and result in various outcomes, but I will only 
focus on apoptosis-related caspases for the purpose of my thesis.  
 
The important role of caspases in apoptosis was discovered in C. elegans, 
in which the death gene ced-3 was shown to be indispensable for the 
execution of cell death (Yuan et al., 1993). In mice, caspase-8 knockout 
has the most dramatic phenotype of all caspase knockouts, demonstrated 
by earliest embryonic lethality (Varfolomeev et al., 1998). Of note, while 
some caspases are indispensible in specific apoptosis pathways, others 
can be compensated, suggesting that caspases induce apoptosis in a 
? ??
highly context-dependent manner. Mammalian apoptotic caspases can 
be divided into initiator and executioner caspases according to the 
sequential activation of the zymogens in the caspase cascade. 
 
Figure 8. Phylogenetic tree and schematic domain presentation of 
the human caspase family. All caspases have similar structures, 
consisting of an N-terminal prodomain followed by C-terminal 
protease domain, a large α subunit (indicated as p20) and a small β 
subunit (p10). The N-terminal domains, CARD or tandem DEDs,
and C-terminal amino acid number are indicated. The structures of 
either extrinsic or intrinsic initiator caspases (medium grey), and 
shorter effector caspases (dark grey) are drawn. The lineage is not 
drawn to scale (adapted from Inoue et al., 2009; Roschitzki-Voser et 
al., 2012). 
 
  
As already discussed, initiator caspase-8, caspase-9, and caspase-2 are 
activated at the DISC, apoptosome, and PIDDosome, respectively. They 
are first in line of the caspase cascade to be activated, hence called 
initiator caspases. The initiator procaspases must homodimerize for their 
autoactivation to occur, and therefore, DEDs or CARD-dependent 
recruitment of the procaspases to the death signaling complexes are 
essential. These initiator procaspases are dimerized in death signaling 
complexes and autocleaved through induced proximity (Chang et al., 
2003; Fuentes-Prior and Salvesen, 2004). The autocleavage stabilizes the 
homodimers and form an enzyme with increased activity. Caspase-8 also 
cleaves itself between the DEDs and the large subunit, resulting in the 
release of stable dimers from the DISC to the cytoplasm. These initiator 
caspases converge death signals to the execution phase by activating the 
downstream effector caspases.  
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The executioner or effector caspases, namely caspase-3, caspase-6, and 
caspase-7, are downstream molecules of the caspase cascade (Shi, 2002). 
They lack a long N-terminal prodomain and cannot self-activate, thus 
require activated caspases to process them at the inter-subunit linker. 
There are other less common ways in which caspases may be activated, 
although much of the detail is still to be clarified. In the granzyme B 
pathway, apoptosis-inducing protease granzyme B is excreted by 
lymphocytes onto their target cells to activate the executioner caspases 
(Yang et al., 1998). Furthermore, caspases may be activated by the 
nuclear Pml/PODs/nuclear bodies and converges to a common 
execution phase of apoptosis. The executioner caspases are considered to 
be the generator of apoptotic cell death and they are usually more 
abundantly expressed than their initiator caspases (Budihardjo et al., 
1999). Since all initiator caspases can activate caspase-3, it is here that 
various death stimuli are processed to give one common execution phase 
(Stennicke et al., 1998). Once activated, the executioner caspases function 
as enhancers of the apoptosis, creating a growing cascade of apoptotic 
proteinases by positive feedback activation (Grütter, 2000). Caspase-3 is a 
potent downstream caspase that cleaves the majority of cellular 
substrates in apoptotic cells (Porter and Janicke, 1999), although caspase-
7 is similar to caspase-3 and has close substrate specificity (Degterev et 
al., 2003; Fuentes-Prior and Salvesen, 2004). The activation of the effector 
caspases is considered the hallmark of apoptosis where rapid all-or-none 
progress for commitment to death is achieved and this is commonly 
irreversible.  
 
 
Morphological features of apoptosis 
 
Original observations of dying cells and early studies that distinguished 
apoptosis from other forms of cell death were based exclusively on 
distinct morphological criteria (Kerr et al., 1972). These morphological 
changes occur with remarkable consistency in an extensive variety of cell 
types owing to the similarity of the biochemical events in the late phase 
of apoptosis. Indeed, the proteolytic cleavages by caspases, particularly 
of cytoplasmic and nuclear structural network, are responsible for 
inducing precise sequential apoptotic morphological phenotypes (Van 
Engeland et al., 1997). Over the years, common morphological hallmarks 
of apoptosis were described, which includes cellular shrinkage with 
nuclear chromatin condensation (pyknosis), nuclear fragmentation 
(karyorrhexis), and plasma membrane blebbing (Galluzzi et al., 2007; 
Kerr et al., 1972; Wyllie, 1981). Cellular changes observed by electron 
microscope determines a highly organized form of cell death 
(Cummings, 1997), and the chief reliable technique to determine 
apoptotic cells remains to be the observation of morphological changes 
by electron microscopy (Fig 10). The caspase targets include degradation 
of both nuclear and cytoskeletal structural proteins, as well as 
? ??
deactivating the proteasomes, and many pro-survival signaling proteins
(Earnshaw et al., 1999).
 
Some of the earliest morphological changes in apoptosis appear on the 
cell surface, as cell adhesion to the extracellular matrix decrease and the 
plasma membrane loses its asymmetry. The exposure of 
phosphatidylserine is a well-documented surface modification in 
apoptosis caused by decreased activity of aminophospholipid transferase 
and enhanced activation of scramblase. Phosphatidylserine in viable cells 
is expressed asymmetrically in the inner leaflet of the plasma membrane, 
but redistributed to the outer leaflet in apoptotic cells. The appearances 
of many organelles remain unchanged and they continue to function 
until the last phases of apoptosis. Mitochondria are exceptions as their 
membrane potential collapse and organelle fission occur (Zamzami et al., 
2005). The DNA damage-responsive enzyme poly(ADP-ribose) 
polymerase (PARPs) and in particular PARP1, which alone accounts for 
most of the cellular PARP DNA repair activities, is a well-know target for 
activated caspases (Amé et al., 2004). The ultimate determinant of 
apoptosis is the homogenous condensation of chromatin and genomic 
DNA fragmentation. Activation of CAD (Caspase-activated DNase) is 
dependent on caspase-3 mediated cleavage of its inhibitory subunit, and 
the release of the catalytic enzyme proceeds to internucleosomal DNA 
cleavage and fragmentation of genomic DNA at intervals of 180 to 200 
base pairs (Fischer et al., 2003). To establish if a cell died by apoptosis, 
both caspase activation and DNA fragmentation must be demonstrated 
in most cases (Galluzzi et al., 2012). At later stage of apoptosis, the dying 
cell is easily distinguished from neighboring live cells due to membrane 
blebbing where plasma membrane is convoluted and extensions are  
 
Figure 9. Detection of morphological changes occurring during 
apoptosis. Some morphological changes of a typical dying cell that 
could be detected with the electron microscope are listed as a 
timeline (adapted from Huerta et al., 2007). Pictures represent 
typical appearances of apoptotic HeLa cells under a light microscope 
(images taken by T Asaoka).
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formed (Taatjes et al., 2008; Watanabe et al., 2002; Willingham, 1999; 
Ziegler and Groscurth, 2004). These extensions disaggregate into a 
number of membrane-bound compartments known as apoptotic bodies, 
which are tightly packed and contain well-preserved organelles and 
fragments of nucleus. 
 
 
A peaceful ending for the apoptotic bodies 
 
The purpose of apoptosis is to eliminate dying cells efficiently and 
prevent damages to the neighboring cells. When cells undergo apoptosis, 
the process produce various “eat me” signals, which are recognized by 
phagocytic cells (Edinger and Thompson, 2004; Fadok et al., 1992; Haslett 
et al., 1995). Such signals include phosphatidylserine exposure on the 
plasma membrane and release of fragmented intracellular molecules, 
such as phospholipase A2 to produce lysophatidylcholine (Lauber et al., 
2003). Caspase-8-mediated emission of damage-associated molecular 
patterns (DAMPs) and IL-33 undergoes caspase-dependent proteolysis 
into the nonimmunological forms (Lüthi et al., 2009; Panaretakis et al., 
2009). These processes ensure that the apoptotic cells will not activate 
any inflammatory and autoimmune responses. TRAIL-R DISC complex 
II formation and its kinase stimulation are also reported to signal for cell 
clearance (Varfolomeev et al., 2005). The formation of apoptotic bodies is 
the final cue for surrounding cells to recognize the dying cells, which 
must be removed by phagocytosis. The apoptotic bodies are rapidly 
engulfed by neighboring epithelial cells or macrophages and eventually 
degraded (Platt et al., 1998; Savill and Fadok, 2000). If apoptotic bodies 
are not phagocytosed, the corpse will undergo degradation in a process 
called secondary necrosis with the consequence of inflammation (Lauber 
et al., 2004). 
 
 
2.4 Alternative cell deaths 
 
Apoptosis may be the most common and efficient mode of cell death, but 
there are alternative means in which a cell commits to death. Necrosis is 
an accidental cell death considered to be on the other extreme of 
continuous spectrum of cell death and often contrasted to apoptosis. 
Recent studies, however, have demonstrated that molecular regulations 
in these two pathways are closely connected to each other and this new 
insight will be discussed here. Other cell death mechanisms are listed 
and briefly described in Table 1 at the end of this chapter. 
 
Necrosis was the first form of cell death identified and it may be induced 
by extreme physiological conditions such as heat stress, mechanical 
stress, osmotic shock, and toxin exposure. The cells are rapidly killed and 
exhibit characteristic morphologies, such as cellular swelling and 
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collapse, irregular chromatin destruction, and vacuole formation. 
Ultimately necrotic cells are lysed and release their cellular contents, 
including DAMPs, thereby activating an inflammatory response 
(Chollet-Martin et al., 1991). This phenomenon is often referred to as 
uncontrolled energy-independent mode of cell death and a massive 
necrosis can be extremely damaging to the organism.  
 
The morphological features of necrosis can be induced in a more ordered 
manner (Vandenabeele et al., 2010). Regulated necrosis, also called 
necroptosis, can be defined as cell death mediated through a pathway 
that depends on the receptor-interacting protein kinase (RIPK) complex 
(He et al., 2009; Holler et al., 2000). When caspase-8 is dysfunctional, DD-
containing RIPK1 protein and its homolog RIPK3 are not efficiently 
degraded and engage in functional interactions that ultimately activate 
the execution of necrotic cell death (Cho et al., 2009; He et al., 2009; 
Zhang et al., 2009). Like apoptosis, necroptosis require the formation of 
multiprotein complexes to initiate the signaling pathway. The concept of 
necroptosis emerged when some cells died by exhibiting necrotic 
appearance upon TNFR1-induced apoptosis while caspase activation 
was blocked (Degterev et al., 2005; Holler et al., 2000; Vercammen et al., 
1998). Under conditions where apoptosis is hindered, cells alter their 
mode of cell death to necroptosis by forming 
RIPK1/RIPK3/FADD/inactive procaspase-8 necrosome complex (Fig 7) 
(He et al., 2009; Holler et al., 2000). RIPK1/3 activities are obligatory for 
necrosome formation and can be prevented by the RIPK1-targeting 
inhibitor necrostatin-1 (Cho et al., 2009). Another necrosis-inducing 
complex, the ripoptosome, is currently considered to be a central trigger 
for necroptosis in cancer cells (Feoktistova et al., 2011; Tenev et al., 2011). 
Its core components, namely RIPK1, FADD and caspase-8 spontaneously 
assemble in response to genotoxic-induced depletion of IAPs, which is a 
negative regulator of the components. The ripoptosome can trigger either 
caspase-8-mediated apoptosis or caspase-independent necroptosis, 
depending on the strength of caspase-8 activity in the complex.  
 
The induction of necroptosis provokes strong inflammatory responses 
(Kaczmarek et al., 2013). RIPK-mediated necroptosis is suggested as an 
important mechanism in the clearance of virus-infection or cancer cells 
that escaped apoptosis (Li and Beg, 2000; Upton et al., 2010). Viruses 
express anti-apoptotic proteins that prevent caspase-8-mediated 
apoptosis to prolong cell viability and to facilitate viral replication 
(Thome et al., 1997). RIP3-mediated necroptosis may act as a standby 
mechanisms to clear pathogens by killing infected cells via virus-induced 
necroptotic cells, which are more immunogenic than apoptotic cells, 
hence enhance inflammatory responses and better antigen presentation 
(Weinlich et al., 2011). 
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Table 1. List of other cell deaths. Some less prevalent cell deaths 
and their functional features are described. AIF; apoptosis-inducing 
factor, ENDOG; endonuclease G (adapted from Galluzzi et al., 2012; 
Kroemer et al., 2008). 
 
 
3. FLIP - a modulator of cell death and survival 
 
Cell death is a complex biological process with specific purposes, and its 
regulation is crucial for the organism to live. To achieve an accurate 
execution of targeted cell death, a great degree of molecular regulations 
occur at many levels, especially at the initiation of caspase activation 
when the decision is made in the death signaling complexes. The 
regulatory mechanisms behind programmed cell death are extensively 
studied and many complicated regulatory circuits have been elegantly 
clarified. For example, XIAP can directly inhibit executioner caspases 
and play a critical regulator in type I cells, and anti-apoptotic Bcl-2 
proteins can inhibit apoptosis of type II cells by blocking the 
mitochondrial-dependent pathway. In this thesis, I will focus on the roles 
and mechanisms of apoptosis signaling modulation by FLIP in DR-
mediated apoptosis. 
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3.1 Viral and mammalian isoforms of FLIP
FLIP was first discovered while searching the genomes for the DED-
containing proteins to identify regulators of apoptotic caspases. It was 
found in several γ-herpesviruses and molluscipoxvirus, and collectively 
named as viral-FLIP (v-FLIPs) (Bertin et al., 1997; Thome et al., 1997). 
Since CD95-induced apoptosis can effectively eliminate viral infected 
cells, viruses have evolved strategies to evade this destiny of the immune 
response. They express a number of inhibitory proteins to suppress 
apoptosis of the host cells. v-FLIPs, which consist of two DEDs with 
alternative C-tails, were shown to bind to the DED of FADD and 
interfere with caspase-8 interaction, thereby inhibit apoptosis induced by 
DRs in the infected host cells (Thome and Tschopp, 2001). Furthermore, 
the crystal structure v-FLIP MC195 (Fig 10) revealed that MC195 disrupt 
the DISC formation by preventing FADD-DED self-association rather 
than competing away procaspase-8. Thus, it is proposed that v-FLIPs 
regulate the DISC signaling at multiple levels (Yu and Shi, 2008). 
 
 
Figure 10. Crystal structure of the v-
FLIP MC159 protein. The DED consists 
of six α-helices, as numbered, connected 
by short loops. All FLIP proteins contain 
two DEDs, tightly associated with each 
other through a hydrophobic interface. 
DED1 is divergent from a typical DED 
fold, but DED2 is an authentic domain. 
The conserved Arg-X-Asp-Leu motif in 
the α6 helix is essential for the protein to 
regulate apoptosis (edited from Yu and 
Shi, 2008). 
 
 
 
The long and short mammalian homologues of v-FLIPs were 
characterized soon after and were named cellular-FLIP (c-FLIP), also 
known as Casper, I-FLICE, FLAME-1, CASH, CLARP, MRIT or usurpin 
(Goltsev et al., 1997; Hu et al., 1997; Inohara et al., 1997; Irmler et al., 
1997; Shu et al., 1997). Three isoforms have been detected at the protein 
level in humans, namely c-FLIP Long (c-FLIPL, 55 kDa), c-FLIP Short (c-
FLIPS, 26 kDa), and c-FLIP Raji (c-FLIPR, 24 kDa) (Djerbi et al., 2001). 
Notably, all three isoforms have the same DEDs, but the sequences of the 
splicing tails are isoform-specific (Fig 11). c-FLIPL is composed of 480 
amino acids and contains tandem DEDs and caspase-like domain, p20 
and p12, structurally resembling the initiator procaspase-8 and 
procaspase-10. The c-FLIPL C-terminal domain lacks catalytic activity 
due to the replacement of the crucial cysteine residue within the Gln-Ala-
Cys-X-Gly motif and a histidine residue within the His-Gly-motif 
? ??
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3.1 Viral and mammalian isoforms of FLIP
FLIP was first discovered while searching the genomes for the DED-
containing proteins to identify regulators of apoptotic caspases. It was 
found in several γ-herpesviruses and molluscipoxvirus, and collectively 
named as viral-FLIP (v-FLIPs) (Bertin et al., 1997; Thome et al., 1997). 
Since CD95-induced apoptosis can effectively eliminate viral infected 
cells, viruses have evolved strategies to evade this destiny of the immune 
response. They express a number of inhibitory proteins to suppress 
apoptosis of the host cells. v-FLIPs, which consist of two DEDs with 
alternative C-tails, were shown to bind to the DED of FADD and 
interfere with caspase-8 interaction, thereby inhibit apoptosis induced by 
DRs in the infected host cells (Thome and Tschopp, 2001). Furthermore, 
the crystal structure v-FLIP MC195 (Fig 10) revealed that MC195 disrupt 
the DISC formation by preventing FADD-DED self-association rather 
than competing away procaspase-8. Thus, it is proposed that v-FLIPs 
regulate the DISC signaling at multiple levels (Yu and Shi, 2008). 
 
 
Figure 10. Crystal structure of the v-
FLIP MC159 protein. The DED consists 
of six α-helices, as numbered, connected 
by short loops. All FLIP proteins contain 
two DEDs, tightly associated with each 
other through a hydrophobic interface. 
DED1 is divergent from a typical DED 
fold, but DED2 is an authentic domain. 
The conserved Arg-X-Asp-Leu motif in 
the α6 helix is essential for the protein to 
regulate apoptosis (edited from Yu and 
Shi, 2008). 
 
 
 
The long and short mammalian homologues of v-FLIPs were 
characterized soon after and were named cellular-FLIP (c-FLIP), also 
known as Casper, I-FLICE, FLAME-1, CASH, CLARP, MRIT or usurpin 
(Goltsev et al., 1997; Hu et al., 1997; Inohara et al., 1997; Irmler et al., 
1997; Shu et al., 1997). Three isoforms have been detected at the protein 
level in humans, namely c-FLIP Long (c-FLIPL, 55 kDa), c-FLIP Short (c-
FLIPS, 26 kDa), and c-FLIP Raji (c-FLIPR, 24 kDa) (Djerbi et al., 2001). 
Notably, all three isoforms have the same DEDs, but the sequences of the 
splicing tails are isoform-specific (Fig 11). c-FLIPL is composed of 480 
amino acids and contains tandem DEDs and caspase-like domain, p20 
and p12, structurally resembling the initiator procaspase-8 and 
procaspase-10. The c-FLIPL C-terminal domain lacks catalytic activity 
due to the replacement of the crucial cysteine residue within the Gln-Ala-
Cys-X-Gly motif and a histidine residue within the His-Gly-motif 
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(Cohen, 1997; Tschopp et al., 1998). The short isoforms of c-FLIP are 
DED-only splice variants, similar to v-FLIPs, consisting of short C-
terminal tails of 19 and 17 amino acids for c-FLIPS and c-FLIPR, 
respectively (Fig 11). Several properties of the short isoforms are similar, 
including their protein expression pattern during T cell activation, 
protein turnover and anti-apoptotic efficiencies (Djerbi et al., 2001; Golks 
et al., 2005). 
 
Figure 11. Domain structure of c-FLIP isoforms in viruses and 
mammals. FLIP contains two DEDs (DED1 in lighter and DED2 in 
darker grey), followed by an interlinking region and a C-terminal 
tail, which is unique for each isoforms (c-FLIP C-terminal regions 
are indicated in black). The long isoform of c-FLIP contains caspase-
like domain p20 and p12 subunits. MCV, Molluscum contagiosum 
virus; EHV, equine herpesvirus; HHV, human herpesvirus. 
 
 
The initial discovery demonstrated that the tandem DEDs of c-FLIP 
appeared to antagonize the DR signaling in the same manner as v-FLIP 
by competing with procaspase-8 for FADD interaction at the DISC. 
Despite some reports that characterized c-FLIPL as an anti-apoptotic 
protein that functions in a way analogous to v-FLIPs and c-FLIPS/R, 
others ascribed pro-apoptotic functions in the long isoform, referring to 
its assistance in the autocatalytic activation of procaspase-8 at the DISC. 
The detailed functions of c-FLIP will be discussed in the next chapter. 
 
 
3.2 Regulation of c-FLIP protein expression level  
 
The cellular activities are highly dependent on proteins and there are 
complex regulatory mechanisms that govern the cellular protein levels, 
which may occur at anytime from the transcription of genes to the 
degradation of proteins. c-FLIP is a dynamic regulator of caspase-8 
activation and elicit diverse cellular responses. Therefore, it is not 
surprising that the maintenance of c-FLIP level is indispensable. c-FLIPL 
is widely expressed in mammalian tissues, especially the heart, lymphoid 
tissue, skeletal muscle, and kidney. The short isoforms of c-FLIP are 
more specific to the lymphatic tissues (Irmler et al., 1997; Rasper et al., 
1998). In some cells, either c-FLIPS or c-FLIPR are expressed, whereas in 
v-FLIP 
(EHV-2, HHV-8) 
v-FLIP (MCV) 
DED1 DED2 
c-FLIPS 221 
c-FLIPR 213 
c-FLIPL 480 p20 p12 
1 75 91 172 
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others both short isoforms may be detected. In addition, cell lines contain 
different amounts of the isoforms; c-FLIPL is often more abundantly 
expressed than the short isoforms (Irmler et al., 1997; Rasper et al., 1998). 
The c-FLIP level is an important determinant of the DISC signaling 
outcome in various cell types, and the expression of c-FLIP often directly 
correlates with the sensitivity to DR-induced cell death. The dynamics of 
c-FLIP protein levels are critical to determine the outcome of apoptosis 
and are often regulated in an isoform-specific manner. In accordance 
with this, the expression of c-FLIP is tightly regulated by a number of 
different pathways. 
  
 
c-FLIP abundance regulated by protein synthesis and degradation 
 
The process of protein synthesis begins by transcribing a gene to 
messenger RNA (mRNA), which then is translated into a polypeptide of 
amino acids and folded into a specific conformation to yield a mature 
protein. The c-FLIP gene called CFLAR (CASP8 and FADD-like apoptosis 
regulator) is located on the human chromosome 2 q33-q34, in a cluster of 
approximately 200 kilobases with the initiator procaspase-8 and 
procaspase-10. This close proximity of gene location suggests that c-FLIP 
may have evolved as a gene-duplication of procaspase-8 (Han et al., 
1997; Inohara et al., 1997; Srinivasula et al., 1997). CFLAR is composed of 
fourteen exons and initially transcribed preRNA is processed through 
alternative splicing to yield several mRNA that contain different 
combinations of exons (Djerbi et al., 2001). Inclusion of CFLAR exon 7 
with a stop codon leads to translation of c-FLIPS, whereas c-FLIPL omits 
exon 7 to produce the full-length protein (Fig 12). In humans, the 
decision to express c-FLIPS or c-FLIPR is determined by a nucleotide 
polymorphism in a 3’ splice site of CFLAR. The splice-dead variant 
produces c-FLIPR at lower protein translation rate (Ueffing et al., 2008). c-
FLIPR lacks intron 6 exclusion and a stop codon at the start of the intron 
results in translation of the shortest c-FLIP isoform (Djerbi et al., 2001). 
To date, understanding of the regulation of the stability of c-FLIP mRNA 
is incomplete. In humans, protein-coding genes account for 2% of the 
genome. The rest are mostly transcribed into non-coding RNA. Protein-
coding mRNAs may carry biological activity that is independent of the 
protein it encodes, which may be be unrelated or paradoxal to the 
protein function (Holland et al., 2004). Since c-FLIP have many 
alternative splicing variants and some include introns, studying c-FLIP at 
RNA level may reveal important regulatory mechanism of c-FLIP 
expression and signaling. 
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Figure 12. Splice pattern of the human CFLAR. CFLAR consists of 
fourteen exons and the c-FLIP isoforms detected at the protein levels 
are shown. The start (arrowheads) and stop (asterisks) sites for 
translation are indicated. Black boxes in the short isoforms of c-FLIP 
represent intron sequences (Adapted from (Djerbi et al., 2001). 
 
 
Housekeeping genes are transcribed constitutively to produce proteins 
required for common cellular functions, while inducible genes are 
transcribed temporary upon stimulation to express proteins required for 
adaptive responses. The inducible genes are activated by the binding of a 
stimulated transcription factor to its specific binding site in the promoter 
region of the gene. The human proteome is dynamic and alters in 
response to a multitude of stimuli. Cells must converge various signals to 
activate appropriate transcription factors, which regulate the expression 
of target genes.  
 
c-FLIP is constitutively expressed in a wide array of normal cells, but the 
CFLAR gene is also a transcriptional target for a number of stimuli (Safa, 
2012). Pro-survival singnaling pathways that activate NF-κB (Karin and 
Lin, 2002; Kreuz et al., 2001; Mayo and Baldwin, 2000; Sevilla et al., 2001), 
Akt and ERK can upregulate c-FLIP (Nam et al., 2003; Panka et al., 2001; 
Suhara et al., 2001). These signaling pathways will be discussed more in 
later chapters. Furthermore, the consensus binding sites of the NFAT 
(nuclear factor of activated T cells) family is positioned in the CFLAR 
promoter and is recruited to induce c-FLIP expression (Rao et al., 1997; 
Zaichuk et al., 2004). Other transcription factors including c-Myc, FOXO3 
and c-Fos, on the other hand, binds directly to the promoter of CFLAR 
and suppresses the expression of c-FLIP (Ricci et al., 2004; Skurk et al., 
2004). CaMKII (calcium/calmodulin-dependent protein kinase II) 
activity induces the expression of both long and short isoforms of c-FLIP 
and protects cells from CD95-mediated apoptosis (Yang et al., 2003). The 
tumor suppressor p53 also regulates the expression of c-FLIP by 
upregulating the transcription or promoting protein degradation (Bartke 
et al., 2001). c-FLIP mRNA levels are regulated by many cytokines, an IL-
2 being the most studied. c-FLIP is suppressed in IL-2-dependent manner 
following T cell activation, which sensitizes cells to CD95-mediated 
apoptosis (Refaeli et al., 1998). From the emerging field of miRNA, it has 
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been reported that miR-512-3p negatively regulates c-FLIP expression 
(Chen et al., 2010).  
 
Protein degradation is another process that determines the abundance of 
proteins in a cell. The 26S proteasome is a eukaryotic ATP-dependent 
protease complex where targeted proteins are efficiently degraded. Here, 
the substrate is hydrolyzed into short polypeptides that are released 
from the proteasome, thereby, providing recyclable cell material (Finley, 
2009; Pickart and Eddins, 2004). Many reports have shown that c-FLIP is 
effectively degraded by the proteasome, which could be rescued using 
proteasome inhibitors (Fukazawa et al., 2001; Kim et al., 2002). c-FLIPS 
has a notably shorter half-life than c-FLIPL, although half-lives of the c-
FLIP proteins vary in a cell type-specific fashion. C-terminal tails are 
pivotal in regulating stability of the c-FLIP proteins, especially in the 
short isoforms (Poukkula et al., 2005). The rate of c-FLIP degradation can 
be altered by various stimuli. For example, hyperthermia sensitizes 
activated T cells to CD95-induce apoptosis, primarily due to induced 
down regulation of c-FLIPS by rapidly enhancing the proteasomal 
degradation (Meinander et al., 2007).  
 
 
Subcellular protein localization, a new insight into c-FLIP proteins 
 
The eukaryotic cells are compartmentalized by a plasma membrane, and 
endomembrane systems support the organelles inside the cell. These 
organelles provide distinct regions for a collection of proteins to reside 
and perform specific cellular processes. It is estimated that half of the 
proteins synthesized on cytosolic ribosomes must be transported into or 
across at least one cell membrane to reach their functional destination 
(Wickner and Schekman, 2005). Compartment-specific reactions can 
efficiently change concentration and kinetics by confining the protein in a 
smaller volume and achieve functional diversity and economize on 
protein design and synthesis (Butler and Overall, 2009). 
 
Since the main function of c-FLIP is considered to be anti-apoptotic 
acting at the intracellular region of plasma membrane, c-FLIP has been 
assumed to localize in the cytoplasm. One of the new concepts proposed 
for c-FLIP in the recent years is that c-FLIPL is expressed in both the 
cytoplasm and nucleus. So far, two groups have shown such 
observations in various cell lines and claim that two nuclear localization 
signals (NLSs), short stretches of amino acid sequences that target the 
protein to the nucleus, are found at the C-terminal tail of c-FLIPL and 
mutations at these sites obstructed the presence of nuclear c-FLIP 
(Katayama et al., 2010; Zhang et al., 2009). Additionally, a nuclear export 
signal (NES) between the two NLSs was identified (Fig 13) (Katayama et 
al., 2010). Proteins must localize appropriately to function properly in 
their biochemical reactions. Subcellular compartments have unique 
? ??
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protein compositions and mislocation of these proteins contributes to the 
pathogenesis of many diseases (Hung and Link, 2011). Further 
understanding of subcellular distribution of c-FLIP may contribute 
significantly to their functions. 
 
  1  MSAEVIHQVE EALDTDEKEM LLFLCRDVAI DVVPPNVRDL LDILRERGKL SVGDLAELLY 
 61  RVRRFDLLKR ILKMDRKAVE THLLRNPHLV SDYRVLMAEI GEDLDKSDVS SLIFLMKDYM 
121  GRGKISKEKS FLDLVVELEK LNLVAPDQLD LLEKCLKNIH RIDLKTKIQK YKQSVQGAGT 
181  SYRNVLQAAI QKSLKDPSNN FRLHNGRSKE QRLKEQLGAQ QEPVKKSIQE SEAFLPQSIP 
241  EERYKMKSKP LGICLIIDCI GNETELLRDT FTSLGYEVQK FLHLSMHGIS QILGQFACMP 
301  EHRDYDSFVC VLVSRGGSQS VYGVDQTHSG LPLHHIRRMF MGDSCPYLAG KPKMFFIQNY 
361  VVSEGQLEDS SLLEVDGPAM KNVEFKAQKR GLCTVHREAD FFWSLCTADM SLLEQSHSSP 
421  SLYLQCLSQK LRQERKRPLL DLHIELNGYM YDWNSRVSAK EKYYVWLQHT LRKKLILSYT  
             NES1       NLS                          NES2 
 
Fig 13. Amino acid sequence of human c-FLIPL. Amino acid 
residues of NLSs and NES are shown in bold and sequences are 
underlined and indicated. Domains are shaded in grey; darker grey, 
DED1; lighter grey, DED2.  
 
 
3.3 Post-translational modifications decipher protein behavior 
 
A protein is modified after its synthesis, a process known as post-
translational modifications (PTMs), in which covalent addition of a 
functional group or protein, or proteolytic cleavage of regulatory 
subunits occur. These modifications can appear shortly after translation 
to regulate the function of the protein, until the end to dictate 
degradation of the protein. Certain modifications affect distinct 
downstream responses, thereby increasing the functional diversity of a 
protein. The modifications are often reversible, providing further 
sophisticated means of regulation, and it further offers diversity to a 
protein by potential combinatory modifications. The PTMs play critical 
roles in the regulation of most cellular processes including apoptosis, 
proliferation and cell cycle, by altering a proteins conformation, binding 
properties, changing its activity localization or half-life. c-FLIP protein is 
indeed modified by PTMs, commonly by ubiquitination, 
phosphorylation and proteolysis.  
 
 
Ubiquitination determines the half-life of c-FLIP 
 
Ubiquitin, as the name suggests, is a widely expressed 8.5-kDa protein in 
cells throughout evolution. Its 76 amino acid sequence is highly 
conserved and it is involved in various cellular functions to drastically 
affect the biochemical properties by covalently being conjugated to target 
proteins (Hochstrasser, 2009; Schlesinger et al., 1975). Countless evidence 
demonstrate the involvement of ubiquitin conjugation in apoptosis 
regulation. For example, ubiquitination of the C-terminus of caspase-8 
upon TRAIL-ligand signaling increase its pro-apoptotic potential by 
? ??
stabilizing the dimer and subsequent cell death, while deubiquitination 
decrease caspase-8 activity (Jin et al., 2009). The initial covalent 
conjugation of ubiquitin to a side chain lysine is dependent on a three-
step enzyme cascade (Fig 14). ATP-dependent ubiquitin-activating E1 
yield an active ubiquitin, which is transferred to an E2 ubiquitin-
conjugating enzyme and brings the correct modifier to a suitable E3 
ubiquitin ligase (Pickart and Eddins, 2004). With the help of the E3 ligase, 
the E2 catalyze the binding of ubiquitin to the target protein in a process 
called ubiquitination. The diversity of the enzymes facilitating 
ubiquitination is represented in a hierarchical manner and in humans, 
two E1s, 38 E2s, and approximately 600 to 1000 E3s are expressed 
(reviewed by Ye and Rape, 2009). E3 ligases provide a flexible means of 
linking a conserved ubiquitin to potentially thousands of substrates. 
 
 
Figure 14. Depicted enzymatic cascade of ubiquitination. Ubiquitin 
(Ub) chains are assembled in a stepwise process that involves
ubiquitin-activating E1, ubiquitin-conjugating E2, and ubiquitin-
protein E3 ligases. During ubiquitination, the ubiquitin is either 
transferred from the E2 to the catalytic cysteine of the E3 HECT 
domain before it is conjugated to the target lysine of the substrate, or 
E3 RING ligase transfers the ubiquitin directly to the substrate 
(Rotin and Kumar, 2009). Some examples of ubiquitin linkage chains 
are classified and shown on the right (Ikeda and Dikic, 2008). 
 
 
Ubiquitin can modify substrate proteins in its monomeric form, called 
monoubiquitination, or conjugate proceeding ubiquitin to form 
polyubiquitin chains (Haglund and Dikic, 2005). Ubiquitin contains 
seven lysines (K), K6, K11, K27, K29, K33, K48, and K63, as well as the N-
terminal methionine, which all function as acceptor site for other 
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protein compositions and mislocation of these proteins contributes to the 
pathogenesis of many diseases (Hung and Link, 2011). Further 
understanding of subcellular distribution of c-FLIP may contribute 
significantly to their functions. 
 
  1  MSAEVIHQVE EALDTDEKEM LLFLCRDVAI DVVPPNVRDL LDILRERGKL SVGDLAELLY 
 61  RVRRFDLLKR ILKMDRKAVE THLLRNPHLV SDYRVLMAEI GEDLDKSDVS SLIFLMKDYM 
121  GRGKISKEKS FLDLVVELEK LNLVAPDQLD LLEKCLKNIH RIDLKTKIQK YKQSVQGAGT 
181  SYRNVLQAAI QKSLKDPSNN FRLHNGRSKE QRLKEQLGAQ QEPVKKSIQE SEAFLPQSIP 
241  EERYKMKSKP LGICLIIDCI GNETELLRDT FTSLGYEVQK FLHLSMHGIS QILGQFACMP 
301  EHRDYDSFVC VLVSRGGSQS VYGVDQTHSG LPLHHIRRMF MGDSCPYLAG KPKMFFIQNY 
361  VVSEGQLEDS SLLEVDGPAM KNVEFKAQKR GLCTVHREAD FFWSLCTADM SLLEQSHSSP 
421  SLYLQCLSQK LRQERKRPLL DLHIELNGYM YDWNSRVSAK EKYYVWLQHT LRKKLILSYT  
             NES1       NLS                          NES2 
 
Fig 13. Amino acid sequence of human c-FLIPL. Amino acid 
residues of NLSs and NES are shown in bold and sequences are 
underlined and indicated. Domains are shaded in grey; darker grey, 
DED1; lighter grey, DED2.  
 
 
3.3 Post-translational modifications decipher protein behavior 
 
A protein is modified after its synthesis, a process known as post-
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phosphorylation and proteolysis.  
 
 
Ubiquitination determines the half-life of c-FLIP 
 
Ubiquitin, as the name suggests, is a widely expressed 8.5-kDa protein in 
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stabilizing the dimer and subsequent cell death, while deubiquitination 
decrease caspase-8 activity (Jin et al., 2009). The initial covalent 
conjugation of ubiquitin to a side chain lysine is dependent on a three-
step enzyme cascade (Fig 14). ATP-dependent ubiquitin-activating E1 
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ubiquitin ligase (Pickart and Eddins, 2004). With the help of the E3 ligase, 
the E2 catalyze the binding of ubiquitin to the target protein in a process 
called ubiquitination. The diversity of the enzymes facilitating 
ubiquitination is represented in a hierarchical manner and in humans, 
two E1s, 38 E2s, and approximately 600 to 1000 E3s are expressed 
(reviewed by Ye and Rape, 2009). E3 ligases provide a flexible means of 
linking a conserved ubiquitin to potentially thousands of substrates. 
 
 
Figure 14. Depicted enzymatic cascade of ubiquitination. Ubiquitin 
(Ub) chains are assembled in a stepwise process that involves
ubiquitin-activating E1, ubiquitin-conjugating E2, and ubiquitin-
protein E3 ligases. During ubiquitination, the ubiquitin is either 
transferred from the E2 to the catalytic cysteine of the E3 HECT 
domain before it is conjugated to the target lysine of the substrate, or 
E3 RING ligase transfers the ubiquitin directly to the substrate 
(Rotin and Kumar, 2009). Some examples of ubiquitin linkage chains 
are classified and shown on the right (Ikeda and Dikic, 2008). 
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et al., 2010). In general, ubiquitin E3 ligases are important determinants 
of substrate selection. The majority of know E3s belongs to the HECT 
(homologous to the E6AP carboxyl terminus) or RING (really interesting 
new gene) and RING-like E3 ligases. The topology of ubiquitin chain is 
recognized by the specific ubiquitin receptors containing ubiquitin-
binding domains (UBD), which couple the ubiquitin-modified protein to 
other protein complexes or to a signaling pathway, thereby determining 
the output of the specific ubiquitination event. For example, K48-linked 
ubiquitin chains typically regulate protein stability, while K63-linked and 
M1-linked linear ubiquitin chains have crucial roles in signal 
transduction in the NF-κB signaling pathway (Gerlach et al., 2011; 
Hayden and Ghosh, 2008). The cysteine proteases that cleave ubiquitin 
from substrates to counter E3 ligase actions are called deubiquitinating 
enzymes (DUBs) (Hochstrasser, 1995). They also regulate the fate of 
ubiquitinated proteins and maintain ubiquitin homeostasis by producing 
free ubiquitin from synthesized fused ubiquitin or substrates (reviewed 
by Komander et al., 2009). 
 
The ubiquitin-proteasome system is required to dispose of misfolded and 
denatured proteins via the proteasome and thus the degradation system 
cannot be too discriminating. Nevertheless, certain proteins often 
involved in cell signaling have to be degraded in a selective manner. 
Typically, K48-linked ubiquitin chain of at least four ubiquitin molecules 
is required for the ubiquitin receptors on the proteasome to recognize the 
target for degradation (Thrower et al., 2000). In this way, ubiquitin-
mediated 26S proteasomal turnover regulate protein expression level in 
eukarytotic cells. The c-FLIP protein expression is strongly regulated by 
the ubiquitin-dependent degradation rate (Fukazawa et al., 2001). Several 
E3 ligases have been shown to regulate c-FLIP stability. For example, 
upon TNF-α stimulation, mild induction of JNK activates the E3 ligase 
Itch, which ubiquitinates the long isoform of c-FLIP through interaction 
with the caspase-like domain and leads to c-FLIPL-specific proteasomal 
degradation (Chang et al., 2006). In addition, mTOR (mammalian target 
of rapamycin) complex 2, which is a rapamycin insensitive complex, 
stabilizes c-FLIPS. When mTOR complex 2 is inhibited, c-FLIPS 
expression is decreased by Cbl-dependent ubiquitination and 
degradation of the protein (Zhao et al., 2013). The c-FLIP proteins share 
the 202 N-terminal amino acids but differ in their C-terminal regions, 
and it is these unique tails that dictate their particular stability. K192 and 
K195 in c-FLIPS play an important role in the ubiquitination and 
degradation of the protein (Poukkula et al., 2005). Furthermore, DNA 
repairing protein Ku70 interacts with DED2 of c-FLIP to regulate c-FLIP 
polyubiquitination, thereby protein stability (Kerr et al., 2012). 
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Phosphorylation determines the fate of c-FLIP turnover
Protein phosphorylation and dephoshorylation is the most prominent 
PTM in signal transduction networks in which external stimuli are 
transmitted into cellular responses. It has been estimated that a third of 
the proteins in the human proteome are substrates for phosphorylation 
and are modified at multiple sites (Cohen, 2000). Despite many protein 
modifications by a phosphate group is common, it occurs only at the side 
chain of three hydroxyamino acids, serine (S), threonine, and tyrosine, to 
create phospho-amino acids. They contain a nucleophilic group that 
transfers the terminal phosphate group of ATP to the amino acid side 
chain (Fig 15).  
 
Protein kinases are enzymes that catalyze the transfer of phosphate 
group to their substrates, including proteins, lipids, carbohydrates and 
nucleotides. The human proteome contain more than 500 kinases and 
80% of the mammalian kinome is comprised of Serine/Threonine 
kinases. The relative abundance ratio of phosphorylated 
Serine:Threonine:Tyrosine residues in a cell is estimated to be 1800:200:1 
(Mann et al., 2002). A covalently attached phosphate presents charged 
properties to the protein surface and acts as a new chemical unit. It 
causes conformational changes in the phosphorylated protein and 
regulates the catalytic activity or alters the ability to recruit other 
proteins. The activities of kinases are often under the control of its own 
phosphorylation status. Most kinases in their inactive state are 
dephosphorylated and stimulation-induced phosphorylation activates its 
regulatory units. Activated kinases then phosphorylate their 
corresponding downstream substrates, including other kinases, until the 
response is achieved or signaling is terminated. Protein phosphorylation 
is reversible and dephosphorylation of the substrate is mediated by 
protein phosphatases (Fig 15). It is estimated that the human proteome 
contain 150 phosphatases and together with kinases, facilitate the 
dynamic nature of phosphorylated proteins in a cell. 
 
 
Figure 15.  
Phosphorylation reaction. The 
kinase adds a phosphate group (P) 
from ATP to its substrate on its 
hydroxyl-group. Phosphatases, in 
turn dephosphorylate their 
substrates by hydrolysis. 
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promote recruitment of c-FLIP to the DISC and protects the cell from DR-
mediate apoptosis, while PKC and indirect phosphorylation by bile acid 
glycochenodeoxycholate decrease c-FLIPL affinity for FADD (Higuchi et 
al., 2003; Xiao et al., 2005; Yang et al., 2003). Furthermore, recent studies 
have begun to elucidate how the concerted phosphorylation and 
ubiquitination jointly regulates the stability of c-FLIP. Upon 
mycobacteria infection-induced TNF-α-mediated apoptosis, S4 and Y211 
of murine short c-FLIP isoform are phosphorylated by p38 and c-Abl, 
respectively (Fig 16). These phosphorylations were required to facilitate 
the interaction between murine c-FLIPR and the E3 ligase c-Cbl (Kundu et 
al., 2009). The Akt1-mediated phosphorylation on S273 has been reported 
to mediate proteasomal degradation of c-FLIPL during macrophage 
activation (Shi et al., 2009).  
 
Figure 16. TNFα-mediated PTM of 
murine c-FLIPS. Upon mycobacteria 
infection, phosphorylation (P) of c-FLIP 
induces degradative ubiquitination (Ub). 
Y211 is close to C-terminal tail 
ubiquitination site, thus may partly 
explain the regulation (Kundu et al., 
2009; Poukkula et al., 2005). 
 
 
Proteolytic cleavage of c-FLIP by caspase-8 
 
Proteolysis is a process that cleaves target proteins into smaller 
polypeptides commonly by enzymes called proteases. Proteolytic 
cleavage of a peptide bond is a thermodynamically favorable reaction 
and, therefore, the reaction is irreversible. Degradative proteolysis 
regulates protein concentrations, but proteases can also cleave signal 
peptides from nascent proteins and activating zymogens, or remove 
signal sequences after the protein is transported. As mentioned 
previously, caspases are proteases, which themselves are synthesized as 
precursor proteins and are cleaved to form their final active structure. 
 
c-FLIPL contains two aspartic acid cleavage sites, D198 between DED2 
and the caspase-like domain, and D376 between the subunits p12 and 
p20. They can be cleaved by caspase-8 upon heterodimerization in the 
DISC (Golks et al., 2006; Irmler et al., 1997; Scaffidi et al., 1999). 
Proteolytic cleavage of c-FLIPL after D376 (LEVD) release the p10 
fragment and generates p43-FLIP, and further cleavage of c-FLIP at D198 
generates p22-FLIP. Cleavage of c-FLIPL induces its degradation 
(Fukazawa et al., 2001). Moreover, these cleaved products play powerful 
roles in non-apoptotic signaling pathways and the degree of cleavages 
may influence the survival of a cell. Detailed mechanisms and functions 
of c-FLIP cleavage will be discussed in the next chapter. 
c-FLIPS 221 
P 
S4 
K192/195 
P 
Y211 
Ub Ub Ub 
DED1 DED2 
? ??
 
 
Figure 17. Cleavage sites of c-FLIPL. c-FLIPL may be cleaved after 
D376 by caspase-8 to produce the p43-FLIP isoform (43 kDa; 
cleavage product 1). D198 is found in all c-FLIP isoforms and, hence, 
caspase-8 can cleave all isoforms to produce p22-FLIP (22 kDa; 
cleavage product 2).
4. The dynamics of c-FLIP signaling in cell survival 
 
The specific regulation of the stability and localization of splice variants 
provides flexibility in protein functions and enables the cell to adapt to a 
changing environment. It is important that the expression of c-FLIP is 
tightly regulated, since vital cellular processes are reported to be 
influenced by c-FLIP. c-FLIP not only regulates the DISC signaling 
pathway in an isoform-specific manner, but recent studies have revealed 
that it is an important regulator in necroptosis. Furthermore, 
accumulating data show that c-FLIPL can function beyond cell death 
regulation by directly activating pro-survival signaling pathways. 
 
 
4.1 The anti-apoptotic role of FLIP 
 
The activation of caspase-8 occurs in two phases. Dimerization of 
procaspases at the DISC results in a cleavage to generate two 
intermediate subunits p43 and p12, followed by a second cleavage where 
the prodomain p26 and the fully active enzyme subunits p18 and p10 are 
produced. The active dimeric monomers oligomerize with one another to 
form a stable heterotetramer p102-p182 with full substrate processing 
capacity. These active caspase molecules are released from the DISC to 
the cytosol and initiate the apoptotic proteolytic cascade (Fig 18, left 
signaling) (Hughes et al., 2009; Oberst et al., 2010). Since the first 
discovery of FLIP, a great enthusiasm went into understanding the 
protein function regulating the caspase-8 activity in apoptotic signaling. 
Initially, v-FLIP was defined as an anti-apoptotic viral protein that 
blocked caspase-8 activation at the DISC, thereby inhibiting the 
mammalian host cell from cell death.  
 
 
 
 
c-FLIPL 480 p20 p12 
D198 D376 
DED1 DED2 
p43-FLIP 
p22-FLIP 
Cleavage 
products 
1 
2 
? ??
promote recruitment of c-FLIP to the DISC and protects the cell from DR-
mediate apoptosis, while PKC and indirect phosphorylation by bile acid 
glycochenodeoxycholate decrease c-FLIPL affinity for FADD (Higuchi et 
al., 2003; Xiao et al., 2005; Yang et al., 2003). Furthermore, recent studies 
have begun to elucidate how the concerted phosphorylation and 
ubiquitination jointly regulates the stability of c-FLIP. Upon 
mycobacteria infection-induced TNF-α-mediated apoptosis, S4 and Y211 
of murine short c-FLIP isoform are phosphorylated by p38 and c-Abl, 
respectively (Fig 16). These phosphorylations were required to facilitate 
the interaction between murine c-FLIPR and the E3 ligase c-Cbl (Kundu et 
al., 2009). The Akt1-mediated phosphorylation on S273 has been reported 
to mediate proteasomal degradation of c-FLIPL during macrophage 
activation (Shi et al., 2009).  
 
Figure 16. TNFα-mediated PTM of 
murine c-FLIPS. Upon mycobacteria 
infection, phosphorylation (P) of c-FLIP 
induces degradative ubiquitination (Ub). 
Y211 is close to C-terminal tail 
ubiquitination site, thus may partly 
explain the regulation (Kundu et al., 
2009; Poukkula et al., 2005). 
 
 
Proteolytic cleavage of c-FLIP by caspase-8 
 
Proteolysis is a process that cleaves target proteins into smaller 
polypeptides commonly by enzymes called proteases. Proteolytic 
cleavage of a peptide bond is a thermodynamically favorable reaction 
and, therefore, the reaction is irreversible. Degradative proteolysis 
regulates protein concentrations, but proteases can also cleave signal 
peptides from nascent proteins and activating zymogens, or remove 
signal sequences after the protein is transported. As mentioned 
previously, caspases are proteases, which themselves are synthesized as 
precursor proteins and are cleaved to form their final active structure. 
 
c-FLIPL contains two aspartic acid cleavage sites, D198 between DED2 
and the caspase-like domain, and D376 between the subunits p12 and 
p20. They can be cleaved by caspase-8 upon heterodimerization in the 
DISC (Golks et al., 2006; Irmler et al., 1997; Scaffidi et al., 1999). 
Proteolytic cleavage of c-FLIPL after D376 (LEVD) release the p10 
fragment and generates p43-FLIP, and further cleavage of c-FLIP at D198 
generates p22-FLIP. Cleavage of c-FLIPL induces its degradation 
(Fukazawa et al., 2001). Moreover, these cleaved products play powerful 
roles in non-apoptotic signaling pathways and the degree of cleavages 
may influence the survival of a cell. Detailed mechanisms and functions 
of c-FLIP cleavage will be discussed in the next chapter. 
c-FLIPS 221 
P 
S4 
K192/195 
P 
Y211 
Ub Ub Ub 
DED1 DED2 
? ??
 
 
Figure 17. Cleavage sites of c-FLIPL. c-FLIPL may be cleaved after 
D376 by caspase-8 to produce the p43-FLIP isoform (43 kDa; 
cleavage product 1). D198 is found in all c-FLIP isoforms and, hence, 
caspase-8 can cleave all isoforms to produce p22-FLIP (22 kDa; 
cleavage product 2).
4. The dynamics of c-FLIP signaling in cell survival 
 
The specific regulation of the stability and localization of splice variants 
provides flexibility in protein functions and enables the cell to adapt to a 
changing environment. It is important that the expression of c-FLIP is 
tightly regulated, since vital cellular processes are reported to be 
influenced by c-FLIP. c-FLIP not only regulates the DISC signaling 
pathway in an isoform-specific manner, but recent studies have revealed 
that it is an important regulator in necroptosis. Furthermore, 
accumulating data show that c-FLIPL can function beyond cell death 
regulation by directly activating pro-survival signaling pathways. 
 
 
4.1 The anti-apoptotic role of FLIP 
 
The activation of caspase-8 occurs in two phases. Dimerization of 
procaspases at the DISC results in a cleavage to generate two 
intermediate subunits p43 and p12, followed by a second cleavage where 
the prodomain p26 and the fully active enzyme subunits p18 and p10 are 
produced. The active dimeric monomers oligomerize with one another to 
form a stable heterotetramer p102-p182 with full substrate processing 
capacity. These active caspase molecules are released from the DISC to 
the cytosol and initiate the apoptotic proteolytic cascade (Fig 18, left 
signaling) (Hughes et al., 2009; Oberst et al., 2010). Since the first 
discovery of FLIP, a great enthusiasm went into understanding the 
protein function regulating the caspase-8 activity in apoptotic signaling. 
Initially, v-FLIP was defined as an anti-apoptotic viral protein that 
blocked caspase-8 activation at the DISC, thereby inhibiting the 
mammalian host cell from cell death.  
 
 
 
 
c-FLIPL 480 p20 p12 
D198 D376 
DED1 DED2 
p43-FLIP 
p22-FLIP 
Cleavage 
products 
1 
2 
? ??
Inhibition of apoptosis at the DISC
c-FLIP proteins are recruited to the DISC via DED interactions (Irmler et 
al., 1997; Scaffidi et al., 1999). Short c-FLIP isoforms effectively block DR-
induced apoptosis via binding to the DISC and inhibiting procaspase-8 
processing into its active form, thereby functioning as dominant-negative 
regulators (Fig 18, right signaling) (Golks et al., 2005; Krueger et al., 
2001). c-FLIPL was simultaneously identified by several groups, who 
inconsistently described either anti- or pro-apoptotic regulatory role in 
the DISC. Anti-apoptotic behavior of c-FLIPL was shown at high levels of 
ectopic expression, by competing with procaspase-8 for the DED binding 
sites of FADD (Scaffidi et al., 1999). Furthermore, c-FLIP knockout mouse 
embryonic fibroblasts (MEFs) are highly sensitive to caspase-8 mediated 
apoptosis compared to the wild-type MEFs (Yeh et al., 2000).  
 
 
Figure 18. Different signaling pathways initiated at the DISC by 
modulation of c-FLIP. Homodimeric procaspase-8 is processes to its 
activated form by autocleavage to generate prodomains and a 
heterotetramer of two p10 and two p18 active subunits. The 
prodomains of caspase-8 molecules stay in the DISC, whereas the 
active subunit dissociates to the cytoplasm (left signaling). Hetero-
dimerization of procaspase-8 and c-FLIPL permits partial processing 
to its p43/p10 cleavage fragment, caspase-8 remains associated 
within the complex and apoptosis is inhibited (middle signaling). 
Short isoforms of c-FLIP prevent caspase-8 activation (right 
signaling). Furthermore, at high concentration of c-FLIP, procaspase-
8 is competed out for binding to FADD at the DISC. 
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On the contrary, endogenous c-FLIPL heterodimerizes with procaspase-8 
to promote partial processing of caspase-8 for non-apoptotic functions 
(Micheau et al., 2002). Heterodimerization of procaspase-8 and c-FLIPL 
allows an activation loop in the C-terminal caspase-like domain of c-
FLIPL to overlap and expose the enzymatic region of procaspase-8 
permitting the first cleavage to occur (Chang et al., 2002). The second 
cleavage of caspase-8 is inhibited however, resulting in a release of the 
p10 fragment and partially active p43-caspase-8 molecule (Fig 18, middle 
signaling). The heterodimer is proteolytically active, but has a restricted 
substrate repertoire due to the low caspase-8 catalytic activity at the 
DISC. Formation of the heterodimers do not initiate apoptotic signaling, 
but result in a low level activation directed against local substrates, 
which include themselves and the necroptosis mediator RIPKs (Irmler et 
al., 1997; Kavuri et al., 2011; Micheau et al., 2002; Scaffidi et al., 1999). 
Interestingly, this heterodimerization of c-FLIP and caspase-8 occur with 
higher affinity and tighter interaction via hydrogen bonds than 
procaspase-8 homodimerization (Boatright et al., 2004; Jong et al., 2009). 
Therefore, at physiological c-FLIPL levels, heterodimerization occur more 
readily and this provides further refining regulation of caspase-8 
activation in the DISC signaling pathways. In such situation, it is only 
after caspase-8 in heterodimer is cleaved by an external protease, that 
caspase-8 becomes pro-apoptotic. 
 
 
c-FLIP as a rheostat in the induction of necroptosis 
 
Recent advances in the study of death inducing complexes revealed that 
c-FLIP could shift the outcome of cell death between apoptosis and 
necroptosis in an isoform-specific manner. The formation of procaspase-8 
homodimers within multiprotein complexes fully activates caspase-8 and 
trigger apoptosis. In contrast, heterodimerization of procaspase-8 and c-
FLIPL results in limited catalytic activity of the caspase, not sufficient to 
initiate apoptosis, but enough to cleave RIPKs, thereby inhibiting the 
induction of necroptosis (O’Donnell et al., 2011; Oberst et al., 2011). This 
regulation by c-FLIP can be observed in TNF-α−TNFR1-mediated 
formation of complex IIa and complex IIb. When the activation of 
caspase-8 is prevented in complex IIa to initiate apoptosis, RIPK1 and 
RIPK3 accumulate, leading to increased formation of the necrosome 
(complex IIb) and consequently initiate necroptosis (Fig 6).  
 
Another example of c-FLIP-mediated cell death decision occurs in the 
ripoptosome, which is a cytosolic death-inducing complex. The 
ripoptosome is spontaneously formed upon depletion of cIAP1/2, which 
function as E3 ligases and degrades RIP1, and accumulated RIPK1, 
FADD and procaspase-8 are assembled, thereby activating RIPK or 
caspase-8 (Tenev et al., 2011). The ripoptosome can stimulate caspase-8-
mediated apoptosis as well as caspase-independent necroptosis, and the 
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modulation of c-FLIP. Homodimeric procaspase-8 is processes to its 
activated form by autocleavage to generate prodomains and a 
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within the complex and apoptosis is inhibited (middle signaling). 
Short isoforms of c-FLIP prevent caspase-8 activation (right 
signaling). Furthermore, at high concentration of c-FLIP, procaspase-
8 is competed out for binding to FADD at the DISC. 
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On the contrary, endogenous c-FLIPL heterodimerizes with procaspase-8 
to promote partial processing of caspase-8 for non-apoptotic functions 
(Micheau et al., 2002). Heterodimerization of procaspase-8 and c-FLIPL 
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Therefore, at physiological c-FLIPL levels, heterodimerization occur more 
readily and this provides further refining regulation of caspase-8 
activation in the DISC signaling pathways. In such situation, it is only 
after caspase-8 in heterodimer is cleaved by an external protease, that 
caspase-8 becomes pro-apoptotic. 
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homodimers within multiprotein complexes fully activates caspase-8 and 
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FLIPL results in limited catalytic activity of the caspase, not sufficient to 
initiate apoptosis, but enough to cleave RIPKs, thereby inhibiting the 
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regulation by c-FLIP can be observed in TNF-α−TNFR1-mediated 
formation of complex IIa and complex IIb. When the activation of 
caspase-8 is prevented in complex IIa to initiate apoptosis, RIPK1 and 
RIPK3 accumulate, leading to increased formation of the necrosome 
(complex IIb) and consequently initiate necroptosis (Fig 6).  
 
Another example of c-FLIP-mediated cell death decision occurs in the 
ripoptosome, which is a cytosolic death-inducing complex. The 
ripoptosome is spontaneously formed upon depletion of cIAP1/2, which 
function as E3 ligases and degrades RIP1, and accumulated RIPK1, 
FADD and procaspase-8 are assembled, thereby activating RIPK or 
caspase-8 (Tenev et al., 2011). The ripoptosome can stimulate caspase-8-
mediated apoptosis as well as caspase-independent necroptosis, and the 
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outcome of the complex formation is regulated by c-FLIP in an isoform-
specific manner. The presence of c-FLIPL will partially activate caspase-8 
with enough catalytic action to cleave and deactivate RIPK1. When 
procaspase-8 and c-FLIPS heterodimerization predominates, on the other 
hand, caspase activation and RIPK1 cleavage are prevented, and if 
caspase-8 activity remains absent, active RIPK will eventually execute the 
cell death by necroptosis. In this situation, apoptosis is blocked and the 
mode of cell death is instead switched to necroptosis (Feoktistova et al., 
2011). Thus far, c-FLIP is the only protein identified that can prevent 
RIPK or caspase-8 full activation to cell death. Taken together, caspase-8-
c-FLIPL heterodimers are important in maintaining homeostasis by 
negatively regulating necroptotic cell death.  
 
 
4.2 Pro-survival roles of FLIP in signal transduction 
 
Accumulative studies have revealed that the apoptosis signaling 
pathway is regulated by various mediators and that there is a dynamic 
crosstalk with other signaling pathways. The expression of inducible 
genes coordinated by various transcription factors is an important 
determinant in regulating the level of apoptotic proteins. In contrast to c-
FLIPS/R, the biological functions of c-FLIPL extend beyond being a 
regulator of DR-mediated apoptosis. In addition to its function in cell 
death, c-FLIPL is implicated in cell survival and proliferation. c-FLIPL 
itself is processed by caspase-8 after D379 to produce p43-FLIP, a cleaved 
product with survival promoting properties. p43-FLIP functions by 
recruiting the adaptor proteins involved in different pro-survival 
signaling pathways. c-FLIP clearly has multiple roles in pro-survival 
pathway, but further studies are required to clarify the source of 
variations between different studies. 
 
 
c-FLIP determines the outcome of NF-κB signaling 
 
NF-κB proteins are an evolutionary conserved family of nuclear 
transcription factors that regulate approximately three hundred genes, 
including those regulating inflammation, immune response to infections, 
apoptosis, and cell proliferation (Bonizzi and Karin, 2004; Gerondakis et 
al., 1999; Gilmore, 2006; Hayden and Ghosh, 2004; Pasparakis et al., 2006; 
Sen and Baltimore, 1986). In unstimulated cells, NF-κB is sequestered by 
inhibitor of κB (IκB) that binds and retains NF-κB in the cytoplasm 
(Ghosh and Karin, 2002). In the conventional pro-inflammatory TNF-α 
signaling pathway, TNFR1 recruit TRADD and NF-κB activating 
components to form complex I. The multiprotein complex is an 
ubiquitin-dependent signaling platform. It is modified by K63-linked 
ubiquitination of RIPK1 by the E3 ligases TNF receptor-associated factor 
2 (TRAF2) and cIAP1/2, and linear ubiquitination of the IκB kinase (IKK) 
? ??
complex by linear ubiquitin chain assembly complex (LUBAC), which 
provides stability to the complex for efficient activation of the IKK 
complex regulatory unit, NF-κB essential modulator (NEMO) (Haas et 
al., 2009; Poyet et al., 2000; Zhang et al., 2000). The IKK complex is 
postulated to be a gatekeeper of NF-κB activation as it phosphorylates 
IκB, which subsequently ubiquitinates and leads to degradation of IκB by 
the 26S proteasome (reviewed by Perkins, 2007). Freed NF-κB exposes its 
NLS and translocates to the nucleus, where it regulate gene expression 
by binding to the κB sites (Fig 19) (Hayden and Ghosh, 2004). Survival 
pathways induced via DRs are primarily mediated via the TNFR, 
although low-level stimulations of CD95 and TRAIL signaling also have 
been reported to convey survival signaling properties (Falschlehner et 
al., 2007; Siegel et al., 2000). Activation of the canonical NF-κB pathway 
induces resistance to both extrinsic and intrinsic apoptotic pathways by 
upregulating the expression level of anti-apoptotic and pro-survival 
proteins (Van Antwerp et al., 1996). The regulatory circuit of NF-κB 
signaling reinforces the decision-making, which leads to a rapid 
amplification and dominates the survival signaling. c-FLIP is one potent 
and early target of NF-κB and indeed contributes greatly to NF-κB-
mediated regulation of death signals. Expression of c-FLIP under the 
control of the NF-κB results in increased resistance to the DR-mediated 
apoptosis (Kreuz et al., 2001; Micheau et al., 2001). Deubiquitination of 
RIPK1 drives the conversion of the complex I to II, where the complex 
dissociate into the cytoplasm to form other signaling platforms; complex 
IIa to initiate apoptosis by recruiting FADD and procaspase-8, or 
complex IIb to initiate necroptosis by activating RIPK1 and RIPK3 (Fig 6) 
(Gerlach et al., 2011; Ikeda et al., 2011). c-FLIP takes part in the regulatory 
circuit by inhibiting the activation of caspase-8 in complex IIa (Fig 19) 
(Kreuz et al., 2001; Micheau et al., 2001; Yeh et al., 2000). c-FLIPL acts as a 
dual functioning molecular switch in complex II by regulating both the 
apoptotic and necrotic programmed mode of cell death (Fig 2). If the c-
FLIP expression is low, it is inadequate to inhibit the activation of 
caspase-8 induced by complex IIa (Micheau and Tschopp, 2003). For 
example, TNFα-mediated JNK activation antagonizes NF-κB activation 
by increasing the turnover of c-FLIPL (Chang et al., 2006).  
 
Furthermore, overexpression of c-FLIPL in various cell lines has been 
shown to trigger strong activation of the NF-κB signaling pathway in a 
DED-dependent manner (Chaudhary et al., 2000; Hu et al., 2000; Kataoka 
et al., 2000). Procaspase-8 proteolytic cleavage of the flexible intersubunit 
linker within the c-FLIPL protease-like domain produces p43-FLIP and 
promotes the recruitment of TRAF2 and RIP1. This leads to the RIP1 
ubiquitination and interaction with NEMO, thereby activating NF-κB 
efficiently (Dohrman et al., 2005; Kataoka and Tschopp, 2004). This 
phenomenon was further supported by v-FLIPs that potently activate the 
pathway via interacting with TRAF2 (Chaudhary et al., 1999; Field et al., 
2003; Guasparri et al., 2004). p43-FLIP cleaved by procaspase-8 generates 
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promotes the recruitment of TRAF2 and RIP1. This leads to the RIP1 
ubiquitination and interaction with NEMO, thereby activating NF-κB 
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2003; Guasparri et al., 2004). p43-FLIP cleaved by procaspase-8 generates 
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a p22-FLIP isoform that only consists of its amino terminal tandem DEDs 
and directly interacts with NEMO in non-apoptotic cells (Golks et al., 
2006). In addition, c-FLIP was shown to interact with p105, a precursor of 
the NF-κB subunit and atypical IκB molecule, and inhibited the 
processing of p105 into p50 and IκB-γ (Li et al., 2003). Furthermore, c-
FLIP regulates DR-induced NF-κB activity. Some studies indeed show 
induced NF-κB activation upon DR stimulation in the presence of c-FLIP, 
while other studies convincingly show that c-FLIP strongly inhibits NF-
κB in the presence of the same DRs (Iyer et al., 2011; Kataoka et al., 2000; 
Kavuri et al., 2011; Micheau and Tschopp, 2003; Wachter et al., 2004). 
 
Figure 19. Simplified canonical NF-κB signaling pathway with 
emphasis on the regulatory roles of c-FLIP. Stimulation of TNFR1 
by TNF-α induces the formation of complex I. Activation of the IKK 
complex (depicted as the regulatory component, NEMO) releases 
NF-κB from IκB. Activated NF-κB rapidly transcribes a number of 
anti-apoptotic genes including c-FLIP. Some components of complex 
I form complex IIa and induce apoptosis. c-FLIP can augment the 
survival signaling by p43-FLIP association with RIP1, TRAF2 and 
NEMO to promote NF-κB activation, or inhibit apoptosis in complex 
II, as indicated with dotted lines.  
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Regulation of MAPK pathways by c-FLIPL 
 
The mitogen-activated protein kinase (MAPK) family transmits signaling 
from extracellular stimuli and regulates pro-survival processes, such as 
cell differentiation, inflammation, and immune regulations. The MAPK 
family consists of different signaling cascades including the extracellular 
signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and the 
p38 kinase pathway.  
 
Various c-FLIP-mediated alterations have been observed in MAPK 
signaling pathways. The protein kinase Raf, MAPK kinase (MEK) and 
ERK constitute the classical ERK pathway. This kinase signaling cascade 
transmits mitogenic signals from Ras, which is activated by the cell 
surface receptors, to the nucleus and regulates the transcription of genes 
that drives cell proliferation and differentiation. The ERK activity has 
been shown to directly inhibit DR-induced apoptosis by preventing the 
caspase activation (Holmström et al., 2000; Tran et al., 2001). c-FLIP 
recruitment to the TRAIL-R DISC inhibits caspase-8 cleavage and 
couples NF-κB and ERK for cell survival in TRAIL-resistant cells (Song 
and Lee, 2008). Overexpression of c-FLIPL has been shown to augment 
ERK in T cells upon TCR activation (Kataoka et al., 2000). Furthermore, c-
FLIP-induced ERK activation is dependent on the presence of PI3K in B 
cell receptor signaling (Fang et al., 2004). On the contrary, non-apoptotic 
CD95 stimulation-induced ERK1/2 and p38 activations are inhibited by 
high expression of all c-FLIP isoforms (Kober et al., 2011). Although c-
FLIP is not required for JNK activation (Yeh et al., 2000), c-FLIPL inhibits 
JNK in a TNF-α-mediated signaling by directly binding to MAPK kinase 
(MKK)-7 (Nakajima et al., 2006). 
 
 
Induced Wnt signaling by overexpression of c-FLIPL 
 
The Wnt signaling pathway is important for the embryonic development, 
where it regulates proper formation of various tissues and organs. The 
canonical Wnt signaling pathway is dependent on β-catenin, a signal 
transducer that also plays a role in cell-cell adhesion. In unstimulated 
cells, free cytosolic β-catenin is maintained at low level by 
phosphorylation-induced proteasomal degradation regulated by a 
multiprotein complex containing GSK-3β  (glycogen synthase kinase-3β). 
Upon the activation of Wnt, β-catenin degradative ubiquitination is 
inhibited, causing β-catenin to accumulate and translocate to the nucleus. 
Here, β-catenin interacts with transcription factors of the TCF/LEF (T-
cell factor/lymphoid-enhancer factor) family, which in turn activate their 
target genes important in development to promote the cell growth 
(Clevers, 2006; Logan and Nusse, 2004).  
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Overexpressed FLIP proteins are prone to aggregation and cause 
impairment to the ubiquitin-proteasome system, thereby accumulating 
short-lived proteins in the cell. β-catenin is one of such proteins, and as a 
consequence, the downstream Wnt signaling pathway is enhanced 
(Ishioka et al., 2007; Naito et al., 2004; Nakagiri et al., 2005). Conversely, 
depletion of the endogenous c-FLIP protein reduces the signaling (Naito 
et al., 2004). Moreover, a report further described that nuclear c-FLIPL has 
a positive role in Wnt signaling by directly modulating the β-catenin-
mediated gene expression (Katayama et al., 2010). 
 
 
PI3K/Akt signaling pathway and c-FLIPL 
 
Akt (also known as protein kinase B) is a serine/threonine kinase, which 
plays a role in cell viability by promoting survival and inhibiting 
apoptosis. Akt is activated via phospho-inositides, which in turn are 
generated by phosphatidylinositide-3-kinase (PI3K) upon mitogen-
induced activation of Ras (Toker, 2000). The PI3K/Akt pathway 
upregulates the protein level of c-FLIP to inhibit DR-mediated apoptosis 
(Moriyama and Yonehara, 2007). Respectively, hindering PI3K or Akt 
activity reduces the expression of c-FLIP and sensitizes cells to DR-
mediated apoptosis (Suhara et al., 2001).  
 
c-FLIPL, in turn, has been demonstrated to mediate the activation of 
PI3K/Akt pathway. c-FLIPL can enhance the anti-apoptotic activity of 
Akt by modulating GSK-3β (Quintavalle et al., 2010). CD95 activates 
several survival signaling pathways, including NF-κB and PI3K/Akt. 
The latter has an inhibitory effect on NF-κB activation upon CD95 
stimulation and c-FLIPL has been suggested to regulate the crosstalk by 
augmenting phosphorylation of Akt in the presence of CD95L (Iyer et al., 
2011). Furthermore, c-FLIP can directly interact with Akt and acts as a 
substrate for the kinase upon the activation of macrophage (Shi et al., 
2009). 
 
 
Autophagy regulation by c-FLIP 
 
Macroautophagy, or simply referred to as autophagy, is a homeostatic 
response in which intracellular constituents are engulfed to form double-
membrane autophagosomes, which are delivered to lysosomes for a bulk 
catabolic degradation. The degradation mobilizes nutrient products and 
the process is also utilized as a response to stress. Autophagy has 
cytoprotective physiological roles in starvation adaptation, protein and 
organelle clearance, and elimination of microorganisms and apoptotic 
cells. A cell death as the result of progressive cellular consumptions has 
been attributed to excessive autophagy.  
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Emerging evidences indicate that both viral and cellular FLIPs suppress 
the initiation of autophagosome biogenesis by binding to Atg 
(Autophagy-related)-3 E2-like enzyme and preventing Atg3 from 
processing LC3 ubiquitin-like proteins. LC3 must be inserted into the 
membrane of autophagic vesicle for expansion, and therefore, short c-
FLIP isoforms prevent autophagosome formation. Subsequently, the 
autophagic killing was rescued by overexpression of FLIP (Lee et al., 
2009; Liang, 2010). Furthermore, LC3 is rapidly translocated to death cell-
containing phagosomes, but the role of c-FLIP is yet to be determined. 
 
 
Regulation of caspase-8 in pro-survival signaling 
 
The activity of caspase-8 also has functions outside the extrinsic 
apoptotic signaling. Caspase-8 is sequestered in different cellular 
compartments following an initiation of cell proliferation or death, 
thereby profoundly altering the access of caspase-8 to its substrates. A 
diverse role of caspase-8 has been reported. For example, caspase-8 can 
initiate the NF-κB activation independently of its proteolytic activity (Jun 
et al., 2004). Furthermore, it can interact with integrins to regulate cell 
migration (Barbero et al., 2009). More recent studies have shown that 
caspase-8 is activated in the inflammasome to induce apoptosis 
(Sagulenko et al., 2013), or to modulate the production of IL-1β upon 
macrophage activation (Man et al., 2013). c-FLIP is an important 
regulator that can fine-tune the degree of caspase-8 activation at the 
DISC. Therefore, c-FLIP may further influence various signaling 
pathways indirectly via regulating caspase-8 activity in its diverse 
functions. The role of c-FLIP is yet to be defined in many of these atypical 
caspase-8 signaling pathways. For these arising questions to be 
answered, quantification analysis of isoform-specific c-FLIP functions, 
such as absolute subcellular protein concentrations and rate of reactions, 
would advance the understanding of c-FLIP signaling. 
 
 
4.3 Modeling the dynamic cell death signaling pathway 
 
The biochemical properties of key proteins in apoptosis are well 
understood and much of the introduction focused on the qualitative 
descriptions of c-FLIP protein and its related aspects. However, not all 
the information reported on c-FLIP is referred to, since it is simply 
overwhelming to read and fit all the c-FLIP data available into one thesis. 
Conjointly, understanding quantitative descriptions, which are highly 
influential in a biological system, makes it difficult to determine the exact 
context-dependent outcome of c-FLIP signaling. Comprehending the 
network-based interplay and resulting outcome of c-FLIP signaling is 
? ??
Overexpressed FLIP proteins are prone to aggregation and cause 
impairment to the ubiquitin-proteasome system, thereby accumulating 
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network-based interplay and resulting outcome of c-FLIP signaling is 
? ??
therefore necessary. To understand such highly complex biological 
responses on a system biology scale mathematical modeling approach is 
increasingly being employed. It adds significance to the qualitative 
signaling pathways by analyzing the dynamic co-regulation of 
components and interactions, and describes the statistical properties of 
the network as a summary of biological system.  
 
To construct a mathematical model, a scheme that depicts the signaling 
pathway of interest is designed and a set of mathematical equations for 
each reaction is fitted. Sensitivity analysis and parameter estimation 
identify the important components in the modeled signaling pathway 
and to determine the parameter values and the fit of simulated model. A 
model is usually trained against data obtained by laboratory experiments 
for validation so they can be applied to deterministic biochemical models 
(Fig 20). Measurements and quantitative data is an important task in 
computational cell biology. Although the development of biologically 
representative models of mammalian cells for computation remains a 
challenge, with the development of quantitative molecular-biological 
techniques, mathematical modeling is becoming more reliable for 
biological use. It is through the development and analysis of such models 
that we will be able to understand the basic design principles of a cell 
and it enables the identification of components that are critical in the 
signaling system.  
 
Owing to the amount of information available from diverse cell death 
studies, development of mathematical models has been expanding since 
the first mathematical model, merging caspase function and apoptotic 
pathway was published (Fussenegger et al., 2000). Various mathematical 
models of apoptotic signaling are cumulatively generated to convey the 
cell death circulatory (Rehm and Prehn, 2013). Such model equations 
include ordinary differential equations (ODEs) (Albeck et al., 2008; 
Bentele et al., 2004; Fricker et al., 2010; Fussenegger et al., 2000; Neumann 
et al., 2010; Rehm et al., 2006), Boolean modeling (Calzone et al., 2010; 
Schlatter et al., 2009), Petri nets (Chen et al., 2007; Heiner et al., 2004; 
Heiner, 2009), cellular automata (Düssmann et al., 2009), and agent-based 
models (Schleich et al., 2012).  
 
? ??
 
Figure 20. Workflow for creating a mathematical model.   First, the 
signaling pathway of interest is determined and mathematical 
equation is applied to build a model. Sensitivity analysis and 
parameter estimation is performed to determine each reaction, 
which are compared with quantitative experimental data to fit the 
model (adapted from Cho et al., 2003). 
 
 
Advance in quantitative modeling of extrinsic apoptotic signaling 
pathway, especially of the kinetics of DR-induced caspase-8 activation, 
has given new insight into the cell death mechanisms. When cells are 
stimulated with death ligands, there is a rapid activation of upstream 
signaling, followed by a duration in which cells enforce their decision to 
die or survive. Should a cell decide to die, a sudden activation of 
downstream signaling occurs to insure an efficient removal of the cell 
(Rehm et al., 2002; Tyas et al., 2000; Vaughan et al., 2002). Modeling has 
revealed that this duration of delayed responses varies between cells due 
to differences in the activities of receptor-proximal biochemical reactions 
(Albeck et al., 2008). The source of cellular heterogenicity has been 
demonstrated by collective modeling studies. The variability in the 
timing and probability for DR-mediated apoptosis to occur within a 
population of cells is mainly due to naturally occurring differences in the 
levels and status of proteins (Spencer et al., 2009). The cell fate is 
transiently inherited as the protein status is transmitted to daughter cells 
after cell division (Rosenfeld et al., 2005). Later, however, protein 
synthesis promotes divergence and therefore sister cells no longer 
respond similarly to the same death ligand (Kaufmann et al., 2007; Sigal 
et al., 2006). The stoichiometry of the DISC components is highly crucial 
in determining how the DR signal will be transduced in the cell. The 
CD95-FADD homotypic DD complex predominantly assembles at a ratio 
of 5:5 (Esposito et al., 2010; Wang et al., 2010). An endogenous DISC 
structural model proposes that DED-dependent caspase-8 chain 
assembly upon DR ligation is common for inducing apoptosis by TRAIL 
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parameter estimation is performed to determine each reaction, 
which are compared with quantitative experimental data to fit the 
model (adapted from Cho et al., 2003). 
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timing and probability for DR-mediated apoptosis to occur within a 
population of cells is mainly due to naturally occurring differences in the 
levels and status of proteins (Spencer et al., 2009). The cell fate is 
transiently inherited as the protein status is transmitted to daughter cells 
after cell division (Rosenfeld et al., 2005). Later, however, protein 
synthesis promotes divergence and therefore sister cells no longer 
respond similarly to the same death ligand (Kaufmann et al., 2007; Sigal 
et al., 2006). The stoichiometry of the DISC components is highly crucial 
in determining how the DR signal will be transduced in the cell. The 
CD95-FADD homotypic DD complex predominantly assembles at a ratio 
of 5:5 (Esposito et al., 2010; Wang et al., 2010). An endogenous DISC 
structural model proposes that DED-dependent caspase-8 chain 
assembly upon DR ligation is common for inducing apoptosis by TRAIL 
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and CD95 (Dickens et al., 2012; Schleich et al., 2012). In silico comparison 
of amplification of caspase cascades revealed that the balance of caspase-
8 dimerization and dissociation was an important regulatory mechanism 
that avoids unwanted cell death (Würstle et al., 2010). 
 
A great interest focuses on elucidating the crosstalk mechanisms by 
using models that integrate consistent data from literatures on DR-
mediated apoptosis versus its opposing survival signaling (Calzone et 
al., 2010). NF-κB and apoptosis signaling pathways are closely integrated 
and they can be induced from the same DRs (Shishodia and Aggarwal, 
2002). Neumann and colleagues predicted that the CD95-mediated 
pathways diverge at the DISC, and the balance between c-FLIPL and 
caspase-8 is highly influential. The model postulated a direct interaction 
between p43-FLIP and the IKK complex, which was later validated with 
experimental data (Neumann et al., 2010). Their continuous work 
proposed an underlying mechanism for the dual role of c-FLIPL upon the 
DR stimulation. They demonstrated that c-FLIP displays its pro-
apoptotic behavior when c-FLIPL is expressed at the physiological level 
and the cells receive strong receptor stimulation, or when the short 
isoforms of c-FLIP are present at high levels (Fricker et al., 2010). 
 
The apoptotic signaling pathway has a complex dynamic behavior 
involving several reactions with regulatory feedback loops. Therefore, it 
is often difficult to infer its overall response by examining segments of 
the signaling pathway separately. On average, more than fifty articles are 
published everyday on apoptosis. Mathematical modeling and 
simulation would provide valuable insights into the behavior of 
apoptosis by incorporating new data and identifying outlier studies. 
Additionally, models enable the identification of components that are the 
most susceptible to biological interventions. This could identify new 
targets within the cell for therapeutic interventions for diseases, as well 
as predicting patient outcome and responsiveness to personalized 
treatment strategies. For example, an ODE system biological model, 
APOPTO-CELL, was developed to simulate the ability of cancer cells to 
undergo mitochondria-mediated apoptosis (Rehm et al., 2006). The 
model has been extended to provide the proof-of-concept for a clinical 
setting to colorectal cancer patients in assessing individual patient 
responses to novel targeted therapeutics (Hector et al., 2012).  
 
 
5. Abnormality of c-FLIP in disease 
 
Apoptosis is not only necessary for normal tissue development (Wyllie, 
1981), but it is also a distinctive pathological process leading to various 
diseases once misregulated. Therefore, detection of apoptosis together 
with investigation of regulatory mechanisms that augment or inhibit 
? ??
apoptosis is of importance for clinical purposes. It is palpable that defects 
in DR-mediated apoptosis have detrimental effects on a wide range of 
implications in human diseases. The loss-of-function of a DED-
containing protein demonstrates the clearest phenotype to support its 
role in the extrinsic apoptosis pathway, as well as in the embryonic 
development and the adult tissue maintenance. c-FLIP profoundly 
affects various cell signaling networks and a collapse of c-FLIP signaling 
can lead to pathological conditions, including developmental 
abnormalities, autoimmune diseases, and cancer. 
 
 
5.1 c-FLIP in development 
 
Programmed cell death is common during embryonic development and 
the mechanism is well conserved among various species. During 
organogenesis and tissue remodeling, cells are produced in excess only 
to be eliminated to obtain the optimal state (Penaloza et al., 2006). It is 
proposed that cell death is the default state during the development of a 
multicellular organism, and for the cells to stay alive, they must compete 
for sufficient survival factors in their specific microenvironment 
(reviewed by Raff, 1992). Therefore, it was speculated that deficiency of 
key apoptotic proteins would result in accumulation of cells. The 
knockout animals of key pro-apoptotic genes presented phenotypes 
consistent with failure to eliminate cells. Interestingly however, the key 
components of DR pathway suffered early embryonic lethality. 
Deficiency of FADD, caspase-8 or c-FLIP gene in mice caused lethality at 
embryonic gestation day 12.5 and 10.5, respectively. They presented 
similar phenotypic effects, including defects in myocardial development 
and extreme abdominal hemorrhage (Rasper et al., 1998; Varfolomeev et 
al., 1998; Yeh et al., 2000). Recent studies show that the lethality caused 
by deficiency of FADD or caspase-8 occur due to unregulated RIPK1/3-
dependent necroptosis, whereas c-FLIP carries a role in embryogenesis 
distinct from that of other DED-containing proteins, to which apoptotic 
cell death proposed to be the reason (Dillon et al., 2012). It has been 
suggested that caspase-8-FLIPL is a catalytically active complex that 
protects mice by suppressing necrotic death. Defects in T cell 
development in the caspase-8 knockout mice can be rescued by 
catalytically active caspase-8 that is not processed (Leverrier et al., 2010). 
This unprocessed caspase-8 activity with different substrate specificity 
from the initiator activity in apoptosis, functions to preserve the 
embryonic development (Pop et al., 2011). Of note, there are 
discrepancies between mouse and human studies; caspase-8 is not 
essential in human embryogenesis due to the presence of caspase-10, 
which is not found in the mouse genome (Chun et al., 2002; Kischkel et 
al., 2001). Moreover, murine caspase-8 only has one cleavage site, and 
therefore, dimerization studies in mice may be different when studying 
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organogenesis and tissue remodeling, cells are produced in excess only 
to be eliminated to obtain the optimal state (Penaloza et al., 2006). It is 
proposed that cell death is the default state during the development of a 
multicellular organism, and for the cells to stay alive, they must compete 
for sufficient survival factors in their specific microenvironment 
(reviewed by Raff, 1992). Therefore, it was speculated that deficiency of 
key apoptotic proteins would result in accumulation of cells. The 
knockout animals of key pro-apoptotic genes presented phenotypes 
consistent with failure to eliminate cells. Interestingly however, the key 
components of DR pathway suffered early embryonic lethality. 
Deficiency of FADD, caspase-8 or c-FLIP gene in mice caused lethality at 
embryonic gestation day 12.5 and 10.5, respectively. They presented 
similar phenotypic effects, including defects in myocardial development 
and extreme abdominal hemorrhage (Rasper et al., 1998; Varfolomeev et 
al., 1998; Yeh et al., 2000). Recent studies show that the lethality caused 
by deficiency of FADD or caspase-8 occur due to unregulated RIPK1/3-
dependent necroptosis, whereas c-FLIP carries a role in embryogenesis 
distinct from that of other DED-containing proteins, to which apoptotic 
cell death proposed to be the reason (Dillon et al., 2012). It has been 
suggested that caspase-8-FLIPL is a catalytically active complex that 
protects mice by suppressing necrotic death. Defects in T cell 
development in the caspase-8 knockout mice can be rescued by 
catalytically active caspase-8 that is not processed (Leverrier et al., 2010). 
This unprocessed caspase-8 activity with different substrate specificity 
from the initiator activity in apoptosis, functions to preserve the 
embryonic development (Pop et al., 2011). Of note, there are 
discrepancies between mouse and human studies; caspase-8 is not 
essential in human embryogenesis due to the presence of caspase-10, 
which is not found in the mouse genome (Chun et al., 2002; Kischkel et 
al., 2001). Moreover, murine caspase-8 only has one cleavage site, and 
therefore, dimerization studies in mice may be different when studying 
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the function of caspase-8-c-FLIPL heterodimers in humans (van Raam 
and Salvesen, 2012). 
 
In addition to the embryonic development, c-FLIP has been shown to 
play a vital role in the heart development, cardiac myocyte survival 
during injury, and pathological cardiac hypertrophy. Highest levels of c-
FLIP expression are found in cardiac tissue and the importance of c-FLIP 
in regulation of susceptibility of cardiac myocytes to apoptotic stimuli 
have been demonstrated in a number of studies. c-FLIP play a 
indispensable role in cardiac remodeling following myocardial infarction 
by interrupting JNK1/2 signaling and augmenting Akt signaling, 
thereby promoting cardioprotection (Imanishi et al., 2000; Steenbergen et 
al., 2003). In line with this, reduced c-FLIP expression at the end-stage of 
failing human hearts has been reported. Apoptosis is important in 
atherogenesis and vascular remodeling (Han et al., 1995), and studies 
indicate that c-FLIP is involved in these cellular processes. c-FLIP plays a 
role in anti-apoptotic resistance of vascular smooth muscle cells (Wang et 
al., 2002). Moreover, the c-FLIP protein expression is induced in tunica 
intima and media after artery injury and remodeling (Imanishi et al., 
2000).  
 
 
5.2 The role of c-FLIP in the immune system and in autoimmune 
diseases 
 
We are constantly exposed to potentially harmful substances, such as 
microorganisms and toxins, from the environment. Fortunately, our 
immune system effectively defends off such destructive elements. The 
innate immune system includes the physiological barriers and 
phagocytic cells, where as the adaptive immune response functions via 
the lymphocytes to specifically recognize particular antigens by 
lymphocytes. B cells are antibody-producing cells, while T cells directly 
kill the infected host cells or assist other lymphocytes. The foundation of 
the adaptive immune response relies on its ability of clonal expansion of 
antigen-specific lymphocytes upon infection to clear out the antigens. 
Regulation of the lymphocyte population is important to maintain a 
functional immune system, and impaired homeostasis is often associated 
with both immunodeficiency and autoimmune diseases. 
 
c-FLIP signaling in the immune system is thoroughly studied 
physiological process, as it demonstrates the most biological relevance of 
the protein. In a broad range of lymphocytes, induced high level of c-
FLIP rescues the cells from death ligand-mediated apoptosis. Following 
clonal expansion of the antigen-specific lymphocytes, subsequent 
efficient elimination of these activated cells by apoptosis occur, a process 
known as activation-induced cell death (AICD). AICD relies on CD95L-
CD95-mediated apoptosis to terminate the immune response and in the 
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induction of peripheral T cell self-tolerance. Following the TCR 
stimulation, the level of c-FLIPS/R is upregulated, which is primarily 
responsible for the resistance towards CD95-mediated apoptosis by 
limiting caspse-8 activation in the activated T cells (Park et al., 2005). 
After clonal expansion, the c-FLIP levels decrease in an IL-2-dependent 
manner (Algeciras-Schimnich et al., 1999; Refaeli et al., 1998), and 
sensitize T cells towards CD95L-stimulation (Kirchhoff et al., 2000; 
Schmitz et al., 2004). The short c-FLIP isoforms also inhibit NF-κB 
activity, resulting in decreased T cell activation and survival. In vitro 
restimulation of preactivated primary human T cells induces the 
expression of c-FLIPS, rendering the proportion of cells that survive 
another AICD (Kirchhoff et al., 2000). The relative levels of c-FLIP might 
therefore provide a crucial balance of caspase and NF-κB activities in the 
effector T cells.  
 
In addition to the regulation of DR-mediated apoptosis, the core DISC 
components are crucial in T cell survival, proliferation, and activation 
(reviewed by Budd, 2002). T cell stimulation activates caspase-8 at the 
lipid rafts, and blocking the caspase activation in turn prevents T cell 
activation and proliferation (Alam et al., 1999; Simons and Toomre, 2000; 
Simons and Ikonen, 1997). c-FLIP is also recruited to the lipid rafts, 
where it is rapidly cleaved to p43-FLIP (Misra et al., 2007). The 
phenotype of c-FLIP deficient T cells is closely parallel that of caspase-8 
deficient T cells (Salmena et al., 2003). The loss of c-FLIP profoundly 
affects thymocyte development, and the proliferation of c-FLIP deficient 
T cells is greatly reduced in response to IL-2 and TCR crosslinking 
stimulations (Chau et al., 2005; Zhang and He, 2005). Overexpression of 
c-FLIPL in Jurkat cells produces more IL-2 and increases proliferation 
following TCR stimulation via NF-κB and ERK signaling pathways 
(Kataoka et al., 2000; Lens et al., 2002). The c-FLIP expression in 
transgenic mice causes the T cell hyperproliferation upon activation, but 
they may be more sensitive to cell death, owing to simultaneously 
augmented caspase activity (Dohrman et al., 2005). Taken together, 
increased expression of c-FLIP in T cells cause the accumulation of 
lymphocytes or resist CD95-mediated apoptosis. These characteristics 
may attribute in various autoimmune diseases, multiple sclerosis, 
rheumatoid arthritis, Graves’ disease, and inflammatory arthritis (Budd 
et al., 2006; Stassi et al., 2000). 
 
c-FLIP also function in other immune cells, such as antigen-presenting 
cells. The c-FLIP level alteration occurs during differentiation of 
peripheral blood monocytes into macrophages. Monocytes contain very 
low levels of c-FLIP and are highly sensitive to CD95-induced cell death, 
but macrophages and immature DCs express substantial amounts of c-
FLIP and are, therefore, resistant to the same stimulus (Ashany et al., 
1999; Perlman et al., 1999). Activation of B cell receptors through the 
PI3K/Akt pathway upregulates c-FLIP expression and protects the B 
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the function of caspase-8-c-FLIPL heterodimers in humans (van Raam 
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cells from CD95-induced cell death (Moriyama and Yonehara, 2007). 
Hemin-differentiated K562 cells show reduced c-FLIP expression and 
higher sensitivity to TRAIL-induced apoptosis than undifferentiated cells 
(Hietakangas et al., 2003). Microglia are resident macrophages in the 
immune privileged organs that are important for an active immune 
defense. TGF-β is produced in such immune privileged sites and it can 
increase c-FLIP levels in an MKK-dependent pathway to protect cells 
from CD95-mediated apoptosis (Schlapbach et al., 2000). c-FLIP inhibits 
HIV-1 replication in lymphocytes by preventing apoptotic cell death 
induced by HIV-1 infection and upregulating the expression of viral 
restriction factors (Tan et al., 2013; Wang et al., 2010). 
 
 
5.3 Targeting c-FLIP for cancer therapy 
 
Cancer is a leading cause of death. On the worldwide scale, death from 
cancer was accounted for 7.6 million (around 13% of all deaths) in 2008 
and it is predicted to rise to over 13 million by 2030 (World Health 
Organization). Cancer is collective of many diseases, each with distinct 
characteristics and therapeutic options. However, all cancers confer 
survival advantages that contribute to uncontrollable cell proliferation 
and major molecular changes arising in tumorigenesis are well 
understood. The change in expression level of proteins involved in 
apoptosis regulation and impaired ability to undergo programmed cell 
death in response to death stimuli is one of the hallmarks of cancer 
(Hanahan and Weinberg, 2000). In cells, apoptosis by metabolic stress is 
crucial to suppress tumorigenesis and inability to die acquires cancer 
cells a selective advantage for progression and metastasis, as well as 
resistance to chemotherapies. Overcoming this resistance to conventional 
and targeted therapies remains a key challenge in the fight against cancer 
and interest in developing therapeutics that kill cancer cells via the 
extrinsic apoptotic pathway has emerged.  
 
Many cancer cells are more susceptible to TRAIL than normal cells due 
to an impaired expression of decoy receptors in cancer cells (Pan et al., 
1997; Sheridan et al., 1997). Some of the potential examples of targeting 
TRAIL for cancer therapy include: TRM-1, a TRAIL-R1 monoclonal 
antibody, which has completed the phase II clinical trials for relapsed 
non-small carcinoma lung cancer (NSCLC) and non-Hodgkin’s 
lymphoma (NHL) (Human genome sciences); and AMG 951 for NSCLC, 
NHL and colorectal cancer, which have completed early phases of the 
clinical trials (Amgen and Genentech). However, highly malignant 
tumors are resistant to apoptosis induced by TRAIL and some cancers 
that were originally sensitive can acquire the resistance. During the 
evolution of tumors in vivo, selection occurs for malignant clones capable 
of withstanding immune attack, thus successful therapy depends on 
restoring the competence of DR-mediated apoptosis. Apoptosis 
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regulatory proteins are intensively studied as potential targets to restore 
the responsiveness to chemotherapy. c-FLIP is highly expressed in 
various tumor cells and often correlates with resistant to the DR-
mediated apoptosis (Table 2) (Verbrugge et al., 2009). Furthermore, 
higher c-FLIP levels are shown to correlate with more aggressive tumors 
(Shirley and Micheau, 2010). c-FLIP silencing restores sensitivity to death 
ligands in various cancer cells, and therefore, c-FLIP would be an 
important target for TRAIL targeted therapy. Indeed, small interfering 
RNAs (siRNAs) can be used to knockdown c-FLIP and enhance TRAIL-
induced DISC formation and caspase-8-dependent apoptosis in cancer 
cells (Mathas et al., 2004). 
 
???????????? ???????????????????????????
?????? ????????
?????????
????? ????? ???????? ???????????? ???????? ?????? ????????????????????????????????????????????
??????????
?????????
????? ??????????? ??? ??????? ???????? ??? ????? ??????????
?????????????????????????????
?????????? ?????????????? ????? ?????? ??????? ?????????????????????????????????????
???????????????? ??????????????????????????????????? ??????????????????????????
???????????
???????
??????? ?????? ??????? ??? ????????????? ??????????? ????
????????????????????????????????????????????????????????
??????
???????????????
???????????? ???????? ?????????????? ????????? ?????????????????????????????????????????????????????????????
??????????????????????????????????????
?????????
??????????
????????????? ????? ???????????????? ????????? ???????????????????????????????????????????????????????????
???????????????
???????
?????????? ??? ??????? ??????????? ?????? ??? ????????????
????????????????????????????????????
??????????
?????????
???κ??????????????????????????????????????????????
???????????????????????????????????????????
???? ?????????????????????????????????????????????????????????????????????????????????????????
?????? ???????? ??????????????? ???? ??????????? ??? ?????????????????????????????????????
???????????
???????
??????? ??????????????? ???????? ???????????????
??????????????????????????????
???????????????? ????????? ????????????????????????????????????????????????????????????????????? ?????????????????????
  
Table 2. Tumors with elevated expression level of c-FLIP. Some of 
the tumors with high levels of c-FLIP are listed here together with 
the signaling pathway responsible for the overexpression or relative 
prognosis, if known. 
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higher c-FLIP levels are shown to correlate with more aggressive tumors 
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ligands in various cancer cells, and therefore, c-FLIP would be an 
important target for TRAIL targeted therapy. Indeed, small interfering 
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induced DISC formation and caspase-8-dependent apoptosis in cancer 
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the tumors with high levels of c-FLIP are listed here together with 
the signaling pathway responsible for the overexpression or relative 
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The PI3K/Akt signaling pathway predominantly regulates the c-FLIP 
expression level in tumor cells and it is one major signaling target for 
sensitizing cancer cells to TRAIL (Garg and Aggarwal, 2002; Karin et al., 
2002). Several small molecule inhibitors have the potential to 
downregulate c-FLIP proteins by disruption of the PI3K/Akt pathway 
(Fulda et al., 2000). Some of the most recent studies include the 
therapeutic potential of Sorafenib and histone deacetylase (HDAC) for 
gastrointestinal cancer (Hamed et al., 2013), tocotrienols for breast cancer 
(Sylvester et al., 2013), tectorigenin for paclitaxel-resistant ovarian cancer 
(Yang et al., 2012), Bortezomib for myelodysplastic (Huang et al., 2011), 
and LY294002 for gastric cancer (Liu et al., 2011). 
 
Furthermore, other signaling pathways may be targeted to diminish the 
anti-apoptotic behavior of c-FLIP in cancer. CDDO-Me, which is in the 
phase II clinical trial as a combination therapy for lung cancer, triggers 
induction of apoptosis by targeting c-FLIPs to ubiquitin-dependent 
proteasomal degradation (Safa et al., 2008). Flavopiridol, an inhibitor of 
cyclin-dependent kinase shown to sensitize breast tumor cells to TRAIL 
by inducing proteasome-dependent degradation of c-FLIP (Palacios et 
al., 2006). Other therapeutic targets involving c-FLIP regulations include 
several HDAC inhibitors significantly downregulate c-FLIP synthesis in 
various cancer cells (Lucas et al., 2010; Yerbes and López-Rivas, 2012). 
Similarly the endoplasmic reticulum stress-inducing agents sensitize 
cells to TRAIL-mediated apoptosis by altering different apoptosis-related 
proteins including decline in the level of c-FLIP (Martín-Pérez et al., 
2012). Etoposide-mediated depletion of IAPs led to spontaneous 
assembly the ripoptosome (Tenev et al., 2011). c-FLIP is the determinant 
that regulates caspase-8 activity in ripoptosome, thereby it could 
influence the outcome of cell death via RIP3-dependent nectoptosis or 
caspase-dependent apoptosis (Feoktistova et al., 2011). 
 
It is fascinating to see how two structurally similar proteins, procaspase-
8 and c-FLIP, can have similar effects as well as very opposing functions. 
Furthermore, the gross overall structural conformations of homodimers 
and heterodimers of caspase-8 and c-FLIPL are similar. Thus, restricted 
substrate specificity of the heterodimers is likely to be caused by higher 
regulatory mechanisms. c-FLIP plays an important role in determining 
cell survival, but often observations contradict. Further molecular 
understanding of c-FLIP is required to translate our knowledge to more 
effective clinical uses. 
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OUTLINES OF THE STUDY 
 
The aim of this thesis was to determine the regulation of PTMs of c-FLIP 
and how they in turn modulate the c-FLIP behavior. When I joined the 
laboratory, two phosphorylation sites were identified in c-FLIP at serine 
193 (S193) and serine 227 (S227). 
 
My thesis focuses on the role of phosphorylation of c-FLIP in DR-
mediated apoptosis. S193 is phosphorylated in all isoforms of c-FLIP. To 
investigate the mechanism underlying phosphorylation of S193, we first 
identified classical PKCs as the major regulators of the phosphorylation 
site in all isoforms. Since c-FLIP has anti-apoptotic functions and PKC 
can be activated by TRAIL, we defined that TRAIL stimulation can 
induce phosphorylation of c-FLIP. Finally, we demonstrated that c-FLIP 
S193 phosphorylation cause cytoplasmic accumulation of c-FLIP, thereby 
contributing to the DISC signaling outcome upon TRAIL-R activation. 
 
With accumulating data on cell death and the DISC activation, various 
mathematical models are utilized to provide an alternative method to 
comprehend the cell death signaling. Another aspect of my thesis was to 
establish interdisciplinary collaborations with chemical engineers from 
Åbo Akademi University to construct mathematical models that revealed 
the importance of c-FLIP expression levels upon the DR-mediated DISC 
signaling. 
  
My continuous work extends from observations made during the first 
studies. When the distribution of phosphorylated c-FLIP was analyzed 
by confocal microscopy, we observed distinct localizations of c-FLIP in a 
phospho-dependent manner. Furthermore, we classified the subcellular 
localizations of differentially phosphorylated c-FLIP and their functions 
in non-extrinsic apoptosis signaling. We identified that phosphorylation 
on S227 is required for c-FLIPL to form filamentous structures, which was 
previously reported not feasible. Separately, the global phosphorylation 
of c-FLIP was accumulated at the centrosomes throughout the cell cycle, 
and c-FLIPL phosphorylation was necessary to sustain c-FLIPL-induced 
increase in cell population via hyperproliferation. 
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MATERIALS AND METHODS 
 
More detailed information on the materials and methods can be found in 
the original publications and manuscripts. 
 
Cell lines 
⋅ Human K562 chronic myelogenous leukemia  (I, III) 
⋅ Human Jurkat T-lymphoma cells (Clone E6-1) (III, IV) 
⋅ Human HeLa cervical carcinoma cells (III, IV, unpublished) 
⋅ Human LNCaP prostate adenocarcinoma (III) 
⋅ Human MCF7 breast adenocarcinoma (III) 
⋅ Human PC3 prostate adenocarcinoma (III, IV) 
⋅ Human embryonic kidney 293 cells (III) 
⋅ Mouse primary T cells (III, IV) 
 
Reagents 
Name (Manufacture) Application Publication 
Calyculin A (Sigma-
Aldrich) Inhibit phosphatases I, III 
Cycloheximide (Sigma-
Aldrich) 
Inhibit protein 
synthesis I 
DAPI (Sigma) Nuclear staining III, IV, unpublished 
FLAG-tagged TRAIL 
(Alexis) DISC formation I 
G418 (Sigma) Neomycin resistant selection I 
GÖ6976 (Sigma-Aldrich) Inhibit PKCα and β I 
Isoleucine zipper human 
recombinant TRAIL (Dr. 
Walczak) 
FLIP 
phosphorylation, 
induce apoptosis 
I, III 
Nocodazole Destabilize microtubule Unpublished 
Paclitaxel  Stabilize microtubule Unpublished 
Pseudosubstrate 
(Calbiochem) Inhibit PKCα and β I 
Superkiller TRAIL (Alexis) Induce apoptosis I 
TNF-α (R&D Systems) Stimulate TNF receptors I 
TPA/PMA (Sigma-Aldrich) Activate PKC I, III 
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Antibodies 
Target (Manufacture) Application Publication 
Caspase-3 (BD Pharmingen) WB III 
Caspase-8 (clone C-15, Alexis) WB I, III 
DR4 (Alexis) IP I 
DR5 (Alexis) IP I 
c-FLIP (clone NF6, Alexis) WB I, III, IV 
FLAG M2 (Sigma-Aldrich) IP I 
GFP (clone JL-8, Clontech) WB I 
HA (Santa Cruz Biotechnology) IP I 
Hsc 70 (SPA-810, StressGen) WB I, III, IV 
PARP1 (clone C-2-10, Sigma-
Aldrich) WB I, III 
Pericentrin (Abcam) IF IV 
PKCα IF III 
PKCβ IF III 
Ubiquitin (clone FK-1, BioMol) WB I 
Abbreviations: WB, Western blot; IP, immunoprecipiration 
 
Preparation of anti-FLIP phospho-specific antibodies (I, III, IV, 
unpublished):  
Anti-pS193 phosphopeptide: AIQK(pS)LKDPS 
Anti-pS227 phosphopeptide: EPVKK(pS)IQES 
 
Secondary antibodies: 
HRP-conjugated secondary antibodies were used for WB (I, III, IV). 
Fluoresence-conjugated secondary antibodies were used for IF (III, IV, 
unpublished). 
 
Plasmid constructs  
⋅ FLAG-tagged c-FLIPL and c-FLIPS, kind gift from Dr. Jürg Tschopp 
(I, III, IV) 
⋅ FLAG-tagged c-FLIPR was constructed by PCR using FLAG-tagged 
c-FLIPL as a template with following primers: 
Forward: 5’-ACAGTTGAATTCATGTCTGCTGAAGTC-3’ 
Reverse: 5’-TCTAGACTCGAGTCATGCTGGGATTCCATTCCATA 
TGTTTTCTCCAGACTCACCCTGAAGTTATTTGAAGG-3’ 
⋅ c-FLIP point mutations were made using the QuikChange site-
directed mutagenesis kit (Stratagene) (I, III, IV) 
⋅ HA-tagged ubiquitin, kindly provided by Dr. Dirk Bohmann (I) 
⋅ GFP-tagged KD PKCα/β, kind gift from Dr. Christer Larsson (I) 
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MATERIALS AND METHODS 
 
More detailed information on the materials and methods can be found in 
the original publications and manuscripts. 
 
Cell lines 
⋅ Human K562 chronic myelogenous leukemia  (I, III) 
⋅ Human Jurkat T-lymphoma cells (Clone E6-1) (III, IV) 
⋅ Human HeLa cervical carcinoma cells (III, IV, unpublished) 
⋅ Human LNCaP prostate adenocarcinoma (III) 
⋅ Human MCF7 breast adenocarcinoma (III) 
⋅ Human PC3 prostate adenocarcinoma (III, IV) 
⋅ Human embryonic kidney 293 cells (III) 
⋅ Mouse primary T cells (III, IV) 
 
Reagents 
Name (Manufacture) Application Publication 
Calyculin A (Sigma-
Aldrich) Inhibit phosphatases I, III 
Cycloheximide (Sigma-
Aldrich) 
Inhibit protein 
synthesis I 
DAPI (Sigma) Nuclear staining III, IV, unpublished 
FLAG-tagged TRAIL 
(Alexis) DISC formation I 
G418 (Sigma) Neomycin resistant selection I 
GÖ6976 (Sigma-Aldrich) Inhibit PKCα and β I 
Isoleucine zipper human 
recombinant TRAIL (Dr. 
Walczak) 
FLIP 
phosphorylation, 
induce apoptosis 
I, III 
Nocodazole Destabilize microtubule Unpublished 
Paclitaxel  Stabilize microtubule Unpublished 
Pseudosubstrate 
(Calbiochem) Inhibit PKCα and β I 
Superkiller TRAIL (Alexis) Induce apoptosis I 
TNF-α (R&D Systems) Stimulate TNF receptors I 
TPA/PMA (Sigma-Aldrich) Activate PKC I, III 
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Antibodies 
Target (Manufacture) Application Publication 
Caspase-3 (BD Pharmingen) WB III 
Caspase-8 (clone C-15, Alexis) WB I, III 
DR4 (Alexis) IP I 
DR5 (Alexis) IP I 
c-FLIP (clone NF6, Alexis) WB I, III, IV 
FLAG M2 (Sigma-Aldrich) IP I 
GFP (clone JL-8, Clontech) WB I 
HA (Santa Cruz Biotechnology) IP I 
Hsc 70 (SPA-810, StressGen) WB I, III, IV 
PARP1 (clone C-2-10, Sigma-
Aldrich) WB I, III 
Pericentrin (Abcam) IF IV 
PKCα IF III 
PKCβ IF III 
Ubiquitin (clone FK-1, BioMol) WB I 
Abbreviations: WB, Western blot; IP, immunoprecipiration 
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unpublished):  
Anti-pS193 phosphopeptide: AIQK(pS)LKDPS 
Anti-pS227 phosphopeptide: EPVKK(pS)IQES 
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HRP-conjugated secondary antibodies were used for WB (I, III, IV). 
Fluoresence-conjugated secondary antibodies were used for IF (III, IV, 
unpublished). 
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⋅ FLAG-tagged c-FLIPL and c-FLIPS, kind gift from Dr. Jürg Tschopp 
(I, III, IV) 
⋅ FLAG-tagged c-FLIPR was constructed by PCR using FLAG-tagged 
c-FLIPL as a template with following primers: 
Forward: 5’-ACAGTTGAATTCATGTCTGCTGAAGTC-3’ 
Reverse: 5’-TCTAGACTCGAGTCATGCTGGGATTCCATTCCATA 
TGTTTTCTCCAGACTCACCCTGAAGTTATTTGAAGG-3’ 
⋅ c-FLIP point mutations were made using the QuikChange site-
directed mutagenesis kit (Stratagene) (I, III, IV) 
⋅ HA-tagged ubiquitin, kindly provided by Dr. Dirk Bohmann (I) 
⋅ GFP-tagged KD PKCα/β, kind gift from Dr. Christer Larsson (I) 
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SiRNA 
⋅ ON-TARGETplus Human CFLAR siRNA and ON-TARGETplus 
Non-targeting Pool were purchased from Thermo Scientific (III) 
 
Methods 
Name Publication 
CAM IV 
Cell culture I, III, IV, unpublished 
Densitometry quantification I, III 
DISC analysis III, IV 
FLAG Immunoprecipitation I 
Image analysis I, III, IV, unpublished 
Ki67 staining IV 
Luminometric caspase-8 activity assay I 
Microscopy III, IV, unpublished 
Nuclear fractionation assay III 
Propedium Iodide staining IV 
SDS-PAGE and Western blotting I, III, IV 
Stable cell lines I, III 
Statistical analysis I, III, IV 
Transient transfections III, IV 
Trypan blue exclusion assay III, IV 
Tunel assay (Invetrogen) IV 
Ubiquitination assay I 
WST-1 (Roche) IV 
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RESULTS AND DISCUSSION 
 
1 Phosphorylated c-FLIP in death receptor activation 
 
1.1 Phosphorylation of c-FLIP on serine 193 (I, III, IV) 
  
Before this thesis was initiated, little was known about c-FLIP 
phosphorylation and its mechanisms and biological implications. To 
provide insights into the PTM of c-FLIP, phosphorylation sites were 
identified. In brief, K562 erythroleukemic cells stably overexpressing c-
FLIPL or c-FLIPS were treated with the phosphatase inhibitor calyculin A 
and 32P in vivo orthophosphate labeling was performed to detect 
phosphorylation by electrophoresis and autoradiography (Fig 1A, Article 
I). Following the observation that c-FLIP is indeed phosphorylated in our 
system, phosphopeptide mapping and mass spectrometric analysis were 
performed to identify S193 as a novel phosphorylation site common to all 
isoforms of c-FLIP (Fig 1B-G, I). A polyclonal antibody against the 
phosphorylation was developed to provide a tool for biochemical 
analysis (Fig 2A, I and Supplementary Fig 2, III). In the first article, 
immunoprecipitated exogenous c-FLIP in K562 cells was used to 
principally understand the mechanisms of c-FLIP phosphorylation. 
Endogenous phosphorylation of S193 was observed in all untreated cell 
lines thus far being tested. They include Jurkat T cell leukemia, K562 
cells, PC3 prostate carcinoma cells, HeLa cervical adenocarcinoma cells, 
human embryonic kidney 293 cells and mouse primary T cells (Fig 2 and 
supplementary data 2, III, and unpublished observations). 
 
 
c-FLIP S193 phosphorylation is mediated by classical PKC 
 
Bioinformatics analysis was performed to find kinase consensus site on c-
FLIP and revealed a number of candidate kinases for S193 
phosphorylation. To identify the kinase phosphorylating c-FLIP S193, we 
manipulated the activities of various kinases with pharmacological 
activators and inhibitors, as well as genetic exploitation to observe if any 
would alter the status of c-FLIP S193 phosphorylation. 
 
  1  MSAEVIHQVE EALDTDEKEM LLFLCRDVAI DVVPPNVRDL LDILRERGKL SVGDLAELLY 
 61  RVRRFDLLKR ILKMDRKAVE THLLRNPHLV SDYRVLMAEI GEDLDKSDVS SLIFLMKDYM 
121  GRGKISKEKS FLDLVVELEK LNLVAPDQLD LLEKCLKNIH RIDLKTKIQK YKQSVQGAGT 
181  SYRNVLQAAI QKSLKDPSNN FRMITPYAHC PDLKILGNCS M  
                                           * *   * 
Fig 21. Amino acid sequence of human c-FLIPS. The domains are 
shaded in grey; darker grey, DED1; lighter grey, DED2. c-FLIPS-
specific C-terminal tail is underlined. Relevant PTM sites for this 
study are marked with asterisks; S193 phosphorylation site (S) and 
Lysine 192 and 195 ubiquitination sites (K). The numbers on the left 
indicate starting amino acid residues of each line. 
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When we treated K562 cells with GÖ6976, an inhibitor of the classical 
protein kinase C (cPKC) isoforms α and β, S193 phosphorylation was 
considerably reduced (Fig 2B, I). Likewise, treatment with 
pseudosubstrate of PKCα and PKCβ provided similar results (data not 
shown). Moreover, when the PKC activity was induced with phorbol 
ester PMA (or TPA in article I), phosphorylation of c-FLIP S193 was 
significantly increased (Fig 2C, I). PMA-mediated phosphorylation of c-
FLIPS was mostly abolished by GÖ6976 pretreatment, indicating that the 
phosphorylation of c-FLIPS S193 is mainly mediated by PKCα and PKCβ. 
Similar results were obtained with c-FLIPR (Fig 2D-E, I). GÖ6976 
pretreatment in turn showed less effect on the phosphorylation of c-
FLIPL S193, implying that c-FLIPL may be subject to phosphorylation by a 
broader range of kinases (Fig 2D, I). To ensure the specificity of results 
obtained by the pharmacological PKC inhibitors, we transfected c-FLIP 
overexpressing K562 cells with kinase-dead PKCα and PKCβ, which act 
as dominant negative inhibitors of the endogenous PKCs. They indeed 
interfered with the induction of PMA-induced c-FLIP phosphorylation of 
both c-FLIPS and c-FLIPL (Fig 2F, I).  
 
Calmodulin (CaM) is a major calcium sensing protein, which upon 
binding to calcium, undergoes a major conformational change and the 
complex interacts with a variety of target proteins. Direct interaction 
between CaM and c-FLIPL was demonstrated to regulate CD95-induced 
signaling (Pawar et al., 2008). CaMKII, which is regulated by the 
calcium/CaM complex, has also been shown to phosphorylated c-FLIP. 
c-FLIP proteins get threonine-phosphorylated by CaMKII, which blocks 
recruitment of all isoforms to the DISC (Yang et al., 2003). In our system, 
CaMKII inhibition did not affect S193 phosphorylation (data not shown). 
 
PKC is a well-understood kinase that transduces cell surface signals by 
phosphorylating substrate proteins. Once activated upon cell 
stimulation, cytosolic PKC is translocated to membranes, or sometimes to 
the nucleus, where it exhibits catalytic activity. Eleven isoforms of PKC 
has been identified in mammalian cells, which are assorted as cPKC, 
novel PKC (nPKC) and atypical PKC (aPKC). cPKC are Ca2+-dependent 
and PMA-responsive, nPKC that are Ca2+-independent and aPKC not 
responseive to phorbol esters. Initially, we used prolonged treatment of 
PMA to identify PKC as the mediators of c-FLIP S193 phosphorylation 
(Article I). Since PKC signaling is rapid, we continued by investigating if 
PMA-mediated S193 phosphorylation could be a rapid response. Upon 
10 minute PMA treatment, activated PKCα proteins were found mostly 
in the cytosol of Jurkat cells (unpublished observation). In accordance 
with this, endogenous c-FLIP phosphorylation was indeed increased in 
the cytosol (Fig 3A, III). After one hour of treatment, activated PKCs 
were found also in the nucleus, and c-FLIP phosphorylation was 
increased throughout the cell (Fig 3B, III). These data indicate that PKC-
mediated c-FLIP S193 phosphorylation is an acute signaling mechanism. 
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c-FLIP S193 phosphorylation is induced upon DR stimulation 
 
After identifying cPKC as the chief kinases that phosphorylates c-FLIP 
S193, we wanted to elucidate its purpose in the cells. Since c-FLIP is 
critical in cell death, we first investigated its relevance in the extrinsic 
apoptotic pathway. In the context of cell death, PKC has been reported to 
modulate the DR signaling both positively and negatively. PKC plays a 
protective role by interfering with the formation of the DISC by blocking 
FADD recruitment and subsequent caspase-8 activation (de Thonel et al., 
2001; Gomez-Angelats and Cidlowski, 2003; Harper et al., 2003; Leroy et 
al., 2005) (Supplementary Fig 6, III). Furthermore, DR-mediated PKC 
activation has been observed in various cell lines. TRAIL at killing 
concentration induces PKC activation rapidly although the activation 
mechanism is yet to be determined. 
 
We determined S193 phosphorylation upon the DR stimulations and 
found in a K562 c-FLIP overexpressed system that TRAIL and TNF-α 
indeed increased S193 phosphorylation (Fig 5A-B, I). In more acute 
activation of the DRs, Jurkat cells were treated with TRAIL, CD95 or 
TNF-α for 10 minutes and endogenous phosphorylation of S193 was 
detected. Intriguingly, TRAIL and CD95 induced S193 phosphorylation 
by 15% or more, whereas no change was observed with TNF-α (Fig 7A, 
III and unpublished data). Taken together, the DR stimulation indeed 
affect the phosphorylation status of c-FLIP, speculatively via PKC 
activated by signals transmitted from the DR signaling complexes. How 
PKC is activated via the DR stimulation is not yet described and the 
physiological relevance of the acute DR-mediated PKC activation is 
unknown. It is conceivable from our acute DR stimulation experiment 
that decision to phosphorylate c-FLIP occurs when death signaling is 
initiated. Phosphorylation of c-FLIP occur rapidly upon TRAIL and 
CD95-mediated signaling, while there is a delay in TNF-α-mediated 
signaling, since the complex II must be formed before apoptosis 
signaling can be initiated via TNFR1 stimulation. With this notion we 
continued our study to understand the role of TRAIL-mediated c-FLIP 
S193 phosphorylation in cell death. 
 
 
1.2 PKC-mediated c-FLIP phosphorylation leads to protein stability via 
regulating ubiquitination (I, III) 
 
The c-FLIP S193 residue is positioned in a region that is crucial for c-FLIP 
ubiquitination, between K192 and K195 ubiquitin acceptor sites in c-
FLIPS (Poukkula et al., 2005). Many E3 ligases typically recognize 
substrates that are phosphorylated on specific serine or threonine 
residues. We were thus prompted to investigate whether c-FLIP S193 
phosphorylation influenced this ubiquitination, all of which are PTMs 
found in every isoform of c-FLIP. We first performed S193 site-directed 
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mutagenesis to produce a non-phosphorylatable c-FLIP at S193 by 
replacing the serine with alanine (S193A), or with aspartic acid  (S193D) 
to mimic constitutively phosphorylated c-FLIP. The inhibition of 
phosphorylation by the S193A mutation increased the ubiquitination of 
all isoforms of c-FLIP, while the S193D efficiently decreased the 
ubiquitination  (Fig 3A-C, I). Furthermore, when PKC was inhibited by 
GÖ6976, wild type (WT) c-FLIP was more ubiquitinated, whilst 
ubiquitination of c-FLIPR S193D was not affected by the same treatment 
(Fig 2E, I). Hence, S193 phosphorylation does regulate the ubiquitination 
in all c-FLIP isoforms, although it does not exhibit the typical 
phosphorylation-induced ubiquitination. 
 
Next, we produced the DED-only c-FLIP (1-202) S193A mutant, which 
can be ubiquitinated but lacks the crucial C-terminal tail for degradation. 
In the absence of the C-terminal tail, the protein could not be modified by 
ubiquitin, but S193 phosphorylation was not affected in vivo, indicating 
that the C-terminal part of c-FLIP is required for ubiquitination but not 
for PKC kinase recruitment (Fig 2D, I and data not shown). Finally, we 
introduced S193A into c-FLIPS mutant that could not be ubiquitinated at 
K192 and 195. The phosphorylation mutant still increased ubiquitination, 
which signifies that the dephosphorylation impose strong destabilizing 
effect on c-FLIP even when the principal ubiquitin targeted lysines are 
unavailable. Taken together, c-FLIP ubiquitination is determined 
prominently by phosphorylation of S193. 
 
Ubiquitin modification functions to target proteins to various cellular 
processes, protein degradation by K48-linked ubiquitin conjugation 
being the commonly described. Since majority of reported ubiquitin 
modification of c-FLIP function in protein degradation, we continued to 
decipher the role of S193 phosphorylation on the stability of c-FLIP. We 
overexpressed c-FLIP S193 WT and phospho-mutants for each isoforms 
and inhibited the protein synthesis by cycloheximide to compare their 
half-lives (Fig 4A-C, I). S193A mutants of c-FLIPS/R had shorter half-lives, 
whereas S193D mutant prolonged their half-lives (Fig 4A-B, I). These 
results signify that phosphorylation on S193 alone can specifically affect 
the stability of the short c-FLIP isoforms. To further reveal the relevance 
of S193 phosphorylation-mediated ubiquitination, we induced PKC 
activity by PMA and observed that prolonged treatment indeed 
increased the total amount of both isoforms of endogenous c-FLIP in 
Jurkat cells (Fig 3C, III). 
 
The c-FLIPS/R turnover is determined by S193 phosphorylation and 
degradative ubiquitination. Since the short isoforms have short half-lives, 
PTMs could ensure the quick change of c-FLIP levels in the cells and 
provides the opportunity to generate rapid response to the DR-mediated 
signaling (Fig 22). Furthermore, endogenous phosphorylation of c-FLIP 
S193 is observed in various unstimulated cells, indicating that these 
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PTMs occur possibly to maintain the c-FLIP level by protecting the 
proteins from being degraded.
 
Fig 22. Interplay of phosphorylation and ubiquitination on 
protein stability of c-FLIPS. S193 phosphorylation affects the 
ubiquitination of all c-FLIP isoforms, but specifically regulates the 
stability of the short c-FLIP proteins. Rapid PTM can alter c-FLIPS/R 
concentration thus the outcome of cell death and survival (adapted 
from Asaoka et al., 2011). 
 
 
c-FLIP proteins are short-lived, with the half-lives of c-FLIPS/R and c-
FLIPL were estimated to be 40 and 120 minutes, respectively. Upon 
sensitization of activated T cells with the protein synthesis inhibitor 
cycloheximide, c-FLIPL was slowly downregulated while c-FLIPS 
becomes undetectable (Meinander et al., 2007; Schmitz et al., 2004). This 
differential stability is determined by degradative ubiquitin chains. The 
mutation of K192 and K195 in the linker area between DED2 and the 
splicing tail significantly decreased c-FLIPS ubiquitination, but it did not 
affect the overall c-FLIPL ubiquitination in K562 cells (Poukkula et al., 
2005). c-FLIP S193 phosphorylation counteracted ubiquitination of 
unidentified sites of c-FLIPL, although mutation of S193 alone did not 
affect the protein stability (Fig 3C and 4C, I). A structural model predicts 
that the K192 and K195 ubiquitination region in the interlinker of tandem 
DEDs and caspase-like domains of the long isoform would be masked by 
S193 phosphorylation (Fig 3D, III). Furthermore, PMA-induced PKC 
activation increased c-FLIPL protein level (Fig 3B, III). Therefore, c-FLIPL 
protein stability is under the regulation of PKC-induced phosphorylation 
and S193 may be one of the determinants, although it would not be the 
sole PTM regulation that we observed in c-FLIPS/R.  
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Ubiquitin modification functions to target proteins to various cellular 
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PTMs occur possibly to maintain the c-FLIP level by protecting the 
proteins from being degraded.
 
Fig 22. Interplay of phosphorylation and ubiquitination on 
protein stability of c-FLIPS. S193 phosphorylation affects the 
ubiquitination of all c-FLIP isoforms, but specifically regulates the 
stability of the short c-FLIP proteins. Rapid PTM can alter c-FLIPS/R 
concentration thus the outcome of cell death and survival (adapted 
from Asaoka et al., 2011). 
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S193 phosphorylation (Fig 3D, III). Furthermore, PMA-induced PKC 
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ubiquitin. Moreover, cysteine, serine, and threonine residues have been 
shown to function as polyubiquitin chain acceptor sites (Cadwell and 
Coscoy, 2005; Wang et al., 2007). The isoform-specific difference we have 
observed in c-FLIP ubiquitination may be caused by the variant tails of c-
FLIP that create dissimilar protein conformations and docking sites for 
E3 ligases, thereby affecting the efficiency or type of ubiquitination. 
Alternatively, the rate of polyubiquitination is determined by the 
activities of E2, E3 ligases and DUBs. The faster ubiquitinated proteins, 
called processive substrates, are polyubiquitinated with only one 
encounter with the ligase and are efficiently degraded. The distributive 
substrates need several binding events for polyubiquitin chain long 
enough for destruction. Therefore, the distributive substrates are not 
efficiently modified before the processive substrates have been 
ubiquitinated. This processivity gradient can discriminate between 
substrates that have to be degraded in a specific timely and sequential 
order (Hochstrasser, 2006; Rape et al., 2006). c-FLIP may function in such 
system, where the short isoforms could be processive substrates and the 
long isoform a distributive substrate. 
 
 
1.3 c-FLIPL S193 determines protein distribution (III) 
 
During this thesis work, studies reported that c-FLIPL was found in the 
nucleus (Katayama et al., 2010; Zhang et al., 2009). In the reports, it was 
stated that the C-terminal tail of c-FLIPL express two NLS and one NES, 
which were conserved throughout mammalian c-FLIP (Fig 1A, III). At 
first, this evidence seemed apprehensive, since c-FLIP was always 
assumed as a cytoplasmic protein that regulated cytosolic signaling 
pathways. However, our data on various cell lines also supported the 
observation of nuclear c-FLIP. Initially, endogenous c-FLIP was detected 
in the nucleus by confocal microscopy (Fig 1B and supplementary Fig 1, 
III). We then performed subcellular fractionation on Jurkat cells to 
separate the nucleus and cytoplasm fractions. Western blot analysis 
revealed that most of endogenous c-FLIPL indeed resided in the nucleus, 
whereas endogenous c-FLIPS was found only in the cytoplasmic fraction 
(Fig 1C, III). The transient overexpression of c-FLIP did not distinguish 
the localization of c-FLIP, and even the exogenous FLAG-tagged c-FLIPS 
was found in the nucleus (data not shown). Stably overexpressed c-FLIP 
proteins, however, showed protein distribution that mimics the nuclear 
c-FLIPL observation previously observed (Fig 1D, III). 
 
Fascinatingly, when Jurkat cells were stained for c-FLIP and protein 
localization was analyzed by imaging, most of the c-FLIP 
phosphorylated at S193 was localized outside the nucleus, which was 
defined by DAPI co-staining (Fig 2A, III). To strengthen our hypothesis 
that c-FLIP S193 phosphorylation resides mostly in the cytoplasm, we 
stably overexpressed c-FLIPL WT and S193 phospho-mutants in Jurkat 
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cells and performed subcellular fractionation. The phospho-mimicking c-
FLIPL S193D was found more in the cytoplasm compared to WT or 
S193A (Fig 2A, III). Furthermore, we treated Jurkat cells with PMA to 
phosphorylate c-FLIP on S193. PMA induced phosphorylation of S193 in 
endogenous c-FLIP, and after a four-hour prolonged treatment, the 
amount of c-FLIPL in the cytoplasmic fraction was increased in the 
detection by Western blot (Fig 3, III). Our data revealed that c-FLIPL is 
mostly expressed in the nucleus, and this localization can be regulated by 
c-FLIPL S193; when phosphorylated, c-FLIPL preferentially resides in the 
cytoplasm. The S193 residue is located in the linker region between the 
second DED and the C-terminal domain of c-FLIPL, where as the NLS 
and NES are located in the C-terminal tail (Fig 2C, III). Structural 
modeling by Pymol predicted that phosphorylation of S193 can influence 
the folding of the interlinker region and thus, expose the NLS and NES 
that determines the nuclear localization of the protein (Fig 2D, III). 
DEDD contains a NLS, and when diubiquitinated, it shuttles out of the 
nucleus (Lee et al., 2002). Therefore, it is possible that localization of c-
FLIPL may be regulated by ubiquitination, as S193 phosphorylation does 
inhibit ubiquitination of the protein (Fig 4C, I). It would be interesting to 
investigate if c-FLIPL ubiquitination may be indicative for a nuclear 
localization, especially as it did not affect the half-life. 
 
DEDD2 is a minor DED-containing protein and upon overexpression, it 
sequesters c-FLIP in the nucleoli (Roth et al., 2002). Here, we observed c-
FLIPL WT in the nucleoplasm, thus the regulatory mechanisms of c-FLIP 
is probably independent of DEDD2. Studies have shown that pro-
apoptotic DED-containing proteins can enter the nucleus under certain 
conditions. For example, FADD S194 phosphorylation regulates 
subcellular distribution, where a bulk of the protein resides in the 
nucleus (Gomez-Angelats and Cidlowski, 2003; Screaton et al., 2003). 
FADD may translocate to cytoplasm in response to apoptotic insults that 
lead to cell death via DISC formation, or alternatively to the nucleus to 
regulate cell cycle progression. Hence the DISC formation via homophilic 
interaction of DEDs for induction of apoptosis probably would not occur 
in the nucleus. Furthermore, it has been shown that sumoylation of 
caspase-8 can translocate the protein to the nucleus (Besnault-Mascard et 
al., 2005), and activated caspase-8 enters the nucleus to directly cleave 
PARP to amplify the cell death signaling (Benchoua et al., 2002). 
Interestingly, we observed p43-FLIP fragments in the nucleus fraction 
upon apoptosis induction, indicating that c-FLIPL might also be cleaved 
in the nucleus (unpublished data). c-FLIPS/R is not localized in the 
nucleus, thus the nuclear localization is not likely to be dependent of the 
DED region, which is consistent with the suggested NLS location. Here, 
we introduce for the first time that a phosphorylation modification on c-
FLIP, independent of a regulatory role in protein stability via 
ubiquitination, is an important determinant for subcellular localization. 
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shown to function as polyubiquitin chain acceptor sites (Cadwell and 
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substrates need several binding events for polyubiquitin chain long 
enough for destruction. Therefore, the distributive substrates are not 
efficiently modified before the processive substrates have been 
ubiquitinated. This processivity gradient can discriminate between 
substrates that have to be degraded in a specific timely and sequential 
order (Hochstrasser, 2006; Rape et al., 2006). c-FLIP may function in such 
system, where the short isoforms could be processive substrates and the 
long isoform a distributive substrate. 
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stated that the C-terminal tail of c-FLIPL express two NLS and one NES, 
which were conserved throughout mammalian c-FLIP (Fig 1A, III). At 
first, this evidence seemed apprehensive, since c-FLIP was always 
assumed as a cytoplasmic protein that regulated cytosolic signaling 
pathways. However, our data on various cell lines also supported the 
observation of nuclear c-FLIP. Initially, endogenous c-FLIP was detected 
in the nucleus by confocal microscopy (Fig 1B and supplementary Fig 1, 
III). We then performed subcellular fractionation on Jurkat cells to 
separate the nucleus and cytoplasm fractions. Western blot analysis 
revealed that most of endogenous c-FLIPL indeed resided in the nucleus, 
whereas endogenous c-FLIPS was found only in the cytoplasmic fraction 
(Fig 1C, III). The transient overexpression of c-FLIP did not distinguish 
the localization of c-FLIP, and even the exogenous FLAG-tagged c-FLIPS 
was found in the nucleus (data not shown). Stably overexpressed c-FLIP 
proteins, however, showed protein distribution that mimics the nuclear 
c-FLIPL observation previously observed (Fig 1D, III). 
 
Fascinatingly, when Jurkat cells were stained for c-FLIP and protein 
localization was analyzed by imaging, most of the c-FLIP 
phosphorylated at S193 was localized outside the nucleus, which was 
defined by DAPI co-staining (Fig 2A, III). To strengthen our hypothesis 
that c-FLIP S193 phosphorylation resides mostly in the cytoplasm, we 
stably overexpressed c-FLIPL WT and S193 phospho-mutants in Jurkat 
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cells and performed subcellular fractionation. The phospho-mimicking c-
FLIPL S193D was found more in the cytoplasm compared to WT or 
S193A (Fig 2A, III). Furthermore, we treated Jurkat cells with PMA to 
phosphorylate c-FLIP on S193. PMA induced phosphorylation of S193 in 
endogenous c-FLIP, and after a four-hour prolonged treatment, the 
amount of c-FLIPL in the cytoplasmic fraction was increased in the 
detection by Western blot (Fig 3, III). Our data revealed that c-FLIPL is 
mostly expressed in the nucleus, and this localization can be regulated by 
c-FLIPL S193; when phosphorylated, c-FLIPL preferentially resides in the 
cytoplasm. The S193 residue is located in the linker region between the 
second DED and the C-terminal domain of c-FLIPL, where as the NLS 
and NES are located in the C-terminal tail (Fig 2C, III). Structural 
modeling by Pymol predicted that phosphorylation of S193 can influence 
the folding of the interlinker region and thus, expose the NLS and NES 
that determines the nuclear localization of the protein (Fig 2D, III). 
DEDD contains a NLS, and when diubiquitinated, it shuttles out of the 
nucleus (Lee et al., 2002). Therefore, it is possible that localization of c-
FLIPL may be regulated by ubiquitination, as S193 phosphorylation does 
inhibit ubiquitination of the protein (Fig 4C, I). It would be interesting to 
investigate if c-FLIPL ubiquitination may be indicative for a nuclear 
localization, especially as it did not affect the half-life. 
 
DEDD2 is a minor DED-containing protein and upon overexpression, it 
sequesters c-FLIP in the nucleoli (Roth et al., 2002). Here, we observed c-
FLIPL WT in the nucleoplasm, thus the regulatory mechanisms of c-FLIP 
is probably independent of DEDD2. Studies have shown that pro-
apoptotic DED-containing proteins can enter the nucleus under certain 
conditions. For example, FADD S194 phosphorylation regulates 
subcellular distribution, where a bulk of the protein resides in the 
nucleus (Gomez-Angelats and Cidlowski, 2003; Screaton et al., 2003). 
FADD may translocate to cytoplasm in response to apoptotic insults that 
lead to cell death via DISC formation, or alternatively to the nucleus to 
regulate cell cycle progression. Hence the DISC formation via homophilic 
interaction of DEDs for induction of apoptosis probably would not occur 
in the nucleus. Furthermore, it has been shown that sumoylation of 
caspase-8 can translocate the protein to the nucleus (Besnault-Mascard et 
al., 2005), and activated caspase-8 enters the nucleus to directly cleave 
PARP to amplify the cell death signaling (Benchoua et al., 2002). 
Interestingly, we observed p43-FLIP fragments in the nucleus fraction 
upon apoptosis induction, indicating that c-FLIPL might also be cleaved 
in the nucleus (unpublished data). c-FLIPS/R is not localized in the 
nucleus, thus the nuclear localization is not likely to be dependent of the 
DED region, which is consistent with the suggested NLS location. Here, 
we introduce for the first time that a phosphorylation modification on c-
FLIP, independent of a regulatory role in protein stability via 
ubiquitination, is an important determinant for subcellular localization. 
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1.4 c-FLIP protein level is crucial in determining the outcome of death 
receptor-mediated apoptosis (I-III) 
 
Our studies so far indicated that c-FLIP S193 phosphorylation is 
important in mediating c-FLIP concentration in the cytoplasm and this 
may play a role in the DR-mediated signaling. Since c-FLIP is a potent 
inhibitor of caspase-8 activation at the DISC, it is critical to determine if 
S193 phosphorylation could regulate the DR signaling outcome. 
 
 
c-FLIP S193 phosphorylation in TRAIL-induced apoptosis 
 
Phosphorylation has been proposed as a mechanism that regulates the 
recruitment of c-FLIP to the DISC. Phosphorylation of c-FLIP by CaMKII 
promotes c-FLIPL recruitment to the DISC. In contrast, phosphorylation 
of c-FLIPL by other kinases, such as PKC or bile acid 
glycocheondeoxycholate results in reduced c-FLIPL recruitment by 
lowering its affinity to FADD leading to sensitization to TRAIL-mediated 
apoptosis (Higuchi et al., 2003; Yang et al., 2003). We did not detect any 
changes in the recruitment efficiency of c-FLIP to the TRAIL-DISC by c-
FLIP S193 phosphorylation modification alone (Fig 5C, I). Furthermore, 
caspase-8 activity was not altered by S193 phosphorylation of any c-FLIP 
isoforms. However, cycloheximide-induced degradation of the WT or 
S193A c-FLIPS showed that the phospho-mutant overexpressing cells 
died earlier than in the WT (Fig 5E, I). These data suggest that S193 
phosphorylation does not directly affect the potential of c-FLIP to inhibit 
apoptosis, however, the effects are likely to have profound consequences 
on cell death sensitivity by regulating the stability of c-FLIPS and 
therefore the anti-apoptotic protein availability at the DISC (Fig 22). 
 
Since we have established that c-FLIPS/R S193 phosphorylation stabilized 
the protein to increase its protein concentration that could influence the 
DISC signaling, we wanted to investigate if c-FLIPL S193 
phosphorylation also played an anti-apoptotic effect by translocating the 
protein to the cytoplasm. To this end, we constructed a mathematical 
model to simulate TRAIL-induced PKC activation, which in turn 
phosphorylate c-FLIP S193 and translocate the nuclear c-FLIPL to the 
cytoplasm (Fig 4, III). Simultaneously, we generated a c-FLIPS S193 
phosphorylation signal that stabilized the short isoform upon TRAIL-
mediated PKC activation. Experimental data validated this model as 
acute TRAIL treatment indeed translocated c-FLIPL from the nucleus to 
cytoplasm, probably as well as stabilizing the protein (Fig 8, III).  
 
Following an acute TRAIL treatment in Jurkat cells, we observed that 
processing of procaspase-8 reaches a plateau at 15 minutes until 45 
minutes, then rapidly cleaved once again (Fig 5C, III). Nuclear c-FLIPL 
started to translocate to the cytoplasm around the same time when 
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caspase-8 activation was slowed (Fig 6 and 8, III). The dissociation kinetic 
rate of the heterodimer of caspase-8 and c-FLIPL is significantly lower 
compared to homodimer of caspase-8, hence the heterodimerization is 
presumed to be formed preferentially upon DR stimulation (Boatright et 
al., 2004; Donepudi et al., 2003). The concentration of c-FLIP is limited 
and upon persistent death-inducing ligand stimulation, such as in our 
experiments, the homodimers of caspase-8 will form to induce apoptosis. 
The caspase activation plateau may represent a period when c-FLIP is 
recruited to the DISC to regulate type II cells that require mitochondria-
dependent cell death activation. This early caspase-8 activation period 
when the cells were making decisions were difficult to model with 
accuracy. A model published by Shi and coworkers on TRAIL-induced 
apoptosis in HeLa cells also showed difficulties in mimicking the in vitro 
experiments of early caspase-8 activation, where it exhibited transient 
decrease in activity, together with c-FLIP upregulation (Shi et al., 2013).  
 
We tried to show that shuttling of c-FLIPL was important for TRAIL-
induced apoptosis by utilizing stable Jurkat cells overexpressing c-FLIPL 
mutants. To our surprise, c-FLIPL S193D, which had more c-FLIPL in the 
cytosol, died faster than the WT or phospho-mutant S193A (data not 
shown). This is probably due to the presence of high cytoplasmic level of 
c-FLIP in S193D at basal level, which encourage the activation of 
procaspase-8 cleavage, mimicking previously reported situations when 
c-FLIPL is overexpressed at high level. S193A may not shuttle out upon 
TRAIL treatment and relatively low concentration of cytoplasmic c-FLIP 
are maintained compared to the WT or S193D mutant c-FLIP, when these 
exogenous proteins are expressed at equal amount. The model revealed 
that c-FLIP concentration at the time of TRAIL-induced apoptotic 
signaling is vital, and that phosphorylation of c-FLIP induced by TRAIL 
is indeed important in determining the time-to-death. The model 
predicted that 10-fold higher rate of c-FLIPL phosphorylation prolong 
plateau lag phase by approximately 5 minutes, which is equivalent to 
more than 10 % delay for the full activation of caspase-8 to occur (Fig 7E, 
III). Accordingly, the model showed that a decrease in phosphorylation 
cause slower translocation of c-FLIPL from the nucleus and less 
processing to p43-FLIP (Fig 7C-D, III). Consequently, caspase-8 
activation occurred more rapidly. Since Jurkat cells have significantly 
lower amount of c-FLIPS, the model suggested that it is not a strong 
determinant. In cells with higher amount of short isoforms of c-FLIP, 
however, S193 phosphorylation-mediated stability would be of an 
importance in TRAIL-mediated apoptosis (data not shown). 
 
Mathematical modeling and in silico analysis of biological systems have 
become important tools for simulation-based hypothesis testing. To date, 
many mathematical modeling studies still remain merely in silico 
exercises, often with limited practical relevance to biologists. Close 
interdisciplinary collaboration allowed us to employ integrated 
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Following an acute TRAIL treatment in Jurkat cells, we observed that 
processing of procaspase-8 reaches a plateau at 15 minutes until 45 
minutes, then rapidly cleaved once again (Fig 5C, III). Nuclear c-FLIPL 
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modeling and experimental approach to predict a signaling pathway 
otherwise tricky to evaluate endogenously. Cellular components often 
dynamically shuttle between cellular organelles and our compartmental 
model treat the same molecule in different compartments as distinct 
species instead of assuming that they are regulated in the same manner. 
One of the difficult experimental challenges is the measurement of 
localization-specific chemical kinetics parameters and molecular 
concentrations in vivo. Our model will help to guide our future 
experimental design and integrate newly emerging data to store, 
visualize and interact, as well as further advance the models and will 
contribute to the development of models in the field of apoptosis.  
 
 
Bench-to-Model, quantitative study of c-FLIP behavior  
 
The DR sensitivity is dynamically regulated in response to 
environmental stimuli and the intracellular status of cells, and differing 
observations have been reported. The DISC is a central mediator of the 
CD95 and TRAIL signaling pathway and it can be comprised of several 
isoforms of initial procaspases and c-FLIP. Caspase-8 is often expressed 
at high abundance compared to c-FLIP, but c-FLIP has higher affinity to 
the DISC (Chang et al., 2002), primarily to delay or inhibit the DR-
mediated apoptosis. c-FLIP protein expression differ in isoforms and in 
quantity, thus numerous modes of the DISC complex can be formed 
simply by altering the expression of c-FLIP (Supplementary Fig 2, I). In 
accordance with our previous results and data published by others, we 
know that c-FLIPS is a potent inhibitor of caspase-8, whereas c-FLIPL 
permits the activation of caspase-8 in the DISC (Fig 5D, I). With such 
complexity, many mathematical models are emerging to combine 
experimental data to understand the behavior of the DISC in apoptosis. 
The expression level of c-FLIP is an important determinant in the 
outcome of DR-mediated apoptosis. Bentele and colleagues have 
established a detailed extrinsic apoptosis signaling model to verify a 
threshold for CD95 stimulation (Bentele et al., 2004). The model 
presented that outcome of CD95 signaling depends on the concentration 
of c-FLIP in the DISC and initial concentration of CD95L. Since the 
dynamic turnover of the c-FLIP protein level is readily altered in an 
isoform-specific manner, we investigated how c-FLIP stability regulates 
apoptotic signaling in both individual cells and population using in silico 
analysis. 
 
The short isoforms of c-FLIP contain unique amino acid sequences at 
their C termini and these sequences contain crucial lysine residues that 
promote their ubiquitination and proteasomal degradation, a responsible 
mechanism for a rapid turnover of c-FLIPS/R compared to c-FLIPL. By 
inhibiting de novo synthesis, the half-lives of c-FLIPR and c-FLIPL in K562 
cells were determined to be 40 and 120 minutes, respectively (Poukkula 
? ??
et al., 2005). We integrated the regulatory mechanism of c-FLIP synthesis 
and isoform-specific degradation to the framework of the DISC model 
presented, to demonstrate the importance of c-FLIP expression as a 
regulatory mechanism in extrinsically-induced apoptosis (Bentele et al., 
2004). Our modified model simulated that the dynamic regulation of c-
FLIP protein levels certainly plays a role for DR-mediated apoptosis. The 
apoptotic outcome was determined largely by the concentration of c-
FLIP at the time of death receptor activation, and this concentration is 
influenced by the overall degradation of c-FLIP but not significantly by 
protein synthesis (Fig 1, II). Such observation has already been made in 
biological studies, such as during heat shock that causes c-FLIP protein 
level to decrease via proteasomal degradation without affecting the 
protein synthesis rate (Meinander et al., 2007). Our model, in addition, 
predicted that the threshold of ligand concentration that triggers 
apoptosis correlates with an increase in the initial c-FLIP concentration, 
as qualitatively observed by many reports (Fig 2, II).  
 
Within a population of cells, the distribution of protein concentration 
fluctuates (Feinerman et al., 2008; Sigal et al., 2006), and individual cells 
differ widely in their responsiveness to the uniform physiological stimuli 
(Albeck et al., 2008). In case of apoptosis mediated by TRAIL, a striking 
divergence in apoptotic sensitivity and signaling outcome is 
demonstrated, where it is common for some cells in a clonal population 
to die while others survive. Furthermore, among the cells that die, the 
time between the death ligand exposure and caspase activation is highly 
variable. The original model described the behavior of a single cell with 
specific protein concentration and kinetic parameters, thus it was not 
compatible for experimental studies. To account for differences between 
the behaviors of different cells in a population and to transform the 
model applicable to experimental settings, we introduced distributions in 
the initial concentration of proteins and reaction rates of the biochemical 
network. The model indicated that the time-to-apoptosis was well 
defined when the intercellular parameter variation was moderate, but 
when the parameter variations were large, the outcome was highly 
variable (Fig 3, II). Despite the statistical distributions, a noticeable 
threshold behavior for cell death was observed with regard to the initial 
ligand concentration (Fig 4, II). Furthermore, the average time-to-
apoptosis was a nearly linear function of the logarithm of the ligand 
concentration (Fig 5, II). In experimental studies, the apoptotic process is 
often shown as a proportion of dying cells obtained at given times after a 
ligand exposure. By depicting the proportion of apoptotic events as a 
function of time, we obtained the stochastic simulations that can 
represent the proportion of cells that are predicted to undergo apoptosis 
within a given time interval (Fig 6, II). Further simulation verified that 
the model was able to reproduce qualitative experimental observations 
presented in the literature, showing that the proportion of death ligand-
induced apoptosis occurring during a given time depends on ligand 
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modeling and experimental approach to predict a signaling pathway 
otherwise tricky to evaluate endogenously. Cellular components often 
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model treat the same molecule in different compartments as distinct 
species instead of assuming that they are regulated in the same manner. 
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presented, to demonstrate the importance of c-FLIP expression as a 
regulatory mechanism in extrinsically-induced apoptosis (Bentele et al., 
2004). Our modified model simulated that the dynamic regulation of c-
FLIP protein levels certainly plays a role for DR-mediated apoptosis. The 
apoptotic outcome was determined largely by the concentration of c-
FLIP at the time of death receptor activation, and this concentration is 
influenced by the overall degradation of c-FLIP but not significantly by 
protein synthesis (Fig 1, II). Such observation has already been made in 
biological studies, such as during heat shock that causes c-FLIP protein 
level to decrease via proteasomal degradation without affecting the 
protein synthesis rate (Meinander et al., 2007). Our model, in addition, 
predicted that the threshold of ligand concentration that triggers 
apoptosis correlates with an increase in the initial c-FLIP concentration, 
as qualitatively observed by many reports (Fig 2, II).  
 
Within a population of cells, the distribution of protein concentration 
fluctuates (Feinerman et al., 2008; Sigal et al., 2006), and individual cells 
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(Albeck et al., 2008). In case of apoptosis mediated by TRAIL, a striking 
divergence in apoptotic sensitivity and signaling outcome is 
demonstrated, where it is common for some cells in a clonal population 
to die while others survive. Furthermore, among the cells that die, the 
time between the death ligand exposure and caspase activation is highly 
variable. The original model described the behavior of a single cell with 
specific protein concentration and kinetic parameters, thus it was not 
compatible for experimental studies. To account for differences between 
the behaviors of different cells in a population and to transform the 
model applicable to experimental settings, we introduced distributions in 
the initial concentration of proteins and reaction rates of the biochemical 
network. The model indicated that the time-to-apoptosis was well 
defined when the intercellular parameter variation was moderate, but 
when the parameter variations were large, the outcome was highly 
variable (Fig 3, II). Despite the statistical distributions, a noticeable 
threshold behavior for cell death was observed with regard to the initial 
ligand concentration (Fig 4, II). Furthermore, the average time-to-
apoptosis was a nearly linear function of the logarithm of the ligand 
concentration (Fig 5, II). In experimental studies, the apoptotic process is 
often shown as a proportion of dying cells obtained at given times after a 
ligand exposure. By depicting the proportion of apoptotic events as a 
function of time, we obtained the stochastic simulations that can 
represent the proportion of cells that are predicted to undergo apoptosis 
within a given time interval (Fig 6, II). Further simulation verified that 
the model was able to reproduce qualitative experimental observations 
presented in the literature, showing that the proportion of death ligand-
induced apoptosis occurring during a given time depends on ligand 
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concentration (Fig 7, II). Modifications that were introduced to the 
original model provided it to be applied to qualitatively predict results 
obtained from others. Indeed, we were able to simulate heat-shock-
induced destabilization of c-FLIP and its effect on apoptosis sensitivity as 
an example to validate the concept and transfer empirical data to the 
model (Fig 8 and 9, II).  
 
Our model predicts that variations among any given cell population is 
largely as a result of inter-cell variability in the c-FLIP levels. The results 
of this study and the developed model provide insight into how small 
system perturbations may have pronounced effects on cell sensitivity. 
Previous studies either disregarded protein turnover kinetics, or only 
adjusted initial c-FLIP levels (Laussmann et al., 2012). Inclusion of the 
protein turnover was a key advance over previous models that described 
the influence of c-FLIP in apoptosis initiation. 
 
Many anti-cancer drugs exhibit functional killing, in which each round of 
therapy kills some but not all of the cells in a tumor (Berenbaum, 1972). 
As a consequence, selected drug-resistant cells undergo clonal expansion 
to form more aggressive tumor. The efficiency of DR-mediated killing of 
cancer cells could be increased by reducing the impact of cell-to-cell 
viability, which arises from natural differences in protein levels (Spencer 
et al., 2009). The DR-mediated signaling resulting in life or death 
decisions is made by a complex dynamic system rather than by the 
influence of a single protein. There are various models, which focus 
different regulatory pathways in both extrinsic and intrinsic apoptosis 
signaling, as well as related pro-survival signaling pathways. The 
feasibility of combining mathematical models to produce a dynamic 
biology approach will reveal global behavior of cell population upon DR-
mediated signaling. Abnormality of cell death is often associated with 
diseases and more integrated studies are in need to understand the 
consequence of c-FLIP defects on a higher system level. Successful 
construction of quantitative and predictive computational models would 
be significant for research and clinical perspectives (Spencer and Sorger, 
2011).  
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2 Formation of c-FLIPL-mediated death effector 
filaments (unpublished) 
 
2.1 Serine 227 is phosphorylated in c-FLIPL 
 
Along with the identification of the c-FLIP S193 phosphorylation site, the 
S227 residue was also detected to be phosphorylated (Fig 23) (Vitaly 
Kochin, PhD thesis). This modification was long isoform specific, since 
the short isoforms are spliced too early for them to carry the amino acid 
residue. S227 is positioned before the first caspase-8 cleavage site D376, 
thus p43-FLIP also includes S227 and is, thus, potentially 
phosphorylated. 
 
  1  MSAEVIHQVE EALDTDEKEM LLFLCRDVAI DVVPPNVRDL LDILRERGKL SVGDLAELLY 
 61  RVRRFDLLKR ILKMDRKAVE THLLRNPHLV SDYRVLMAEI GEDLDKSDVS SLIFLMKDYM 
121  GRGKISKEKS FLDLVVELEK LNLVAPDQLD LLEKCLKNIH RIDLKTKIQK YKQSVQGAGT 
181  SYRNVLQAAI QKSLKDPSNN FRLHNGRSKE QRLKEQLGAQ QEPVKKSIQE SEAFLPQSIP 
241  EERYKMKSKP LGICLIIDCI GNETELLRDT FTSLGYEVQK FLHLSMHGIS QILGQFACMP 
301  EHRDYDSFVC VLVSRGGSQS VYGVDQTHSG LPLHHIRRMF MGDSCPYLAG KPKMFFIQNY 
361  VVSEGQLEDS SLLEVDGPAM KNVEFKAQKR GLCTVHREAD FFWSLCTADM SLLEQSHSSP 
421  SLYLQCLSQK LRQERKRPLL DLHIELNGYM YDWNSRVSAK EKYYVWLQHT LRKKLILSYT  
 
Fig 23. The amino acid sequence of human c-FLIPL. The DEDs are 
shaded in grey; darker grey, DED1; lighter grey, DED2. The c-FLIPL-
specific C-terminal tail is underlined; single line, p20 subunit; double 
line, p12 subunit. The S227 phosphorylation site unique only to the 
long isoform is in bold (S). 
 
 
Polyclonal antibodies against phosphorylated c-FLIPL S227 and 
corresponding phospho-nonspecific c-FLIPL were produced to obtain a 
tool to study this PTM on c-FLIPL. 
 
 
2.2 c-FLIPL phosphorylated on S227 form death effector filaments 
 
Our initial study of S227 phosphorylated c-FLIPL by immunofluorescence 
imaging analysis revealed unexpected organization of c-FLIPL in HeLa 
cell line. In some cells, we observed distinct high-intensity filamentous 
structures in the cytosol, particularly around the nucleus (Fig 24). In 
unstimulated cells, approximately 30% of the total population contained 
the clear bright filamentous structures in HeLa cells. 
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tool to study this PTM on c-FLIPL. 
 
 
2.2 c-FLIPL phosphorylated on S227 form death effector filaments 
 
Our initial study of S227 phosphorylated c-FLIPL by immunofluorescence 
imaging analysis revealed unexpected organization of c-FLIPL in HeLa 
cell line. In some cells, we observed distinct high-intensity filamentous 
structures in the cytosol, particularly around the nucleus (Fig 24). In 
unstimulated cells, approximately 30% of the total population contained 
the clear bright filamentous structures in HeLa cells. 
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Fig 24. Endogenous c-FLIPL 
phosphorylation at S227 form 
filamentous structure in some cells. 
(A) Immunofluorescence image of 
HeLa cells stained for c-FLIPL (left 
panel) or phosphorylated S227 (right 
panel), and their merged images with 
DAPI are shown below. The scale bar 
indicates 50 μm. (B) Magnified HeLa 
cell with c-FLIPL S227 
phosphorylated filamentous structure 
(green) and co-stained with DAPI 
(blue). The scale bar indicates 25 μm. 
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Siegel and colleagues have demonstrated that DEDs of FADD and 
procaspase-8 can self-oligomerize and form filaments upon 
overexpression. They called this highly ordered oligomerization of pro-
apoptotic DEDs death effector filaments (DEFs) (Siegel et al., 1998). 
Overexpression of the c-FLIP DED region, however, did not self-
associate to form the structure, but instead blocked the formation of 
caspase-8 chain by recruiting to the DEFs (Garvey et al., 2002; Siegel et 
al., 1998). Additionally, isolated tandem DEDs of v-FLIP proteins were 
found to exist as monomerics and did not form filament structures (Li et 
al., 2006; Yang et al., 2005). Our data suggest that C-terminal tail of c-
FLIPL and phosphorylation of S227 is a requirement for c-FLIP to form 
DEFs. 
 
Interestingly, reported pro-apoptotic DEFs assembled into cage or lariat-
like structures, which resembled cytoskeletal filaments. These 
descriptions are similar to what we have observed with endogenous 
filaments of c-FLIPL phosphorylated at S227. I believe our c-FLIP DEF 
observation is not due to artifacts, since we have verified the specificity 
of our antibodies (in article III), and the c-FLIP DEFs are restricted to 
certain cells. Nonetheless, further control experiments are idyllic, for 
example by using null background cells, to eliminate unspecific 
immunereactivity. Our observation of c-FLIP DEFs was surprising and 
may provide an important insight into the function of C-terminal 
caspase-like domain of the long isoform of c-FLIP. 
 
 
2.3 c-FLIPL death effector filaments are affected by the cytoskeletal 
network 
 
Following our observation on c-FLIP DEFs, we next investigated if the 
filamentous structures of phosphorylated c-FLIPL may be related to the 
structural proteins in the cytosol. DEDs of procaspase-8, when 
overexpressed, were found to interact with stable microtubule structures, 
such as the centrosomes and midbodies, and correspondingly, a 
microtubule-binding motif was identified in the procaspase-8 DED2 
(Mielgo et al., 2009). In the same study, they showed that DEDs of c-FLIP 
did not bind to microtubule structure. Microtubules are tubulin 
polymers involved in intracellular structural organization and organelle 
transport as well as a key role in regulating normal cell division. 
Paclitaxel promotes stabilization of microtubule structures and induce 
apoptosis in cancer cells. It has been reported that caspase-8 DEFs are 
stabilized upon paclitaxel treatment via DED association with 
microtubules thereby providing a platform where procaspase-8 can 
oligomerize and induce close proximity activation (Mielgo et al., 2009). 
The study demonstrated that c-FLIP overexpression can rescue this mode 
of cell death, and therefore we investigated if microtubule organization 
can influence the c-FLIP DEFs that we observed. We treated HeLa cells 
? ??
 
Fig 24. Endogenous c-FLIPL 
phosphorylation at S227 form 
filamentous structure in some cells. 
(A) Immunofluorescence image of 
HeLa cells stained for c-FLIPL (left 
panel) or phosphorylated S227 (right 
panel), and their merged images with 
DAPI are shown below. The scale bar 
indicates 50 μm. (B) Magnified HeLa 
cell with c-FLIPL S227 
phosphorylated filamentous structure 
(green) and co-stained with DAPI 
(blue). The scale bar indicates 25 μm. 
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caspase-8 chain by recruiting to the DEFs (Garvey et al., 2002; Siegel et 
al., 1998). Additionally, isolated tandem DEDs of v-FLIP proteins were 
found to exist as monomerics and did not form filament structures (Li et 
al., 2006; Yang et al., 2005). Our data suggest that C-terminal tail of c-
FLIPL and phosphorylation of S227 is a requirement for c-FLIP to form 
DEFs. 
 
Interestingly, reported pro-apoptotic DEFs assembled into cage or lariat-
like structures, which resembled cytoskeletal filaments. These 
descriptions are similar to what we have observed with endogenous 
filaments of c-FLIPL phosphorylated at S227. I believe our c-FLIP DEF 
observation is not due to artifacts, since we have verified the specificity 
of our antibodies (in article III), and the c-FLIP DEFs are restricted to 
certain cells. Nonetheless, further control experiments are idyllic, for 
example by using null background cells, to eliminate unspecific 
immunereactivity. Our observation of c-FLIP DEFs was surprising and 
may provide an important insight into the function of C-terminal 
caspase-like domain of the long isoform of c-FLIP. 
 
 
2.3 c-FLIPL death effector filaments are affected by the cytoskeletal 
network 
 
Following our observation on c-FLIP DEFs, we next investigated if the 
filamentous structures of phosphorylated c-FLIPL may be related to the 
structural proteins in the cytosol. DEDs of procaspase-8, when 
overexpressed, were found to interact with stable microtubule structures, 
such as the centrosomes and midbodies, and correspondingly, a 
microtubule-binding motif was identified in the procaspase-8 DED2 
(Mielgo et al., 2009). In the same study, they showed that DEDs of c-FLIP 
did not bind to microtubule structure. Microtubules are tubulin 
polymers involved in intracellular structural organization and organelle 
transport as well as a key role in regulating normal cell division. 
Paclitaxel promotes stabilization of microtubule structures and induce 
apoptosis in cancer cells. It has been reported that caspase-8 DEFs are 
stabilized upon paclitaxel treatment via DED association with 
microtubules thereby providing a platform where procaspase-8 can 
oligomerize and induce close proximity activation (Mielgo et al., 2009). 
The study demonstrated that c-FLIP overexpression can rescue this mode 
of cell death, and therefore we investigated if microtubule organization 
can influence the c-FLIP DEFs that we observed. We treated HeLa cells 
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with paclitaxel and saw increase in the proportion and intensity of 
phosphorylated c-FLIPL DEFs formation (Fig 25). Conversely, when we 
induced microtubule depolymerization by nocodazole, c-FLIPL S227 
phosphorylation was decreased and c-FLIPL DEFs were less abundant. 
Microtubule structures were detected by α-tubulin staining to verify the 
efficacy of the treatments (data not shown). We are yet to investigate if c-
FLIPL interacts directly to microtubule organization in S227 
phosphorylation-dependent manner. Another speculation includes the 
potential interaction of S227 phosphorylated c-FLIPL with keratins. c-
FLIP has been demonstrated to associate with the keratin-8/18 complex 
and thereby sensitize cells to DR-mediated apoptosis (Gilbert et al., 
2004). 
 
 
 
 
 
 
 
 
 
 
 
Fig 25. The formation of c-FLIPL S227 phosphorylation DEFs is 
dependent on the microtubule networks. HeLa cells were treated 
with nocodazole or paclitaxel for 6 hours and co-stained for c-FLIPL 
phosphorylated on S227, α-tubulin and DAPI (not shown). The 
image of nocodazole treated cells was taken from a separate sample 
with close resemblance of untreated image.  
 
 
2.4 Possible function of c-FLIP death effector filaments 
 
Formation of protein chains is vital for many biological processes, 
including reorganization of cytoskeletal networks in cell mobility, 
polyubiquitination modifications in protein degradation (Ikeda et al., 
2010), and procaspse-8 chain formation to initiate apoptosis (Dickens et 
al., 2012; Schleich et al., 2012). Overexpression of pro-apoptotic DEDs 
induces self-association and the formation of long cytoplasmic filaments, 
which are capable of inducing apoptosis independent of the DRs (Siegel 
et al., 1998). In fact, aggregation of FADD is common and the protein is 
kept in a monomeric state by chaperons and released upon DR 
stimulation (Liguoro et al., 2003). Pro-apoptotic DED-containing proteins 
were suggested to form DEFs to induce cell death in overexpressed 
systems or with paclitaxel treatment. Both situations provide a stable 
complex for procaspase-8 to oligomerize and activate the apoptosis 
pathway. c-FLIP can reduce DEF-induced apoptosis upon 
overexpression via blocking the dimerization of procaspase-8 (Day et al., 
Untreated Paclitaxel Nocodazole 
? ??
2006). On the other hand, transient overexpression of c-FLIPL can 
enhance cell death probably due to excessive amount of DED-containing 
proteins that results in caspase-8 DEF formation (Siegel et al., 1998).  
 
Our unpublished data strongly suggest that for c-FLIP to form DEFs, the 
caspase-like domain of c-FLIPL is required and the assembly is regulated 
by phosphorylation at S227. Interestingly, overexpression of S194/S203 
double phosphorylation-mimetic mutant form of FADD strongly 
induced caspase-8-mediated DEF formation whereas unphosphorylated 
mutant could not (Jang et al., 2011), further suggesting that 
phosphorylation status of the DED-containing proteins are important in 
the formation of DEFs. Understanding the c-FLIP filamentous structure 
may unearth yet another role of c-FLIP in regulating a different mode of 
cell death, and therefore continuing studies would be important to 
understand the mechanism and role of S227 phosphorylation-mediated 
c-FLIPL DEFs. 
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understand the mechanism and role of S227 phosphorylation-mediated 
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3 Phosphorylation of c-FLIP in cell proliferation (IV) 
 
The DED-containing proteins are essential for cells to sustain viability. 
Overexpression of c-FLIPL activates many regulatory proteins in cell 
proliferation and survival, augmenting the associated signaling 
pathways upon survival stimulation at molecular level. In this study, we 
provide evidence that the phosphorylation status of c-FLIPL may be a 
critical factor that determines the pro-apoptotic or anti-apoptotic 
function of the protein. 
 
 
3.1 Phosphorylated c-FLIP in the cell cycle 
  
During previous studies, we noticed that c-FLIP phosphorylation of both 
S193 and S227 were significantly increased in certain cells. By close 
examination of their nuclear DAPI staining, we identified that they were 
mitotic cells. The cell cycle functions to pass on life from one cell to two 
progenitor cells, which is on the extreme contrast to what cell death is in 
biology. The cell cycle is divided into phases; a cell grows and duplicates 
its DNA in interphase and divides into two individual daughter cells in 
mitosis (Fig 26). The cell cycle is an important process for the survival of 
a healthy cell, where detection and repair of genetic damage occur. The 
regulation is crucial and unidirectional, with various checkpoints for 
correct cell cycle progression.  
Fig 26. The passage through a cell cycle. In eukaryotic cells, the cell 
cycle is distributed into interphase (G1, S and G2), during which the 
cell grows with duplication of DNA, the mitotic (M) phase, when the 
cell divides and finally cytokinesis to produce two daughter cells. 
Cellular components and organelles are labeled in italic. 
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Generally, global protein phosphorylation is most abundant during 
mitosis since numerous kinases phosphorylate a large number of 
substrates to transit through mitosis (reviewed by Medema and 
Lindqvist, 2011). We have observed that base level of c-FLIP 
phosphorylation is low in interphase, but towards metaphase both S193 
and S227 phosphorylation increase rapidly compared to the total protein 
amount (Fig 1A, IV). Upon mitotic arrest by paclitaxel, c-FLIP 
phosphorylation is significantly increased on both S193 and S227 
residues (Fig 1B, IV).  
 
Further observation revealed that every cell contained one or two distinct 
spots when we stained Jurkat cells with S193 or S227 phospho-specific 
antibodies (Fig 2, IV). This was also observed in various cell lines 
including HeLa cells, although less noticeable (Fig 1, IV). Both S193 and 
S227 phospho-spots appeared to occupy space where centrosome 
positions would be expected. For example, when the chromosomes are 
aligned in the metaphase plate, phospho-spots are found on the both 
sides of the chromosomes, and when the cell is divided into two 
progenitor cells, the spots were located symmetrical to each daughter cell 
(Fig 2A, IV). The centrosome is important for bipolar spindle assembly 
during mitosis by nucleating microtubules and organizing their 
dynamics (reviewed by Delaval and Doxsey, 2010). The centrosome is 
composed of a pair of centrioles and pericentiolar material, which is a 
matrix that is composed of proteins required for centrosome-associated 
functions. Pericentrin is an integral component of the centrosome that 
serves as a multifunctional scaffold for anchoring numerous protein 
complexes. Upon co-staining phosphorylated c-FLIP and pericentrin, 
which was used as a centrosomal marker, all c-FLIP phospho-spots were 
found to inhabit the same cellular space (Fig 2B, IV). Colocalization 
analysis using image software indeed revealed that c-FLIP phospho-
spots were found at the centrosome. 
 
It has been previously shown that FADD phosphorylation is highest at 
G2/M and low in G1/S phase at S194 (Scaffidi et al., 2000), and that it 
accumulates at the centrosome during the early phase of mitosis. The 
FADD phosphorylation is CKIα-mediated and promotes cell cycle 
progression of T cells (Alappat et al., 2005; Hua et al., 2003). Our 
observation is similar as accumulated c-FLIP phosphorylation is found at 
the mitotic spindles. However, the c-FLIP phospho-spot is present in all 
cells, including those in the interphase. Pericentrin is a scaffold that 
tethers PKCβII to centrosome. Disruption of this interaction by 
expression of the interacting region of pericentrin results in release of 
PKC from the centrosome, microtubule disorganization and cytokinesis 
failure (Chen et al., 2004). PKC is also a candidate for c-FLIP S227 
phosphorylation by analyzing kinase consensus sequences. PKCβ is 
activated during mitosis and closely resemble c-FLIP phosphorylation, 
thus an ideal candidate as a kinase. Moreover, at metaphase-anaphase 
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transition, CaMKII is localized to the centrosomes and between the 
spindle poles. After anaphase, CaMKII translocated to the area between 
separating chromosomes (Skelding et al., 2011). CaMKII inhibition cause 
cells to accumulate in the G2 or M phases, but further analysis is 
required to identify the kinases involved in the global c-FLIP 
phosphorylation during mitosis. Aurora A is a well-known mitotic 
kinase and it is activated at low level during interphase and is increased 
during mitosis. Aurora A phosphorylates S203 of FADD, which serves to 
prime FADD for polo-like kinase 1 (Plk-1)-mediated phosphorylation at 
S194 (Jang et al., 2011), which is required for cells to exit from G2/M 
phase. Both S193 and S227 are predicted to have the consensus 
phosphorylation sequences for aurora kinases. Cellular distribution of 
phosphorylation of c-FLIP during mitosis, especially at the midbody 
where Aurora B would be activated in cytokinesis, suggest aurora 
kinases to be a strong candidate for mitotic phosphorylation of c-FLIP. 
Taken together, many of the kinases suggested to regulate c-FLIP 
phosphorylation are involved in the same phases of the cell cycle. 
 
 
3.2 Phosphorylation of c-FLIP regulates the outcome of cell 
proliferation 
 
In highly proliferating cells with a propensity for malignant 
transformation, close monitoring and ability to respond to cell death 
signaling would be beneficial, while terminally differentiated cells may 
downregulate the pro-apoptotic pathways. In T cells, high levels of c-
FLIP are detected in the resting cells, whereas the levels are lowered 
when cells progress into S phase of cell cycle (Algeciras-Schimnich et al., 
1999). Many studies elucidated that c-FLIP expression level strongly 
influence cell proliferating signaling pathways. We wanted to investigate 
if phosphorylation of c-FLIP is required in cell cycle and proliferation. To 
study the effect of c-FLIP phosphorylation modifications, we constructed 
c-FLIP S193/227 phospho-double mutant where the serine residues were 
mutated to alanine (c-FLIPL-AA), representing a state of non-
phosphorable c-FLIPL. Transient transfection of WT c-FLIPL in HeLa cells 
proliferated faster compared to its control mock that only contained the 
endogenous c-FLIP (Fig 3A, IV). The similar trend of c-FLIPL-induced cell 
proliferation was also obtained in transfected Jurkat cells, but to a lesser 
magnitude possibly due to lower transfection efficiency (data not 
shown). Interestingly, c-FLIPL double phospho-mutant c-FLIPL-AA did 
not augment cell proliferation, although its exogenous expression level 
was equivalent to the WT (Fig 3A, IV). In line with this, when we 
analyzed cell viability by WST assay, the cells overexpressing c-FLIPL 
WT had higher cell count compared to the mock or double phospho-
mutant (data not shown).  
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We next investigated the mechanism underlying the reduced 
proliferative capacity of the c-FLIPL phospho-double mutant. The DNA 
content of transfected cells was analyzed by flow cytometry of 
propedium iodide (PI) staining to determine the cell cycle phases but no 
significant differences were observed between the transfected cells. 
Likewise, Ki67 staining was used to determine the proportion of 
proliferating cells, but we could not see any alteration in c-FLIPL 
overexpressed cells (data not shown). These negative results on cell 
proliferation lead us to look at the opposing effect of c-FLIPL, which is 
cell death. To determine the effect of c-FLIP phosphorylation in 
spontaneous cell death, the apoptotic DNA fragmentation was assessed 
in the transfected cells by TUNEL assay. Cells overexpressing c-FLIPL 
WT had lower number of TUNEL positive cells and, therefore, less 
spontaneous cell death. Intriguingly, the number of cell death was 
significantly higher in c-FLIPL-AA samples compared to the WT 
overexpressed cells (Fig 4, IV). Since the cell count was similar for the 
phospho-mutant and mock, it may be plausible that cell proliferation is 
increased upon transfection with the double phospho-mutant, but 
simultaneously increases cell death and keeps the cell number low. There 
is an increase in the spontaneous in vivo T cell proliferation in c-FLIPL-
transgenic mice (Lens et al., 2002). However, c-FLIPL-transgenic mice 
have apparent similarity to WT mice in the numbers of thymocytes and 
total peripheral T cells due to concomitant increase in T cells apoptosis 
owing to augmented caspase-8 activity (Dohrman et al., 2005). In our 
system, overexpressed c-FLIP proteins were rapidly cleaved to p43-FLIP 
upon transient expression in HeLa cells and the processing of the WT 
and double phospho-mutant was similar (Fig 4, IV). This indicates that 
caspase-8 activity may be similar.  
 
In the recent years, many non-apoptotic roles of DED-containing proteins 
have emerged. Murine FADD S191D mutant is phenotypically identical 
to those from FADD-deficient mice (Hua et al., 2003). We report that c-
FLIP phosphorylation is required for cells to efficiently proliferate and 
sustain viability. Further investigation will include the identification of 
the mechanism underlying the effect of c-FLIP on induced cell 
proliferation, as well as identifying the mode of cell death induced by the 
inhibition of phosphorylation.  
 
T cells are more sensitive to caspase-mediated cell death and clonal 
expansion of antigen-specific T cells in c-FLIPL-transgenic mice is 
followed by rapidly accelerated deletion. In parallel, loss-of-function 
studies using conditional deletion of c-FLIP in the T-cell compartment or 
complementation of Rag1-deficient blastocytes with c-FLIP-deficient 
embryonic cells/Raf chimeric mutant mice have revealed the importance 
of c-FLIP in T cells. Peripheral T cell numbers and proliferation in 
response to IL-2 and TCR crosslinking were greatly reduced (Chau et al., 
2005; Zhang and He, 2005). FLIP mediated T-cell proliferation is reported 
? ??
transition, CaMKII is localized to the centrosomes and between the 
spindle poles. After anaphase, CaMKII translocated to the area between 
separating chromosomes (Skelding et al., 2011). CaMKII inhibition cause 
cells to accumulate in the G2 or M phases, but further analysis is 
required to identify the kinases involved in the global c-FLIP 
phosphorylation during mitosis. Aurora A is a well-known mitotic 
kinase and it is activated at low level during interphase and is increased 
during mitosis. Aurora A phosphorylates S203 of FADD, which serves to 
prime FADD for polo-like kinase 1 (Plk-1)-mediated phosphorylation at 
S194 (Jang et al., 2011), which is required for cells to exit from G2/M 
phase. Both S193 and S227 are predicted to have the consensus 
phosphorylation sequences for aurora kinases. Cellular distribution of 
phosphorylation of c-FLIP during mitosis, especially at the midbody 
where Aurora B would be activated in cytokinesis, suggest aurora 
kinases to be a strong candidate for mitotic phosphorylation of c-FLIP. 
Taken together, many of the kinases suggested to regulate c-FLIP 
phosphorylation are involved in the same phases of the cell cycle. 
 
 
3.2 Phosphorylation of c-FLIP regulates the outcome of cell 
proliferation 
 
In highly proliferating cells with a propensity for malignant 
transformation, close monitoring and ability to respond to cell death 
signaling would be beneficial, while terminally differentiated cells may 
downregulate the pro-apoptotic pathways. In T cells, high levels of c-
FLIP are detected in the resting cells, whereas the levels are lowered 
when cells progress into S phase of cell cycle (Algeciras-Schimnich et al., 
1999). Many studies elucidated that c-FLIP expression level strongly 
influence cell proliferating signaling pathways. We wanted to investigate 
if phosphorylation of c-FLIP is required in cell cycle and proliferation. To 
study the effect of c-FLIP phosphorylation modifications, we constructed 
c-FLIP S193/227 phospho-double mutant where the serine residues were 
mutated to alanine (c-FLIPL-AA), representing a state of non-
phosphorable c-FLIPL. Transient transfection of WT c-FLIPL in HeLa cells 
proliferated faster compared to its control mock that only contained the 
endogenous c-FLIP (Fig 3A, IV). The similar trend of c-FLIPL-induced cell 
proliferation was also obtained in transfected Jurkat cells, but to a lesser 
magnitude possibly due to lower transfection efficiency (data not 
shown). Interestingly, c-FLIPL double phospho-mutant c-FLIPL-AA did 
not augment cell proliferation, although its exogenous expression level 
was equivalent to the WT (Fig 3A, IV). In line with this, when we 
analyzed cell viability by WST assay, the cells overexpressing c-FLIPL 
WT had higher cell count compared to the mock or double phospho-
mutant (data not shown).  
 
? ??
We next investigated the mechanism underlying the reduced 
proliferative capacity of the c-FLIPL phospho-double mutant. The DNA 
content of transfected cells was analyzed by flow cytometry of 
propedium iodide (PI) staining to determine the cell cycle phases but no 
significant differences were observed between the transfected cells. 
Likewise, Ki67 staining was used to determine the proportion of 
proliferating cells, but we could not see any alteration in c-FLIPL 
overexpressed cells (data not shown). These negative results on cell 
proliferation lead us to look at the opposing effect of c-FLIPL, which is 
cell death. To determine the effect of c-FLIP phosphorylation in 
spontaneous cell death, the apoptotic DNA fragmentation was assessed 
in the transfected cells by TUNEL assay. Cells overexpressing c-FLIPL 
WT had lower number of TUNEL positive cells and, therefore, less 
spontaneous cell death. Intriguingly, the number of cell death was 
significantly higher in c-FLIPL-AA samples compared to the WT 
overexpressed cells (Fig 4, IV). Since the cell count was similar for the 
phospho-mutant and mock, it may be plausible that cell proliferation is 
increased upon transfection with the double phospho-mutant, but 
simultaneously increases cell death and keeps the cell number low. There 
is an increase in the spontaneous in vivo T cell proliferation in c-FLIPL-
transgenic mice (Lens et al., 2002). However, c-FLIPL-transgenic mice 
have apparent similarity to WT mice in the numbers of thymocytes and 
total peripheral T cells due to concomitant increase in T cells apoptosis 
owing to augmented caspase-8 activity (Dohrman et al., 2005). In our 
system, overexpressed c-FLIP proteins were rapidly cleaved to p43-FLIP 
upon transient expression in HeLa cells and the processing of the WT 
and double phospho-mutant was similar (Fig 4, IV). This indicates that 
caspase-8 activity may be similar.  
 
In the recent years, many non-apoptotic roles of DED-containing proteins 
have emerged. Murine FADD S191D mutant is phenotypically identical 
to those from FADD-deficient mice (Hua et al., 2003). We report that c-
FLIP phosphorylation is required for cells to efficiently proliferate and 
sustain viability. Further investigation will include the identification of 
the mechanism underlying the effect of c-FLIP on induced cell 
proliferation, as well as identifying the mode of cell death induced by the 
inhibition of phosphorylation.  
 
T cells are more sensitive to caspase-mediated cell death and clonal 
expansion of antigen-specific T cells in c-FLIPL-transgenic mice is 
followed by rapidly accelerated deletion. In parallel, loss-of-function 
studies using conditional deletion of c-FLIP in the T-cell compartment or 
complementation of Rag1-deficient blastocytes with c-FLIP-deficient 
embryonic cells/Raf chimeric mutant mice have revealed the importance 
of c-FLIP in T cells. Peripheral T cell numbers and proliferation in 
response to IL-2 and TCR crosslinking were greatly reduced (Chau et al., 
2005; Zhang and He, 2005). FLIP mediated T-cell proliferation is reported 
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not to be mediated through the NF-κB pathway (Zhang et al., 2008) and 
the exact function of FLIP in T cell proliferation remains elusive. Our 
data support some of the previous studies and suggest that 
phosphorylation of c-FLIP is important in these observations.  
 
Mitotic catastrophe refers to cases of cell death that are triggered by 
aberrant mitosis and executed wither during mitosis or in the subsequent 
interphase (Galluzzi et al., 2012). After aberrant mitosis, cells frequently 
exhibit gross nuclear attractions, for example micro- and 
multinucleation, which have been used as morphological markers for the 
detection of mitotic catastrophe. Although apoptosis seems to be the 
main mechanism by which cells die after an extended mitotic arrest, Z-
vad-fmk or Bcl-2 overexpression failed to completely prevent cell death, 
indicating that other mechanism may have a role in mitotic cell death 
(Manchado et al., 2012). It would be of interest to investigate if this mode 
of cell death play a role in eliminating c-FLIP overexpressed cells where 
phosphorylation status play a strong role in keeping the cell number 
high.  
 
The hallmarks of cancer include sustained proliferative signaling, 
resistance to cell death, ability to replicate immortally, induced 
angiogenesis, evasion of growth suppressors, and activated invasion and 
metastasis (Hanahan and Weinberg, 2000). In addition, genomic 
instability and inflammatory features are common in advanced tumors 
(Hanahan and Weinberg, 2011). The apoptosis-resistant potential of 
cancer cells in correlation to their proliferative dynamics profoundly 
affects malignant phenotypes. Accumulating studies have established 
that pathways governing cell proliferation and cell death are closely 
interconnected. c-FLIPS anti-apoptotic role is well established and we 
indeed demonstrated repeatedly that overexpression of c-FLIPL protects 
Jurkat cells from DR-induced apoptosis (I-III). To examine the effect of c-
FLIPL overexpression on cell proliferation, we used the chorioallantoic 
membrane (CAM) assay. The chick CAM is an extraembryonic 
membrane, which serves embryonic development functions, and we 
applied this non-mammalian in vivo system to study the growth of 
tumors overexpressing exogenous c-FLIP proteins. HeLa cells 
overexpressing c-FLIPL WT established tumors more rapidly compared 
to the control mock or c-FLIPS overexpressing cells (Fig 27). The 
established tumors that contained high expression of c-FLIPL showed 
accelerated growth and weighed almost as twice as the mock or c-FLIPS 
expressing tumors (data not shown). 
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Weight      8.8 mg   13.5 mg   9.6 mg 
 
Fig 27. Overexpression of c-FLIPL alone promotes faster tumor 
growth. Fertilized chicken eggs (LSK Poultry Oy, Finland) were 
prepared for the CAM assay. In brief, the fertilized chicken eggs 
were incubated for 10 days and HeLa cells transiently transfected 
with c-FLIPL, c-FLIPS or mock plasmids were implanted in a plastic 
ring placed on the CAM at embryo development day (EDD) 11. The 
tumor growth was continuously visualized every day from the 
windows cut at the top of the eggs. The grown tumors (indicated by 
arrows) were harvested from the CAM and weighed on EDD 13. 
 
 
The chick CAM model allows for rapid and simple evaluation of the 
implanted samples and is commonly utilized to study angiogenesis. 
Interestingly, we noticed that eggs implanted with c-FLIPL 
overexpressing cells developed a more advanced vascular system. 
Disruption of blood vessels is one of the characteristics reported in the c-
FLIP knockout studies in mice. c-FLIP levels may affect the blood vessel 
growth, since inhibiting angiogenesis downregulate c-FLIP in epithelial 
cells and induce apoptosis (Kamphaus et al., 2000). In addition, the c-
FLIP level is reduced in epithelial cells with impaired blood vessel 
growth. Reversely, various angiogenic factors augment PI3K/Akt 
pathway and cells become resistant to CD95-mediated cell death 
(Papapetropoulos et al., 2000; Sata et al., 2000). Although we do not have 
further evidence to suggest angiogenesis is directly induced by c-FLIPL 
overexpression, our data suggest strongly that the tumor development in 
these cells is more efficient. Our work indicates that c-FLIP further aid in 
establishing tumors by increasing cell proliferation and enhancing 
angiogenesis to support metabolically demanding cells. Chromosome 
2q33 where the initiator caspase genes reside is a commonly deleted 
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region in some cancers (Nishizuka et al., 1998; Otsuka et al., 1996). c-FLIP 
may also be mutated in some cancers and it would be interesting to 
screen if c-FLIP phospho-sites are altered in certain cancer cells, which 
could correlate with development and progression of cancer. 
 
Taken together, this thesis work reveals significant importance of 
phosphorylation as a mode of PTM to regulate c-FLIP cellular 
distribution. Phosphorylation of c-FLIP S193 contributes to the anti-
apoptotic behavior of c-FLIP in DR-mediated cell death, phosphorylation 
of c-FLIPL S227 induce filamentous formation, and global 
phosphorylation of the protein is required for cells to sustain its survival. 
These observations suggest that the functional diversity of c-FLIP may be 
achieved in a phosphorylation-dependent manner. Furthermore, our 
studies demonstrate that c-FLIPL overexpression promotes faster cell 
growth and therefore culture passages will be different compared to 
mock transfected cells. This means that stable c-FLIP overexpression may 
indirectly influence the outcome of cellular processes simply by aging 
the cells faster (from article IV). However, one must also take into 
account that transient transfection studies of c-FLIP may not mimic 
physiological localization of c-FLIP and, therefore its native functions 
(from article III). 
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CONCLUDING REMARKS 
 
Advances in the knowledge of c-FLIP signaling and its interesting 
concepts emerged from various research groups while I was carrying out 
my thesis work. The old schemes of singular anti-apoptotic behavior do 
not apply for c-FLIP anymore, since it can determine fate of a cell by 
influencing various cellular signaling pathways and, therefore, processes. 
Thus far, impact on subcellular localization of c-FLIP has been largely 
ignored in the regulation of apoptosis susceptibility. Our studies strongly 
suggest that the phosphorylation status of c-FLIP determines its cellular 
distribution and reveal c-FLIP isoform-specific subcellular localizations 
may explain how the c-FLIP proteins are involved in various signaling 
pathways, ranging from cell death to survival. Differential c-FLIP 
distribution would provide an efficient way to regulate the protein 
concentration in different organelles, where specific biological functions 
are allocated. For example, c-FLIP at the lipid rafts would regulate the 
DISC signaling, whereas c-FLIP at the centrosome may be involved in 
cell proliferation. Altering the protein localization via phosphorylation 
could also provide more rapid responses for c-FLIP to regulate fast 
signals, which would not be feasible by protein synthesis and 
degradation. Therefore, the absolute quantification of c-FLIP in their 
subcellular localization and systematic study of the protein in cell death 
and proliferation holds a key to accurately understand the dynamic c-
FLIP signaling. 
 
The isoform-specific roles of c-FLIP in apoptosis and necroptosis indicate 
that c-FLIPS/R may act as an all-or-none signaling switch, while the action 
of c-FLIPL is gradually deciphered according to other components 
present in the multiprotein complex at the time of signaling. 
Furthermore, many studies imply that relative abundance of the DED-
containing proteins and their interactions with one another must be 
considered to truly appreciate the significance of each protein, 
particularly in the context of caspase-8 activation. The protective role of 
c-FLIP in keeping caspase-8 as a survival factor to prevent necroptosis, as 
well as c-FLIP-mediated regulatory functions in many non-apoptotic 
signaling pathways suggest that the dominant function of c-FLIPL is pro-
survival more so than its canonical function as an inhibitor of apoptosis. 
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